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A novel in vitro membrane oxygenator circuit was developed to test gas exchange where 
particular elements could be examined whilst keeping other variables constant.   The 
circuit comprises two membrane oxygenators connected to form a continuous blood 
circuit resembling venous and arterial blood conditions.  The effects of Isoflurane, a 
volatile anaesthetic, on oxygen transfer were investigated.  RBC resistance to nitric oxide 
diffusion (DNO) was tested in this circuit by haemolysis and addition of the haemoglobin-
based-oxygen-carrier (HBOC) Oxyglobin. 
 
The circuit was primed with equine blood flowing at 2.5 l/min.  The oxygenator was 
ventilated with 5 l/min air/oxygen/N2 mix providing a range of FiO2.  The deoxygenator 
received 5 l/min 5% CO2 in N2 with 0.2-0.3 l/min CO2.  Isoflurane 1%, NO 4000-16000 
ppb and CO 0.03% were added to the oxygenator gas.  Uptake of O2, CO2, CO and NO 
were calculated by gas inlet and outlet concentrations and flow rates.  Arterial and venous 
oxygen dissociation curve (aODC and vODC) comparisons were made.  
  
Isoflurane uptake by the circuit blood was evident and 1% Isoflurane did not affect oxygen 
uptake (p=0.981), aODC or vODC (p=0.311 and p=0.751).  Haemolysis did not affect O2 
or CO2 transfer but increased DNO (p<0.001).  250ml free Hb solution addition to the 
circuit increased DNO by 91% (p<0.0001).  Addition of 250ml Oxyglobin increased DNO 
by 143% from 7.41±2.77 to 17.97±1.83 ml/min/mmHg.  Oxyglobin caused a right shift of 
aODC and vODC (p<0.0001) but NO-bound Oxyglobin caused a left vODC shift 
(p<0.0001).  
   
Conclusion: Isoflurane administered via a membrane oxygenator does not affect O2 uptake 
or carriage in the blood.  RBC surroundings provide significant resistance to DNO in 
circuit tests.  Significant uptake of NO by Oxyglobin supports the potential of HBOCs to 
scavenge endothelial NO in vivo, causing vasoconstriction.  Oxyglobin binding NO shifts 
the ODC left resulting in poor oxygen delivery to tissues.    
 
 
Keywords: Membrane Oxygenator, Deoxygenator, Isoflurane, Nitric Oxide, HBOC, 
Oxyglobin 
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C v O2  Venous oxygen content ml/dl 
C v CO2  Venous carbon dioxide content mmol/l 
DCO   Carbon monoxide transfer ml/min/mmHg 
DCO2  Carbon dioxide transfer ml/min/mmHg 
Deoxy  Deoxygenator 
Deoxy F  Deoxygenator gas flow ml/min 
DL   Lung diffusion 
DLCO  Lung diffusing capacity for carbon monoxide ml/min/mmHg 
DLNO  Lung diffusing capacity for nitric oxide ml/min/mmHg 
DLO2   Lung diffusing capacity for oxygen ml/min/mmHg 
DM   Membrane diffusion 
DMNO  Membrane diffusing capacity for nitric oxide ml/min/mmHg 
DNO   Nitric oxide transfer ml/min/mmHg 
DO2    Oxygen transfer ml/min/mmHg 
EEG   Electroencephalography 
EU   European Union 
FDA   US Food and Drug Administration 
Fe
+
   Iron 
FeCO2  Expired fractional carbon dioxide content 
FeISO  Expired fractional Isoflurane content 
FeO2   Expired fractional oxygen content 
FiCO2  Inspired fractional carbon dioxide content 
FiISO  Inspired fractional Isoflurane content 
FiO2   Inspired fractional oxygen content 
g/dl   Grams per decilitre 
Hb   Haemoglobin g/dl 
HBOC  Haemoglobin-based-oxygen-carrier 
HCO3  Bicarbonate concentration in blood mmol/l 
Hct   Haematocrit % 
HIV   Human-Immunodeficiency-Virus 
IV   Intravenous 
K
+
   Potassium mmol/l 
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l/min   Litres per minute 
M CO  Carbon monoxide uptake ml/min 
M CO2  Carbon dioxide uptake ml/min 
MI   Myocardial infarction 
ml/dl   Millilitres per decilitre  
ml/min  Millilitres per minute 
ml/min/mmHg Millilitres per minute per millimetre of mercury 
MMC  South African Medical Control Council 
mmHg  Millimetres of mercury 
mmol/l  Millimols per litre 
M O2   Oxygen uptake ml/min 
N2   Nitrogen 
NaCl   Sodium chloride 
NO   Nitric oxide 
NO2   Nitrogen dioxide 
NOin   Concentration of NO in oxygenator inlet gas (ppb) 
NOout  Concentration of NO in oxygenator outlet gas (ppb) 
O2   Oxygen 
O2sat   Oxygen saturation of the blood % 
ODC   Oxygen dissociation curve 
Oxy   Oxygenator 
Oxy F  Oxygenator gas flow ml/min 
P50 Measure of oxygen affinity; oxygen partial pressure at 50% 
saturation 
PACO  Alveolar carbon monoxide partial pressure mmHg  
PaCO2  Arterial carbon dioxide partial pressure mmHg 
PaO2   Arterial oxygen partial pressure mmHg 
PAO2   Alveolar oxygen partial pressure mmHg 
P c CO2  Pulmonary capillary carbon dioxide partial pressure mmHg 
P c O2   Pulmonary capillary oxygen partial pressure mmHg 
PCO2   Partial pressure of carbon dioxide in blood mmHg 
PFC   Perfluorocarbon based oxygen therapeutics 
PH2O Saturated water vapour pressure (for a given laboratory 
temperature) mmHg 
pHa   Arterial pH 
pHv   Venous pH 
PO2   Partial pressure of oxygen in blood mmHg 
ppb   Parts per billion 
ppm   Parts per million 
PVC   Polyvinyl chloride 
P v CO2  Venous carbon dioxide partial pressure mmHg 
P v O2  Venous oxygen partial pressure mmHg 
Q    Blood flow or „cardiac output‟ ml/min 
Q g   Gas flow ml/min 
Q s   Blood flow shunt ml/min 
Q t   Total blood flow ml/min 
RBC   Red blood cell 
SA   Surface area m
2
 
SaO2   Arterial blood oxygen saturation % 
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sO2   Blood oxygen saturation % 
STPD  Standard temperature, pressure and dry gas 
SvO2   Venous blood oxygen saturation % 
t   Laboratory temperature 
°
C 
t⅟2   Half-life min 
Vc   Pulmonary capillary blood volume ml 
vODC  Venous oxygen dissociation curve 
0.93 Membrane absorption correction factor (for half membrane) as 
minor NO uptake was noted in a saline primed membrane 
oxygenator (Borland, 2006) 
1/ DL   Lung diffusion resistance 
1 cell   One membrane oxygenator compartment 
¼”   Quarter of an inch internal diameter tubing 
⅜”   Three eighths of an inch internal diameter tubing 
⅟2”   Half of an inch internal diameter tubing 
2,3-DPG  2,3-diphosphoglycerate 
2 cells  Whole membrane oxygenator (2 compartments) 
Θ   „theta‟ Specific conductance of a gas per 1 ml blood 
β   „beta‟  gas content in the blood ml/min/mmHg 
µm   Micrometre 
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Chapter 1 Introduction 
 
1.1. Membrane Oxygenators 
 
An oxygenator functions as the patient‟s lungs during cardiothoracic surgery requiring 
cardiopulmonary bypass (CPB).  It can also provide respiratory support in acute 
respiratory disorders.  An oxygenator only performs gas exchange so functions such as 
endocrine are suspended during the operative procedure.  The oxygenator allows passage 
of gases (oxygen, carbon dioxide and anaesthetics) between inspired gas and blood so the 
term „oxygenator‟ is incorrect although commonly used.  In clinical practice, a patient‟s 
venous circulation is pumped through the bypass circuit where it is oxygenated and carbon 
dioxide removed by the oxygenator before arterialised blood is returned to the aorta.  
Normally, an oxygenator adds oxygen to venous blood by ventilating the gas side with 
oxygen rich gas and removes carbon dioxide from venous blood by ventilating the gas 
side with carbon dioxide depleted gas.  The oxygenator uses basic gas diffusion whereby 
gas moves from a higher to a lower concentration.   
 
Oxygenators have been classified as bubble, film or membrane depending on the method 
of gas exchange.  Bubble oxygenators allowed bubbles to be generated in the patients‟ 
blood within the device where the surface of the bubble served as the membrane for gas 
transfer.  With film oxygenators blood was passed over gaseous discs in a thin film for gas 
transfer to occur.  Both bubble and film oxygenators were assembled per case using 
sterilised reusable glass and stainless steel parts.  Both oxygenator types caused blood 
damage due to direct blood-gas interface.  Membrane oxygenators imitate the lungs as a 
membrane separates the blood and gas flowing on either side allowing gas transfer.  
Membrane separation of blood and gas phases aids haemocompatibility. Membrane 
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materials used are silicone or poly-4-methyl-1-pentene (true membranes) or microporous 
polypropylene where tiny holes are manufactured into the membrane for gas diffusion.  
The membrane can be a flat sheet or hollow fibres woven into a bundle.  In this study, a 
microporous polypropylene sheet membrane oxygenator was used as an example of a 
current clinical device.  The thesis will concentrate solely on polypropylene membrane 
oxygenators. 
 
1.1.1 Comparison to lungs 
Modern day membrane oxygenators aim to transfer maximum amounts of gas (oxygen 
and carbon dioxide) at a given blood flow rate, thus maximising efficiency.  Despite the 
manufacturers aiming for large gas exchange surface areas, the devices are kept compact 
for ease of use and to minimise blood trauma and priming (fill) volume.    
 
There are many differences between a membrane oxygenator and the lungs.  Structurally, 
the lungs contain 300 million alveoli separated from gas by alveolar epithelium and 
capillary endothelium of combined thickness 0.3 µm (Cotes 1993) whereas a membrane 
oxygenator (e.g. Cobe Duo) has two oxygenator cells separated from gas by 100-150 µm 
polypropylene membrane containing multiple micropores (<0.1 µm).  The blood pathway 
diameter through the membrane oxygenator is very different to the pulmonary capillaries 
of the alveoli.  In alveoli, blood passes one RBC at a time with high vascular compliance 
avoiding resistance to blood flow hence gas transfer distance is very small.  It has not been 
possible to construct a narrow blood pathway in membrane oxygenators due to excessive 
pressure resistance exerted by blood flow.  A much larger blood channel is required 
resulting in greater distance for gas transfer.  Larger blood channels create laminar flow 
where the outer RBC layers exchange gas but are stagnant and the middle layers move 
quickly with less time and greater distance for gas transfer.  Manufacturers induced 
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secondary blood flows to aid mixing within the blood channel thus reducing laminar flow 
but avoiding blood trauma from excessive turbulence.  The surface area for gas exchange 
is very different between the membrane oxygenator at 2.6 m
2
 (Cobe Duo CML) and the 
lungs at 70 m
2
 (Guyton 1976).  To compensate for the smaller membrane surface area, 
manufacturers increased the blood pathway length, keeping blood in contact with the 
membrane for longer (9.6 seconds) allowing gas exchange to occur.  In lungs, the 
pulmonary capillary blood transit time is expected to be 0.3 seconds (Cotes 1993).  The 
gas used to ventilate the membrane oxygenator is continuous, at high velocity and utilises 
a high inspired oxygen fraction (FiO2 65-80%) to achieve high arterial blood saturations.  
In the lungs, gas is inspired and expired, yet the design of airways with multiple branches 
reduces the velocity of the gas flow with diffusion dominating in the alveoli.  The 
simplistic oxygenator gas channel facilitates easier calculation of alveolar oxygen tensions 
based on a semi-logarithmic decline between inlet and outlet concentrations.  The V/Q 
ratio (ventilation/perfusion ratio) in a normal adult lung equals 1 but in the membrane 
oxygenator ratios can be in excess of 2.  The higher gas flow required (i.e. 5 l/min) to 
achieve normoxia for a given blood flow (i.e. 2.5 l/min) compensates for reduced gas 
transfer efficiency.  In this model, the membrane surface area and pulmonary capillary 
volume is fixed whereas in the lung there are changes in these parameters such as 
pulmonary capillary recruitment and distension with increased blood flow. 
 
In the membrane oxygenator, oxygen uptake by the blood from the gas uses both 
convective and diffusive processes. There is convective mixing of the blood in the blood 
channel to reduce stagnant layers compared to pulmonary capillaries with diameter 
approximating the RBC.  Diffusive distances are greater in the membrane oxygenator with 
wider gas and blood channels and thicker membrane compared to the lesser diffusive 
distance of the alveolar to pulmonary capillaries. 
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The anatomical shunt in the lungs comprises venous blood entering the arterial circulation 
without being exposed to ventilated areas of the lung, so is considered a perfusion limited 
shunt. This differs from the shunt within the membrane oxygenator.  The principle is the 
same, where venous blood not exposed to the membrane mixes with the arterial blood; 
however, the shunt is most likely due to the laminar flow characteristics of a larger 
diameter blood channel. 
 
1.1.2 Suitability 
The membrane oxygenator is an alternative device for experimental gas diffusion studies 
compared to rapid reaction apparatus or in vivo work.  Previous in vitro diffusion work has 
utilised rapid reaction apparatus, first reported by Hartridge and Roughton (1923) who 
discovered that O2 and Hb combination was very rapid at 100
th
 of a second.  The apparatus 
comprised two pressurised vessels, one containing dilute O2 free Hb solution and the other 
O2 exposed tap water.  The two fluids were forced under pressure into a mixing chamber 
and down a long, thin observation tube.  Spectroscopy determined oxyHb and deoxyHb 
ratios at known distances along the tube.  The oxygenation time of blood was calculated 
by the distance (cm) divided by fluid velocity (cm/sec).  Similarly, CO and Hb reactions 
were monitored via dissociation of CO and Hb, facilitated by bright light exposure at the 
tube entry (Hartridge and Roughton 1923b).  Modernising modifications were made to the 
original apparatus (i.e. syringe drivers, photoelectric spectroscopy) however, large 
amounts of blood was required for very short run times due to the flow velocities needed 
to observe such quick reactions.  Increased flow velocities induce turbulent flow which 
can cause RBC shear stress.  A stopped-flow methodology was reported (Gibson 1954) 
where the flow is halted abruptly close to the mixing chamber (<1.0 ms) and a complete 
kinetic curve established.  This method allowed observation of change and less reagent 
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use, but stopping flow induced settling of RBCs and formation of an unstirred layer.  The 
unstirred layer may impede gas diffusion (Hughes and Bates 2003).  This proposed circuit 
would comprise two oxygenators acting as the lungs and the tissues, thus a continuously 
operating circuit could be developed resembling venous and arterial blood gas parameters.  
The „lung‟ oxygenator could be used for testing gas diffusion theories.  The compactness 
of the circuit would limit the blood needed to run a battery of experiments, whilst the 
continuous operation would limit unstirred layer formation.  The circuit design would 
facilitate changes in membrane surface area/blood volume, blood flow, gas flow, oxygen 
tensions, haematocrit and red cell integrity whilst keeping other variables constant.   A 
membrane oxygenator circuit would allow diffusion experiments to be conducted in 
conditions that would otherwise be impossible in vivo i.e. haemolysis and low 
haemoglobin states.  Whilst the physiological differences are apparent with in vitro work, 
including rapid reaction apparatus, they provide a functional model of gas transfer.  The 
membrane oxygenator circuit provides an alternative gas diffusion testing apparatus. 
 
 
 
 
1.2 Using a Membrane Oxygenator Circuit to Model Gas Exchange 
 
The aim was to create a compact, efficient and continuously perfused membrane 
oxygenator circuit to replicate arterial and venous blood conditions.  Hypotheses of gas 
exchange were tested using a system where a single variable could be altered over a 
supraphysiological range while keeping the remaining variables unchanged. 
 
The literature review was restricted to peer reviewed journals applicable to the field.   The 
search terms were “in vitro membrane oxygenator modelling” thus excluding older 
oxygenator types, clinical assessments or ex vivo studies whereby the patient or animals 
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provide the venous blood conditioning.  Studies detailing methods for membrane 
oxygenator gas diffusion testing were primarily used as these were likely to include both 
arterial and venous circuitry rather than other studies such as drug testing and effects of 
circuit coatings. 
 
1.2.1 Circuit Design 
Membrane oxygenators undergo rigorous testing by the manufacturers in accordance with 
the AAMI (2009) guidelines prior to commercial approval but manufacturers rarely 
publish this methodology or data.  The AAMI guidelines methodology criteria are not 
specific allowing large variations in test conditions yielding commercially favourable 
results (Fried and Mohamed 1994).  Once approved for clinical use, a device often 
undergoes comparison studies to older devices in the clinical setting which will be subject 
to patient variables i.e. BMI, oxygen consumption, temperature, acid-base balance and 
pre-existing conditions.  In vivo tests are favoured over in vitro testing as ethical 
considerations are less once a product has been approved for clinical use.  To obtain 
comparable gas diffusion data between different membrane oxygenators under simulated 
clinical conditions, several researchers have developed testing circuits.  
 
Vocelka et al (1993) published an in vitro protocol for evaluating and comparing 
membrane oxygenators.  Their circuit compared oxygen and carbon dioxide transfer of 
oxygenators from different manufacturers under the same operating conditions.  The 
circuit was a single-pass system utilising vast quantities of bovine blood (24 litres).  This 
methodology has been used by several researchers with varying quantities of blood (Van 
Meurs et al 1991, Rais-Bahrami et al 1992, Griffiths 1994, Gourlay and Taylor 1994, 
Beckley et al 1996, Matsuda and Sakai 2000, Maeda et al 2000, Kawahito et al 2001 and 
Motomura et al 2003).  Single-pass systems comprise a reservoir of blood deoxygenated 
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to venous blood parameters before being held in another reservoir.  Venous blood is 
pumped through the test membrane oxygenator where it is arterialised and returned back 
to the first reservoir.  Some minor variations such as extra shunting loops, directional 
changes and additional reservoirs may be included.  This creates a large and complex 
circuit which requires blood to be repeatedly reconditioned to venous parameters.  The 
disposables and volumes of blood for these circuits make them expensive.  They were 
popular in the early 1990s when membranes were less efficient and larger in capacity so 
complex circuitry was required to achieve the gas exchange data.   
 
Single-pass systems cannot run for a lengthy duration before exhausting the volume of 
preconditioned venous blood.  In Vocelka‟s study (1993), 24 litres of bovine blood was 
needed to allow a testing duration of 4-12 minutes at typical blood flow rates of 2-6 l/min.  
Single-pass systems do not facilitate changes in gas or haematological parameters during 
the experiment as equilibrium takes a few minutes to achieve.  For example, increasing Hb 
levels during the test run would be difficult to achieve as the blood volumes needed to 
increase the Hb from 1-10g/dl would be vast.  Hb increases are easier to achieve in smaller 
circuits with less amounts of blood.  The main purpose of single-pass methodology is for 
determining overall gas transfer at predetermined conditions.  This single-pass 
methodology was inflexible for this research project.  The circuit design was for a 
compact, continuously run circuit allowing for controlled changes in operating conditions.  
A later study by Walczak et al (2005), a modified Vocelka method, described 
methodology where the deoxygenating and test circuits ran in parallel with both feeding 
into the same reservoir of blood allowing continuous circulation.  He demonstrated that a 
continuous circuit was feasible but the deoxygenating component comprised many units 
so failed to be compact.  It was considered that a compact system with less disposables 
and smaller blood usage was possible for this research.   
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The size and number of deoxygenator units required for the circuit was a concern.  The 
deoxygenator removes O2 from the blood whilst adding CO2.  Transfer of CO2 is very 
efficient as it readily crosses the membrane but O2 liganded with haemoglobin is more 
difficult to remove.  Many researchers cited two or more deoxygenator units or had 
substantially larger deoxygenator membranes compared to the test membranes.  Studies 
conducted by Vocelka et al (1993), Griffiths (1994) and Beckley et al (1996) described 
two oxygenator units whereas Walczak et al (2005) used four units and Gourlay and 
Taylor (1994) utilised “a series of deoxygenating units”: quantity was not specified.  Van 
Meurs et al (1991) and Rais-Bahrami et al (1992) used one deoxygenating unit but the 
deoxygenator membrane surface area was 3.3m
2
 compared to the oxygenator membrane 
surface area of 0.5, 0.6 or 0.8m
2
 thus a 6, 5 or 4 times membrane diffusing area.  This 
difference in deoxygenating and oxygenating membrane number and size reflects the 
inefficient membrane technology in the 1990s.  The volume of blood to deoxygenate was 
large determining deoxygenator membrane size.  Often details of the exact membrane 
oxygenators used for deoxygenation are omitted.  Kawahito et al (2001) demonstrated that 
a smaller deoxygenating to oxygenating membrane surface area was adequate to remove 
O2 from blood: 1.9 m
2
 deoxygenator: 1.0m
2
 prototype oxygenator membrane.  This study 
was a later publication indicating the efficiency of newer membrane oxygenators, i.e. 
Cobe Optima.  These studies show that deoxygenation may be difficult with a single unit 
of an equal membrane surface area to the arterialising unit.  Ideally, this circuit would 
utilise one deoxygenator unit for system compactness and cost.   
 
To replicate tissues and provide venous blood, the deoxygenator must remove O2 from the 
blood and add CO2.  The deoxygenator ventilating gas needs to comprise CO2 but exclude 
O2 for appropriate gas exchange.  Vocelka et al (1993) detailed a deoxygenator gas mix of 
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100% CO2, 100% N2 and 5% CO2 in N2.  Preconditioning of the blood commenced with 
100% CO2 for 12-15 seconds before switching to 5% CO2 in N2.  Additional CO2 or N2 
was added as necessary by constant adjustment.  This adjustment was considered 
unsuitable for this work as a stable deoxygenation method was required for a continuous 
system.  Griffiths et al (1994) modified Vocelka et al‟s (1993) methods with 7% CO2 in 
N2 at 10 l/min with a venous blood flow of 4 l/min.  This demonstrated a stable approach 
although the gas flow to blood flow ratio was high suggesting difficultly in 
deoxygenating.  Other studies described the use of CO2 and N2 but concentrations and gas 
flows were omitted (Gourlay et al 1990, Gourlay and Taylor 1994, Matsuda and Sakai 
2000 and Walczak et al 2005).  To precondition vast quantities of venous blood for single-
pass systems, higher CO2 gas concentrations are needed compared to a smaller 
continuously run circuit. The concentration of CO2 added would be dependent on 
deoxygenator surface area, gas flows and blood flows.  Van Meurs et al (1991), Rais-
Bahrami et al (1992) and Beckley et al (1996) described using CO2, N2 and O2 for their 
deoxygenator yet removal of O2 is the primary role of the deoxygenator unit.  To 
effectively remove O2, an anoxic gas mix maximizes the diffusion gradient for O2 transfer. 
However, if the deoxygenator was for preconditioning venous blood prior to use through 
the test membrane oxygenator, O2 may be needed to achieve venous saturation of 65%.  In 
this circuit the deoxygenator would be used to continuously remove O2 and add CO2 to the 
blood.  The initial deoxygenator gases would be 5% CO2 in N2 (Vocelka et al 1993) and if 
continuous normocapnia was not achieved, additional low flow 100% CO2 would be 
added.   
 
Previous studies utilised bovine blood as vast quantities were required coupled with ease 
of procurement from abattoirs.  The single-pass methodology requires large volumes of 
blood to run the system before exhausting the preconditioned venous blood, i.e. 24 litres 
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pumped at 2 l/min equals 12 minutes operation.  Four studies detailed high blood volumes; 
24 litres (Vocelka et al 1993), 18 litres (Griffiths et al 1994), 12 litres (Gourlay and Taylor 
1994) and 20 litres (Beckley et al 1996).  Implications of large blood volumes would be 
cost, procurement and storage prior to use.  In Walczak et al‟s (2005) study five litres of 
bovine blood was used to run the complex parallel venous and test circuit but this 
exceeded blood volume expectations.  This compact circuit would require 1-2 litres of 
blood based on volume capacity of the components.  Despite this smaller volume per 
circuit, human donation would be ethically ambiguous.  Several donors of the same blood 
group would need to donate 500 ml of blood each.  Expired human blood donations from 
NHS stock would have storage damage (Liumbruno and Aubuchon 2010) rendering it 
unsuitable for extrapolation of gas diffusion data.  In-date human bank blood would be 
unethical to use due to shortages of blood for medical use.   Animal blood donations are 
commercially available and were acquired for this research allowing for reproducibility.  
The equine donor was selected due to body surface area and blood volume enabling three 
litres of blood donation per experimental session.  Donor gender and age specifications 
can be realised to reduce variations in the data.   
 
1.2.2 Calculations 
Literature for both clinical and in vitro oxygenator assessments was reviewed for oxygen 
uptake (M O2) and carbon dioxide uptake (M CO2) calculations.  Most authors cite reverse 
Fick approach to M O2 calculations.  Fick principle, named after Adolf Eugen Fick, 
determines cardiac output by knowing the concentration of a marker substance into and 
out of an organ per unit of time.  This marker substance was oxygen and the organ was the 
whole body represented as: 
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Where  Q  = cardiac output (ml/min) 
M O2 = oxygen uptake (ml/min) 
 CaO2 = pulmonary vein blood O2 content (mg/dl) 
 C v O2 = pulmonary artery blood O2 content (mg/dl) 
 
 
Assuming cardiac output is known the equation can be rearranged to calculate oxygen 
uptake: 
 
QCvOCaOMO  )( 222  
  
The oxygen content of the arterial (CaO2) or venous (C v O2) blood is calculated from the 
following equation: 
 
)003.0()36.1()/( 222 POsatOHbdlmlContO   
 
Where  ContO2 = oxygen content of blood (ml/dl) 
 Hb = Haemoglobin concentration in the blood (g/dl) 
 1.36 = ml of O2 carried by 1g fully saturated Hb 
 O2 sat = O2 saturation of the blood (arterial or venous as appropriate) 
 0.003 = O2 solubility correction factor for plasma (0.003ml O2 /dl /mmHg PO2) 
 PO2 = partial pressure of O2 in the blood (arterial or venous as appropriate) 
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Slight variations of these calculations are presented in the published literature, i.e. for „O2 
content‟ the initial bracketed section determines the content of O2 bound to Hb for a given 
Hb and associated saturation.  The second bracketed section adds the amount of dissolved 
O2 within plasma proportional to the partial pressure (Henrys Law).  Some publications 
assume the plasma O2 content negligible and is not included in the total O2 content 
calculation.  Variation in the 1.36 mlO2/gHb is often presented as 1.34mlO2/gHb.  This is 
due to pure Hb having the capacity to carry 1.39ml O2/gHb but under normal bodily 
conditions Hb is present in alternative non O2 carrying forms such as methaemoglobin, so 
a corrected value is used. 
 
The alternative M O2 calculation utilises inspired and expired gas O2 concentrations to 
provide direct O2 uptake data through the oxygenator, using the following equation: 
 
FFeOFiOMO  )( 222  
 
Where M O2 = oxygen uptake (ml/min) 
 FiO2 = fractional inspired O2 concentration 
 FeO2 = fractional expired O2 concentration 
 F = gas flow through the oxygenator (ml/min) 
 
This approach was not well documented compared to the reverse Fick method.  FiO2 and 
FeO2 values where detailed have been determined via mass spectrometry.  Portable FiO2 
meters were used in this work rather than a mass spectrometer as it is large, subject to 
interference from water vapour and unavailable in many establishments (including 
Papworth.)  The gas method historically had errors in recording patient data so reverse 
Fick was popular.  However, reverse Fick M O2 is calculated from multiple calculations 
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encompassing correction factors, all of which could add error to the overall result.  The 
gas method was chosen for this work as the margins of error were considered less and the 
methodology suited the oxygenator. 
 
M O2 calculations were used alone with the exception of Visser and de Jong (1997) and 
Segers et al (2001).  M O2 provides values of total oxygen uptake across the membrane 
from gas phase to blood phase.  Oxygen diffusion is dependent on the concentration 
gradient between gas and blood phases with increased transfer over larger gradients.  
Comparison of oxygen diffusion in changing conditions cannot be made with the M O2 
equation alone.  Visser and de Jong (1997) devised an equation to measure the driving 
force needed to transfer 1ml O2 per minute based on the partial pressure difference of O2 
in the gas and venous blood phases.  Segers et al (2001) equated the oxygen transfer to the 
pressure gradient between the gas phase and resultant PaO2.  These were both non 
standard variations.  Researchers have measured DO2 and DCO in humans for over a 
hundred years (Bohr 1909, Krogh 1915 and Hughes and Bates 2003).  Piiper and Scheid 
(1980) devised an equation (DO2) where oxygen uptake is adjusted for the concentration 
gradient between „alveoli‟ and blood phases thus facilitating comparison of oxygen 
transfer in changing conditions.  Lilienthal et al (1946) divided oxygen uptake by the 
membrane oxygen partial pressure difference determined from the alveolar and mean 
capillary oxygen tensions.  Both Lilienthal and Piiper equations were incorporated in this 
data evaluation to give comparative oxygen uptake analysis.  
 
CO2 transfer is less widely published as in clinical practice oxygen delivery is more 
important.  CO2 is more soluble and readily transferred across a membrane than O2.  Few 
papers have cited equations for CO2 transfer in the membrane oxygenator.  Of these 
publications, M CO2 is calculated using a version of Fick‟s principle (Gourlay et al 1990, 
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Visser and de Jong 1997, Niimi et al 1997, Kawahito et al 2001 and 2002, Karimova et al 
2005) or a gas method (Van Meurs et al 1991, Kawak et al 1991, Vocelka et al 1993 and 
1997, Griffiths et al 1994, Beckley et al 1996).  The commonly used equation for M CO2 
reflecting Fick‟s principle is: 
 
QCaCOCvCOMCO  )(4.22 222  
 
Where M CO2 = CO2 uptake (ml/min) 
22.4 = conversion factor from mmol to ml 
C v CO2 = content of CO2 in venous blood (mmol/l) 
CaCO2 = content of CO2 in arterial blood (mmol/l) 
Q  = blood flow (ml/min) 
 
The CO2 content of the arterial (CaCO2) or venous (C v CO2) blood is calculated from the 
following equation: 
 
)03.0( 232 PCOHCOTotalCO   
 
Where TotalCO2 = total CO2 in the blood (arterial or venous) (mmol/l) 
HCO3 = Bicarbonate concentration in the blood (mmol/l) 
 0.03 = solubility coefficient of CO2 in plasma (mmol/l/mmHg) 
 PCO2 = partial pressure of CO2 in the arterial or venous blood (mmHg) 
 
M CO2 calculated using the gas method takes the expired CO2 fractional concentration 
multiplied by the gas flow.  These studies calculated the removal rate of CO2 from the 
blood so the inspired ventilating gas was void of CO2. i.e. 
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FFeCOMCO  22   
 
Where M CO2 = CO2 uptake (ml/min) 
FeCO2 = expired fractional CO2 concentration  
 F = gas flow (ml/min) 
 
The deoxygenator was being used to actively add CO2 throughout this continuously 
running circuit.  The gas method of M CO2 would involve determining the inspired and 
expired CO2 concentration difference multiplied by gas flow.  Anaesthetics commonly use 
infrared technology for analysing expired CO2 concentrations which could be adapted for 
the membrane oxygenator.  Error in the gas M CO2 method occurs when the inspired gas 
flow does not equal the expired gas flow i.e. the amount of O2 passing into the lungs being 
greater than the amount of CO2 being removed.  Occasionally, a marker gas such as 
helium is utilised to determine patient inspired and expired gas volumes.  The oxygenator 
environment requires higher continuous gas flows for effective gas transfer and this error 
loses significance compared to lung ventilation.  The reverse Fick M O2 calculation 
limitations also apply to the Fick based M CO2 equation.  For consistency, the M CO2 gas 
method would be used with infrared CO2 gas sensors.  DCO2 was calculated from M CO2 
for comparative CO2 transfer under varying conditions using a modification of both 
Lilienthal and Piiper equations. 
 
Literature reviewed shows no previously described simple, compact and continuously run 
circuit designed for gas diffusion extrapolation.  This work sought to create a compact 
circuit comprising one membrane oxygenator to model the lungs and a second membrane 
oxygenator to deoxygenate the blood and model the tissues.  Both oxygenator and 
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deoxygenator would be run in sequence within the circuit continuously for several hours.  
The blood volume would be kept minimal at 1.5-2.0 litres.  Commercially available 
components and blood would be used facilitating reproducibility of the circuit by this and 
other research groups.  The simplicity of the circuit would allow effects of isolated 
experiments on gas diffusion data to be observed.   
 
 
1.3  Isoflurane Use in Cardiopulmonary Bypass  
 
1.3.1 Isoflurane Anaesthesia 
Isoflurane is a clear, colourless volatile anaesthetic used to induce and maintain 
anaesthesia by depressing the central nervous system.  It acts on receptors of the nervous 
system but its specific mode of action is unclear.  Isoflurane is within the halogenated 
anaesthetic group being halogenated with fluorine and chlorine (Figure 1.1).  Isoflurane 
has a mildly pungent ether-like odour.   
 
Patients are administered Isoflurane via a vaporiser through the ventilator inspired gas.  It 
rapidly passes across the lungs into the blood.  In 4-6 minutes, arterial blood 
concentrations are 50% of the inspired concentrations due to the low solubility of 
Isoflurane in blood and tissues.  This aids a rapid onset of anaesthesia.  Inspired induction 
concentrations are 0.5% and anaesthetic maintenance 1.0-2.5% with supplemental doses 
of muscle relaxants (Rhodia NZ Ltd 1999).  Isoflurane is rapidly cleared from the blood 
once terminated.  The majority of the Isoflurane is expired unchanged via the lungs.  Its 
poor solubility means little Isoflurane is metabolised (0.2%) with small amounts of 
metabolite (trifluoracetic acid) being detected in urine.   
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Isoflurane can be used as an antihypertensive (Alston 1989).  Hypertension can be 
managed using other antihypertensive drugs such as sodium nitroprusside but these can 
cause tachycardia and subsequent rebound hypertension.  Isoflurane decreases 
hypertension by reducing peripheral vascular resistance with minimal cardiac depressant 
effects. 
 
 
 
 
Figure 1.1 Chemical structure of Isoflurane (source; Anaesthesia UK). 
 
Anaesthesia is maintained by volatile agents or IV drug infusions.  In cardiothoracic 
surgery, IV anaesthetics are commonplace but volatile anaesthetics have remained 
popular.  Use of cardiopulmonary bypass during cardiothoracic surgery leads to altered 
pharmacokinetic effects of IV drugs (Gedney and Ghosh 1995) and subsequent clearance 
due to haemodilution, hypothermia and changes in visceral perfusion (Marks 2003).  Poor 
solubility of volatile anaesthetics limits metabolism and renal elimination so they are not 
subjected to the same pharmacokinetic considerations of IV anaesthetics.  Some 
establishments combine IV and volatile anaesthetic use to ensure adequate anaesthesia is 
maintained.   
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During cardiopulmonary bypass, the lungs are deflated to avoid obscuring the surgeon‟s 
field.  Isoflurane administration via the lungs is not possible and so many hospitals 
administer Isoflurane through the membrane oxygenator component of the bypass 
machine.  Isoflurane is added via the inlet gas lines connected to the membrane 
oxygenator.  The volatile agent passes down the concentration gradient across the 
membrane to the patient‟s blood.  Once Isoflurane is terminated the fresh gas flowing 
through the membrane oxygenator aids elimination from the blood via the reverse 
gradient. 
 
1.3.2 Isoflurane and Membrane Oxygenators 
Isoflurane and other volatile agents have been studied in older „bubble‟ types of 
oxygenators (Price et al 1988, Henderson et al 1988, Nussmeier et al 1988 and 1989).  
This literature review encompasses “Isoflurane and membrane oxygenators”.  Most 
manufacturers of membrane oxygenators warn against the use of volatile anaesthetic 
agents through the devices as they have not tested their products for gas transfer and 
device integrity in the presence of such drugs. 
 
There have been concerns regarding the ability to deliver adequate levels of anaesthetic to 
the patient via membrane oxygenators.  The membrane material may provide resistance to 
Isoflurane transfer.  Subsequently, in vitro and in vivo studies have been conducted to 
investigate anaesthetic transfer in membrane oxygenators.  Loomis et al (1986) 
investigated the transfer of Isoflurane across the Cobe membrane oxygenator in relation to 
its hypotensive properties and subsequent adverse effect of EEG suppression.  Patients 
were administered inspired Isoflurane concentrations of 1.5 to 3.0% which yielded 
adequate arterial blood concentrations (36.6 to 84.4µg/ml) indicating the ability of 
Isoflurane transfer in microporous polypropylene membranes.  Further studies examine 
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the wash-in and wash-out durations of Isoflurane in membrane oxygenators (Henderson et 
al 1988, Stern et al 1989, Hickey et al 1996, Lockwood et al 1999 and Wiesenack et al 
2002).  Anaesthetic transfer was verified while gaining knowledge of the duration taken to 
establish adequate blood levels for anaesthesia and the time needed for clearance.  
Isoflurane concentrations increase rapidly within a few minutes of administration followed 
by a slower increase to equilibrium.  The reverse is seen in the wash-out period after the 
vaporiser was turned off.  Isoflurane t½ was quoted as 18.8 minutes (hypothermia) 
(Loomis et al 1986), 14.9 minutes (hypothermia) and 12.2 minutes (warm) (Henderson et 
al 1988).  Wash-in and wash-out times can be influenced by the gas flow rate through the 
device and the type of study.  In vitro studies are not subjected to distribution of Isoflurane 
in tissues, such as muscle and fat, seen in in vivo studies.  Membrane material can affect 
Isoflurane transfer where diffusion type membranes constructed from poly-(4-methyl-1-
pentene) material (Wiesenack et al 2002, Philipp et al 2002) or silicone (Stern et al 1989) 
showed limited transfer of Isoflurane.  They demonstrated a limited loss of Isoflurane 
from the gas flow and poor blood levels being achieved.  The diffusion type membranes 
are not microporous and are considered more biocompatible due to the lack of gas/blood 
interface.  Therefore diffusion of Isoflurane is subject to solubility, concentration gradients 
and gas permeability of the membrane material.  These studies have shown that the 
membrane material plays a fundamental role in Isoflurane transfer.  For this circuit, the 
microporous polypropylene membrane oxygenator that has proven Isoflurane transfer 
properties (Yang et al 2004, Liu and Dhara 2005) was used.  This type of membrane is 
commonly used clinically so effects of Isoflurane on oxygen transfer will be reflective of 
clinical practice. 
 
Halogenated anaesthetic agents can damage the polycarbonate housing of membrane 
oxygenators by weakening the plastic after spillages (Maltry and Eggers 1987, Cooper and 
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Levin 1987 and Walls et al 1988).  Isoflurane effects on the structure and efficiency of the 
membrane within the oxygenator could impact on gas transfer.  Crosbie et al (1998) 
studied polypropylene fibres of the Maxima Plus membrane oxygenator exposed to 
concentrated Isoflurane for 3 hours or one week.  Membrane fibres examined via light 
microscopy showed no change in structure or integrity.  Lanquetot (2005) evaluated 634 
patients undergoing cardiopulmonary bypass with Isoflurane anaesthesia concluding no 
affects of Isoflurane on the membrane.  Neither of these studies quantified O2 transfer to 
support this conclusion.  Muhle et al (2001) determined the effects of Isoflurane on O2 
transfer in the membrane oxygenator.  The in vitro circuit had a preconditioning venous 
system and a single pass through the test microporous polypropylene membrane 
oxygenator (Affinity).  Experimental design included varying gas flows, O2 tensions and 
Isoflurane concentrations but had a constant blood flow of 2 l/min.  The O2 transfer 
calculation was not detailed.  Muhle concluded that O2 transfer in the presence of 
Isoflurane (1, 3 and 5%) was not significantly different to baseline data.  The major 
limitation of this study was the single-pass circuit design with a subsequent run time of 30 
seconds.  Lockwood et al (1999) demonstrated up to five minutes for equilibrium of 
Isoflurane between gas and blood phases.  The wash-in and wash-out studies reviewed 
have shown similar findings with blood concentrations rising to a plateau over the first 
few minutes of administration (Henderson et al 1988, Hickey et al 1996 and Wiesenack et 
al 2002).  A run time of 30 seconds was not considered adequate or clinically 
representative. 
 
Literature demonstrates an understudied area of research regarding the effect of Isoflurane 
on O2 transfer in the microporous polypropylene membrane oxygenator.  Despite this the 
practice of administering volatile anaesthetic agents via the membrane oxygenator is still 
common practice today.  This work was designed to evaluate the effects of Isoflurane on 
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O2 transfer in the membrane oxygenator and the effects on the oxygen dissociation curve 
(ODC).  The circuit would be designed to enable longer and continuous running times for 
each experimental change to allow equilibrium between the gas and blood phases to take 
place.    It is hoped that O2 transfer data from this study will add clarification to the current 
clinical practice. 
 
 
1.4 Nitric Oxide 
 
1.4.1 What is Nitric Oxide? 
Nitric oxide (NO) is a colourless gas also known as nitrogen monoxide.  NO gas is 
relatively safe within the therapeutic range of 1-80 ppm, with a half-life of 15-30 seconds 
in air.  High NO concentrations (5,000 to 20,000 ppm) exert toxic side effects such as 
pulmonary oedema and methaemoglobinemia.  Methaemoglobin is formed when Hb binds 
NO in the presence of oxygen causing the iron atom to become ferric (Fe
3+
) rather than the 
ferrous (Fe
2+
) state.  Methaemoglobin cannot bind and release oxygen affecting the 
oxygen carriage of blood.  Conversion of methaemoglobin back to haemoglobin occurs 
via the NADH-dependent enzyme methaemoglobin reductase (diaphorase I).   
 
NO undergoes spontaneous oxidation to form nitrogen dioxide (NO2) in oxygen rich 
environments.  NO2 is a pulmonary irritant, so exposure should be limited to 5 ppm 
(Weinberger et al 2001).   NO gas administered via a patient ventilation system is at risk 
of forming NO2 if the inspired oxygen concentration is high and the dwell time sufficient 
(Sokol et al 1999).   To limit NO2 formation, NO (<1000 ppm) is mixed with N2 in 
cylinders.  NO is added into the ventilation system close to the patient and mixed with 
oxygen only during administration.  NO2 formation is monitored throughout NO therapy. 
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NO is biologically important as the 'endothelium-derived relaxing factor'.   Blood vessel 
endothelium (inner lining) uses NO to signal the surrounding smooth muscle to relax, 
resulting in vasodilation and increased blood flow.  In lungs, NO regulates pulmonary 
vascular resistance by governing respiratory smooth muscle.  NO has other biological 
functions such as inhibiting platelet adhesion to the vascular endothelium which can be 
extended to protect platelets during extracorporeal circulation.  In long-term membrane 
oxygenator circuits, platelets can be activated by the artificial surface leading to adhesion 
and aggregation on the membrane.  This results in post operative hemorrhage due to low 
platelet counts (thrombocytopenia).  Trans-membrane NO (20 ppm) therapy has 
demonstrated reduction in thrombocytopenia and increased platelet reactivity during in 
vitro extracorporeal circulation (Keh et al 1999).  Additionally, NO has anti-inflammatory 
effects of inhibiting leukocyte adhesion to vascular endothelium.   
 
Inhaled NO is used therapeutically to treat pulmonary hypertension in neonates with 
congenital heart defects or meconium aspiration and in adults with Adult Respiratory 
Distress Syndrome (ARDS) (Beck et al 1999).  Pulmonary hypertension can cause right 
ventricular dysfunction compromising cardiac output.  Systemic treatment of pulmonary 
hypertension (nitroglycerin or nitroprusside) results in pulmonary vasodilation but this 
increases blood flow through non-ventilated alveoli.  Pulmonary capillary blood is 
exposed to anoxic alveoli increasing perfusion-ventilation mismatching.  Additionally, 
these drugs result in systemic vasodilation which may be undesirable.   Inhaled NO is 
distributed throughout ventilated alveoli causing dilatation of the pulmonary blood vessels 
partaking in gas exchange.  NO that passes into the blood is inactivated once bound to 
haemoglobin limiting the effects on the systemic circulation. 
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Recently NO has emerged as an alternative gas to CO for lung function testing in 
pulmonary disease.    
 
1.4.2 DL 
Diffusing capacity measurement (transfer factor) of the lungs (DL) is an important 
diagnostic tool to determine lung disease in patients.  The current lung function testing 
protocols utilise carbon monoxide gas (CO), as it is highly reactive with haemoglobin and 
is diffusion limited.  The diffusing capacity test does not use oxygen (DLO2) as it is a 
perfusion limiting gas, influenced by inspired oxygen concentrations and pulmonary blood 
flow (Vc).  DLO2 calculation is simplistic but the end pulmonary capillary oxygen partial 
pressure (P c O2), known as back tension, is difficult to ascertain. 
 
     
   
         
 
 
Where DLO2 is the lung diffusing capacity for oxygen, M O2 is oxygen uptake in ml/min, 
PAO2 is the alveolar partial pressure of oxygen (mmHg) and P c O2 is the mean pulmonary 
capillary oxygen partial pressure (mmHg). 
 
CO was used to demonstrate that gas transfer in lungs was by passive diffusion from the 
alveoli to the pulmonary capillary blood (Krogh 1915).  It is an alternative gas to oxygen 
in lung function testing as the back tension of carbon monoxide is considered zero (with 
the exception of smokers) due to tight binding of CO to Hb.  The equation for DLCO is a 
simplified version of DLO2. 
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Where DLCO is the lung diffusing capacity for carbon monoxide, M CO is uptake of 
carbon monoxide in ml/min and PACO is the alveolar partial pressure of carbon monoxide 
(mmHg). 
 
Roughton and Forster (1957) demonstrated that DLCO comprises both alveolar membrane 
diffusion and the reaction of CO with pulmonary capillary blood.  Diffusion resistance to 
DLCO is expressed as the reciprocal (1/DL).   
 
 
    
 
 
    
 
 
      
 
 
Where DLCO is the lung diffusing capacity for carbon monoxide, DMCO is the membrane 
diffusing capacity, θCO is the specific transfer conductance of blood for CO and Vc is 
pulmonary capillary volume (ml).  Transfer of gas from alveolar air to blood encompasses 
several separate stages.  Firstly, gas in alveolar air must transfer across the alveolar-
capillary membrane to the blood.  Gas passes through plasma to the RBC where it crosses 
the RBC membrane before passing through the RBC interior for binding with Hb.  
Roughton and Forster‟s equation compartmentalised these stages into two areas; the first 
part of the equation details diffusion limitation and the latter part details CO reaction with 
blood.   
 
An alternative gas for lung function testing has emerged as nitric oxide (NO) (Guenard et 
al 1987, Borland 1989).  NO has stronger binding to haemoglobin, is independent of 
inspired oxygen concentrations and its reaction rate with haemoglobin is effectively 
infinity.  NO has not replaced CO in lung function testing due to issues regarding the 
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length of breath holding, sensitivity of the NO analysers and the potential toxicity of NO.  
The lung diffusing capacity of NO (DLNO) is calculated in the same way as DLCO.  
Roughton and Forster‟s equation (1957) has been applied to DLNO.  Due to the rapid and 
irreversible nature of binding between NO and Hb, θNO was considered infinite.  This 
being the case, DLNO would equal DMNO (Guenard et al 1987).  Consistent with this, 
Heller and Schuster (1998) reported that the diffusion element (DMNO) accounted for 98 
±6% of the overall resistance to alveolar-capillary NO transfer.   
 
Other groups have questioned the importance of the RBC on DLNO suggesting that DLNO 
is not just DMNO but also includes diffusion of NO within the capillary plasma and the 
RBC (Borland et al 2006 and 2010).  Sakai et al (2008) investigated the affects of the 
RBC membrane and interior on DNO by stopped-flow and computer simulation of NO 
uptake in Hb vesicles with different intracellular Hb concentrations.  They determined that 
the vesicle membrane provided no resistance to DNO as vesicles containing low Hb 
concentrations had similar DNO to acellular Hb. They concluded that the RBC interior 
provided resistance to DNO as vesicles with a high Hb concentration had a reduced DNO.  
The Hb at the membrane surface bound NO providing a barrier to further NO transfer 
within the vesicle.  Sakai et al (2008) work did not include the extracellular diffusion 
barrier resistance.  Using Hb vesicles as representation of RBCs is a limitation of their 
study.  Vaughn et al (2000 and 2001) used competition experiment methodology with 
mathematical modelling comparing free Hb to RBCs exposed to NO donors in solution.  
By providing NO uniformly throughout the test solution coupled with the mixing method, 
the influence of an extracellular diffusion barrier was removed, attributing resistance to 
DNO by the RBC membrane or intracellular resistance.  Mathematical modelling assumed 
that RBCs are spherical or planar, RBCs are uniformly spaced and NO donor 
concentrations do not vary spatially.  Liu et al (1998 and 2002) previously determined red 
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cell resistance to DNO, sought to test theories published by Vaughn et al (2000).  Using 
similar competition experiments with mathematical modelling and low RBC 
concentrations, they determined that the boundary layer does exist in competition 
methodology.  Liu (2002) demonstrated that resistance to DNO at varying haematocrit 
was attributed to the unstirred boundary layer of the RBC.   
 
Literature review relating to DNO resistance exerted by the RBC has revealed an 
understudied area with equivocal conclusions.  Much of the published work utilises 
computer modelling techniques (Vaughn et al 2000 and 2001, Liu 2002, Sakai et al 2008) 
which are based on assumptions that may lead to inaccuracies in results and conclusions 
obtained.  Using the model oxygenator circuit, resistance of the RBC to DNO can be 
directly measured and assessed in a simulated, continuously running circuit.  Experimental 
design can be varied by haemolysis or addition of free Hb (such as a haemoglobin-based-
oxygen-carrier) to determine the role of the RBC membrane, RBC interior and the RBC 
surroundings in providing resistance to DNO.  This novel approach will contribute to the 
battery of equivocal results in determining the role of the RBC in resistance to DNO.   
 
 
1.5 Haemoglobin-Based-Oxygen-Carriers (HBOC) and Oxyglobin 
 
„Oxygen therapeutics‟ is used to describe a transfusion fluid that mimics human blood's 
oxygen transport ability.  Oxygen therapeutics is sub-classified into two categories based 
on the mode of oxygen transportation.  Perfluorocarbon (PFC) based oxygen therapeutics 
are short term man-made emulsions that carry oxygen, and haemoglobin-based-oxygen-
carriers (HBOCs) are made of modified haemoglobins.  In this work, the only 
commercially available oxygen therapeutic (Oxyglobin) was used, an HBOC which would 
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facilitate comparison to blood being haem based.  Literature review was solely focused on 
HBOCs.  Oxyglobin was to be added to the circuit blood to determine if free haemoglobin 
enhances DNO, while establishing RBC resistance to DNO.  
 
1.5.1 What are HBOCs? 
HBOCs are extracted haemoglobin (Hb) in solution that has the ability to transport oxygen 
to the tissues.  HBOCs were developed as an alternative to donated packed red blood cells 
with lengthy shelf-life (up to 36 months compared to RBC 42 days) and ambient storage 
conditions, benefitting pre-hospital and operational theatre survival.  Development of 
HBOCs could lead to a sustainable, infection free blood source used in circumstances 
where blood is not readily available, or where blood transfusion poses a serious infection 
risk.  In some parts of the world, donated blood carries high risk of disease transmission 
i.e. many countries in sub-Saharan Africa have an adult HIV-positive prevalence of up to 
30%.  Estimates suggest that at least 25% of transfused blood in Africa is not screened 
leading to a high HIV transmission rate (Jenkins 2007).  The allogenic nature of Hb would 
eradicate the need for meticulous blood grouping and the associated mortality and 
morbidity risk.  The small size of Hb compared to RBCs allows oxygenated blood to 
travel through capillaries where RBCs cannot pass thus theoretically increasing tissue 
perfusion and oxygen availability in ischaemic areas. 
 
Hb is a tetrameric structure comprising two alpha and two beta polypeptide chains each 
bound to a haem unit.  Each unit of haem can bind one molecule of oxygen.  As each 
oxygen molecule is bound to a haem unit, the tetramer undergoes conformational change 
increasing affinity for the next oxygen molecule. The sources of Hb used to create HBOCs 
include human, bovine and swine. Alternative recombinant production has yielded Hb 
cultured from bacteria (Escherichia Coli), yeast (Saccharomyces cerevisiae), tobacco 
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plant (Nicotiana tabacum) or sea lugworm sources (Arenicola marina) (Standl 2004, 
Lowe 2006 and Clark 2007).  Extracted Hb is modified to produce oxygen carrier 
molecules with desirable characteristics such as altered oxygen affinity and increased 
intravascular shelf-life.   
 
The initial extracted Hb undergoes an extensive modification process to enable the HBOC 
to have desirable characteristics (Figure 1.2).  Stroma free Hb has demonstrated a high 
affinity for oxygen with poor offloading in the tissues, due to loss of 2,3-DPG and 
dissociation of the Hb tetramer into diamers.  The dissociated α and β chains are readily 
excreted by the kidneys reducing intravascular half-life.  To compare, the P50 of whole 
blood is 26.5mmHg but in 2, 3-DPG depleted stroma free Hb the P50 is 12-14mmHg 
(Grethlein et al 2007).  To minimise renal excretion of Hb, researchers cross-link the α or 
β chains with covalent bonding which stabilises the haem tetramer unit e.g. diaspirin 
connection.  Hb tetramer stabilisation also increases the P50.  Examples of cross-linked 
HBOCs are Hemolink and HemAssist.  Another technique of chemically modifying the 
Hb at the 2, 3-DPG site can also increase the P50 (Chen et al 2009). 
 
Poor intravascular half-life of HBOCs can be further improved by increasing the 
molecular size of the covalently bonded Hb tetramer by conjugation techniques.   Hb is 
conjugated with a biocompatible polymer such as dextran,  polyethylene glycol or 
gluteraldehyde, increasing  the molecular weight e.g. Hemospan.  Alternatively, linking 
the individual covalently bonded Hb tetramers creates polymerized Hb of greater 
molecular weights.  Four or five Hb tetramers can be polymerised with substances such as 
gluteraldehyde e.g. PolyHeme, Hemopure, Oxyglobin and Oxyvita.   
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Figure 1.2 Schematic diagrams of HBOC production processes (Brown University 
2005).  Cross-linking provides stabilisation of the Hb tetramer from dissociation to 
diamers. Conjugation of the stabilised tetramer increases molecular size and intravascular 
life.  Similarly, polymerisation of several Hb tetramers further increases molecular size.  
Encapsulation would be the ultimate HBOC process. 
 
 
The ultimate HBOC method would involve Hb encapsulation recreating the natural 
membrane characteristics of native RBCs.  2, 3-DPG and reduction enzymes could be 
added to manipulate oxygen affinity and delay oxidation of the Hb to methaemoglobin.  
This methodology is likely to have a good intravascular half-life.   
 
1.5.2 Brief history of HBOCs 
In 1916, Wilson Sellards and George Minot first attempted blood transfusion giving Hb in 
saline to anaemic patients but they developed nephrotoxicity due to transfusion impurities 
(Lowe 2006 and Clark 2007).  World War II stimulated Amberson et al (1949) to 
administer bovine Hb solution to animals and a human Hb solution to a postpartum 
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haemorrhage patient who subsequently died of renal complications.  This approach was 
abandoned with workers believing that RBC stroma deposits in the renal tubules and free 
Hb causes vasoconstriction, resulting in reduced renal blood flow, renal failure and 
hypertension.   Rabiner et al (1967) demonstrated that stroma-free Hb had no renal effects 
when infused into dogs.   
 
Diseases such as Human-Immunodeficiency-Virus (HIV) in 1985 and Creutzfeldt-Jakob-
Disease (CJD) have added enormous interest into blood substitutes.  In 1985, the US 
military and Baxter Healthcare Corp created the HBOC HemAssist.  Baxter Healthcare 
Corp continued with the first HBOC clinical trials (Chen et al 2009) despite animal study 
results being discouraging.  The phase III clinical trials were suspended in 1998 due to 
increased predicted mortality rates in trauma patients receiving HemAssist.  Baxter 
Healthcare Corp is now developing Optro. 
 
In 1998 FDA, and in 1999 EU, approval was granted for Biopure‟s Oxyglobin for 
treatment of anaemia in dogs.  In 2001, approval was granted from South Africa‟s Medical 
Control Council (MCC) for Hemopure (Biopure Corp) use solely for anaemic surgical 
patients since the HIV infection rate amongst the general population and hence donated 
blood was high.  However, evidence against the use of blood substitutes including 
Hemopure (Natanson et al 2008) halted use of Hemopure by the MCC.  In 2009, Biopure 
Corporation ceased operation and sold remaining Oxyglobin stocks to its distributors. 
 
Sangart was founded in 1998 to develop MP4OX (Hemospan).  Phase II and III trials 
continue (2002-2010) with expected US Navy collaboration. 
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PolyHeme ™ (Northfield Laboratories) followed the Vietnam War for use in trauma and 
has been studied in a hospital based trauma trial (Gould et al 2002) and a multicentre pre-
hospital phase III trauma trial (http://www.northfieldlabs.com/polyheme.html accessed 
29
th
 March 2010).  A phase II multicentre pre-hospital trauma trial completed in June 2006 
was surrounded by controversy over the patient selection.  The unpublished results 
showed unfavourable survival in the PolyHeme group compared to usual resuscitation 
(13.4% vs. 9.3%).  Following removal of participants falling outside protocol 
requirements, the data was published showing 11.1% mortality in the PolyHeme group 
with an increased risk of myocardial infarction (3% vs. 1% control) (Moore et al 2009).  
In 2009, the FDA denied approval of PolyHeme due to the associated risks prompting 
Northfield Laboratories to close. 
 
OxyVita Inc was formed in 2003, producing a new generation of polymerised 
haemoglobin (OxyVita ®) reported by the company not to elicit the vasoactivity seen with 
other HBOCs.  Being available as a powder formulation allows reconstitution in remote 
situations.  These products are in the preclinical testing phase (www.oxyvita.us accessed 
14
th
 May 2010). 
 
To date no HBOC has achieved FDA approval for human clinical use due to 
complications (pulmonary and vascular hypertension, gastrointestinal disturbances) and 
increased incidences of MI and strokes.  Safety and efficacy guidelines were drafted by 
the FDA (FDA, 2004) for future HBOC testing.  Research continues to identify the 
mechanism of these complications and thus develop HBOCs. 
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1.5.3 Current Clinical Situation and Problems Limiting Their Use 
Several HBOCs have progressed to phase II and III clinical trials; HemAssist, Hemolink, 
Hemospan, Hemopure and PolyHeme have published trials.  HemAssist, Hemolink, 
Hemopure and PolyHeme have since been abandoned but Hemospan was undergoing 
trials during 2010 (www.sangart.com/newsroom accessed 8
th
 December 2010).  No 
approval for clinical use has been obtained from the FDA to date. 
   
Review of the phase II and III trials have shown an increased risk of MI and death 
associated with HBOC use (Natanson et al 2008).  The study reviewed trials 
encompassing the HBOCs Hemolink, PolyHeme, HemAssist, Hemopure and Hemospan 
in surgical, trauma or stroke patients.  All HBOCs have had incidences of MI or mortality 
in study groups compared to controls.  Despite the high risk patient selection, HBOCs 
contributed to detrimental outcomes with a stated 30 % increase in overall mortality and a 
2.7 fold increase in MI (Natanson et al 2008) however the data reviewed was limited by 
the availability of publications.  This publication was associated with withdrawal of 
HBOC trials as the risks of MI and mortality raised concerns over enlisting low risk 
patients to studies.   
 
The mechanism for HBOC associated MI or stroke has been linked to HBOC related 
vasoconstriction.  Yu et al (2009) suggested that coronary vasoconstriction reduces 
myocardial blood supply resulting in MI.  HBOC transfused patients have reported 
gastrointestinal side effects, abdominal and chest pain which was linked to 
vasoconstriction (Winslow 2003). Two principle mechanisms for causing vasoconstriction 
have been cited; nitric oxide (NO) scavenging or increased oxygen delivery.   
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NO scavenging occurs when the HBOC binds endothelial nitric oxide, a natural 
vasodilator (Irwin et al 2008).  It is hypothesised that HBOCs have a high affinity for NO 
which determines the hypertensive effect (Doherty et al 1998, Olson et al 2004).  
Tetrameric Hb can extravasate through the vasculature where it scavenges NO from 
smooth muscle cells (Tsai et al 2006).  Low molecular weight HBOCs have resulted in 
vasoconstriction regardless of oxygen affinity supporting extravasation (Hare et al 2006).  
Increased molecular size could reduce extravasation of the HBOC (Tsai et al 2006, 
Baudin-Creuza et al 2008, Hu and Kluger 2008).  To further support NO scavenging, 
Doherty et al (1998) synthesized recombinant haemoglobin with genetic alteration of the 
haem pockets which showed reduced affinity for NO.  Mice deficient in the enzyme NO 
synthase did not exhibit hypertension when transfused with HBOC compared to normal 
mice (Yu et al 2009).  Infusion of sodium nitrite, a metabolite of NO, can block the 
vasoconstrictive effects exerted by HBOC transfusion (Yu et al 2009, Arnaud et al 2010).   
Inspired NO treatment prior to or during HBOC administration can reduce 
vasoconstrictive effects in mice and lambs (Yu et al 2008, Yu et al 2009).  Research by 
Yu et al has given a convincing argument to support NO scavenging as the cause of 
HBOC related vasoconstriction.  Secondary to NO scavenging are two other theories.  
Desaturated RBCs release ATP (vasodilator mediator) simulating NO production but 
HBOC release of O2 results in less RBC desaturation with reduced ATP release and 
increased vasoconstriction (Cole et al 2009).  Their study associated ATP release to the 
oxygen affinity of HBOCs.  Alternatively, haemoglobin reduces nitrite to NO which 
compensates for reduced endogenous NO vasodilation in hypoxia but HBOC replacement 
of RBC will limit this secondary NO production (Gladwin et al 2009).    
 
The alternative theory for HBOC induced vasoconstriction involves elevated oxygen 
arteriolar partial pressures which stimulate autoregulation resulting in arteriolar 
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vasoconstriction (Winslow 2003, Cole et al 2008).  RBC travel centrally within the vessel 
lumen creating a boundary effect for O2 transfer whereas the small size of HBOCs 
increases O2 release nearer the vessel wall.  This coupled with a weak affinity for oxygen 
i.e. an elevated HBOC P50, results in hyperoxaemia resulting in autoregulatory responses.  
HBOCs with low P50 and increased molecular weight are beneficial in reducing O2 
delivery (Rohlfs et al 1998, Winslow et al 1998, McCarthy et al 2001, Tsai et al 2003, 
Cole et al 2007).  Newer generation HBOCs processed with low P50 values shift the ODC 
leftwards, decreasing oxygen offloading thus targeting ischaemic tissue oxygenation 
(Hemospan and PolyHeme).  Sangart (Hemospan) claim that their product is not 
vasoactive (Vandegriff et al 2003, Winslow et al 2005).  PolyHeme was associated with 
pulmonary hypertension with resultant reduction in cardiac output (Yu et al 2010) and 
increased risk of MI in clinical trials (Moore et al 2009).  Natanson‟s study (2008) 
incorporated data from HBOCs with varying P50 (Hemospan and PolyHeme having lower 
P50 and Hemopure, Hemolink and HemAssist having higher P50) indicating that P50 does 
not influence HBOC vasoconstriction, casting doubt on this theory. 
 
Current research favours NO scavenging theories for HBOC related vasoconstriction.  
HBOCs are essentially free Hb, so the NO scavenging potential coincides with the debate 
that RBC integrity provides resistance to DLNO.  HBOCs are thought to scavenge NO 
from the vasculature or by extravasation of the vessel wall, manifesting as 
vasoconstriction, yet the affinity of an HBOC to bind NO has not been quantified.  
Contrastingly, in DLNO research, RBC integrity appears to provide resistance to DNO, but 
the mechanism has not been established.  The two areas of research, blood substitutes and 
DLNO, are dissimilar yet the debate regarding RBC/Hb binding NO has implications in 
both areas.  Development of HBOCs may provide a better understanding of RBC integrity 
in DLNO.     
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Yu et al (2008, 2009) described the use of inhaled NO prior to HBOC administration to 
offset vasoactivity.  Therapeutic NO is limited in cardiopulmonary bypass during 
cardiothoracic surgery as the lungs are deflated.  NO administration would be via the 
membrane oxygenator within the cardiopulmonary bypass circuit.  HBOCs remain 
structurally stable and efficacious for oxygen delivery during extracorporeal circulation 
for 5 hr at 2 l/min flow (Neya et al 1998).   For this research, NO transfer across a 
membrane oxygenator within an experimental circuit was investigated and the NO binding 
potential of a HBOC (Oxyglobin) assessed.  Concurrently, RBC resistance to DNO was 
investigated via Oxyglobin addition to the circuit blood.  The impact of NO and 
Oxyglobin on oxygen transfer including the ODC were investigated.  No previous study 
quantifies NO uptake by an HBOC or explores the impact of NO and HBOC on the ODC.  
Oxyglobin was the only licensed HBOC at the time of the experimental phase, licensed for 
canine use allowing direct comparison of this work to that completed with dogs in 
collaboration with this research. 
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Table 1.1 HBOC information Summary 
This table details the HBOC manufacturers and their products, with information on the 
manufacturing process, oxygen affinity, half-life and shelf-life.  Lastly, the clinical trials 
conducted and the status of the HBOC at the end of 2010 has been included. 
 
Sources: Stollings and Oyen 2006, Oxyglobin licence data (2006). Lowe 2006, Chen et al 
2009. Company website press releases. 
  
Product Company HBOC type P50  t½ Shelf-life Clinical 
Trials 
Status 
PolyHeme  Northfield  
USA 
Pyridoxylate 
Polymerized 
human Hb 
20-22 
mmHg 
24 hr 18 months 
refrigerated 
II and 
III 
Abandon 
Hemopure  Biopure, 
USA 
Polymerized 
bovine Hb 
40 
mmHg 
19 hr ≥36 months 
refrigerated 
or  room 
temperature 
II and 
III 
License 
for SA, 
2001 to 
2008 
Abandon 
Oxyglobin 
(canine) 
Biopure, 
USA 
Polymerised 
bovine Hb 
34 
mmHg 
30-
40 hr 
36 months 
refrigerated 
or  room 
temperature 
License 
for 
anaemic 
dogs, 
1998 to 
date 
Stock sold 
off 
Hemolink  Hemosol, 
USA 
O-raffinose 
cross-linked 
Human Hb 
34 
mmHg 
18 hr ≥12 months 
refrigerated 
II and 
III 
Abandon 
Hemospan Sangart, 
USA 
Conjugated 
Human Hb 
5-6 
mmHg 
24-
36 hr 
 I and II Ongoing  
Optro ™ Baxter 
Healthcare 
Corp 
Cross-linked 
human Hb 
genetically 
modified 
from E.Coli 
 2-19 
hr 
18 months 
refrigerated 
II and 
III 
Ongoing 
OxyVita® OxyVita, 
USA 
Polymerised 
bovine Hb 
Low 
P50 
≥10 
hr 
12 months 
room 
temperature 
or 
estimated 
10 years 
frozen 
Pre-
clinical 
trials 
Ongoing 
HemAssist Baxter 
Healthcare 
corp 
Cross-linked 
human Hb 
32mm
Hg 
6-12 
hr 
≥12 months 
refrigerated 
II and 
III 
Abandon 
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1.6 Aims and Objectives of the Thesis 
 
The aim of this research was to design a compact, continuously running membrane 
oxygenator circuit for evaluation of gas diffusion theories.  The circuit would comprise 
commercially available membrane oxygenators, PVC tubing and equine blood to allow 
reproducibility by this or other groups.  The circuit would undergo a battery of 
experiments designed to validate the circuit and to provide baseline data and trends.  The 
circuit would be used for the following gas transfer experiments. 
 
 The circuit would be used to investigate the effects of Isoflurane on oxygen transfer in 
the membrane oxygenator.  Clinically, Isoflurane anaesthetic is administered via the 
membrane oxygenator of cardiopulmonary bypass circuits against the advice of the 
manufacturers.  There is little data on the effects of Isoflurane on gas transfer in the 
device. 
 The effects of red cell integrity on nitric oxide transfer would be investigated in this 
circuit.  The red cell may provide resistance to nitric oxide transfer which is important 
for lung function tests using nitric oxide.  Experimental design incorporates 
haemolysis and haemoglobin-based-oxygen-carrier (HBOC) addition to test the impact 
of red cell integrity on nitric oxide transfer. 
 The nitric oxide scavenging potential of the HBOC Oxyglobin would be assessed in 
this circuit.  HBOC transfusion results in vasoconstriction which has been associated 
with endothelial nitric oxide scavenging.  This study sought to quantify this 
scavenging potential. 
 
Ethics approval was granted by ARU Research and Ethics Sub-Committee and Papworth 
Hospital Research and Development, as the protocol was deemed to have no material 
ethical issues. 
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Chapter 2: Data Handling 
 
2.1 ODC Data Conversion to Hills Plot 
 
The Hills plot was used to transform the sigmoid curve of the ODC to a straight line plot 
(linearised) with the ability to test for an observed deviation in the ODC from the 
calculation of the P50 (Hill 1910).  For the Hills plot log PO2 was calculated (x axis) and 
plotted against saturation in the form log (S/1-S) (y axis). 
 
                  
 
                  
 
     
 
   
       
    
   
   
      
   
   
 
     
 
   
       
    
   
   
      
   
   
 
P50 can be calculated from the intercept and slope of the Hills plot linear trend line for 
each group i.e. Isoflurane versus no Isoflurane, using the following equation. 
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2.2 Statistical Analysis 
 
The data was computed and calculations made via Microsoft Excel Spreadsheet 
(Microsoft Office 2007 software).  The Excel spreadsheet data was imported into SPSS 
software v.16.0 for statistical analysis. Where quoted, the means have been presented with 
standard deviations (±SD) which will have included inter-run variation with donor blood 
and membrane tolerances, unless stated. 
 
Linear correlations were analysed using linear regression with R
2
 values and statistical 
significance reported.  Curvilinear correlations have been analysed using Spearman test 
for non-parametric data or Pearson test for parametric data with r and p values quoted.   
Mean comparison statistics were carried out using the independent t test with t and p 
values presented.  Data summary tables present „statistical values‟ as R2, r or t,  
corresponding to linear regression, curvilinear correlation or means comparison tests, as 
appropriate. 
 
Effects of an experimental group on the ODC compared to the control blood was 
statistically analysed by first converting the data to a Hills plot (section 2.1).  From this 
linear data a t test could be performed to analyse for shift changes in the presence of the 
experimental treatment compared to the control.   
 
Statistical significance was achieved when the alpha level was ≤0.05.  Specific p=values 
have been quoted unless p=0.000.  In this instance the p value has been classified as 
p<0.001 or p<0.0001 to verify the level of significance. 
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Chapter 3: Circuit Design and Validation 
 
Aims 
 
To devise a compact in vitro continuously running experimental circuit that replicates the 
arterial and venous blood circulation oxygen and carbon dioxide tensions using 
commercially available components.  To run a battery of tests with varying parameters i.e. 
varying blood flow, gas flow, haematocrit, to provide baseline data and trends for this 
circuit.  Subsequently, the circuit could be used for exploring gas transfer hypotheses.  
 
3.1 Setting Up the Circuit Design 
 
The circuit comprises two membrane oxygenators, one acting as the „lungs‟ (termed 
oxygenator) and the other as the „tissues‟ (termed deoxygenator).  Blood is continuously 
pumped around the two devices via PVC tubing passing through a positive displacement 
roller pump (Stockert, Sorin Group, Milano, Italy) that compresses the tubing forcing 
forward blood flow.  Gas transfer occurs via passive diffusion through the microporous 
membrane down the partial pressure gradients.  To create arterialised blood the 
oxygenator is ventilated with oxygen in balanced nitrogen.  Oxygen in the gas will 
passively diffuse across the membrane oxygenating the blood to arterial parameters as it 
passes through the device.  The oxygenator gas, devoid of carbon dioxide, is set at an 
adequate flow rate (5 l/min determined in pilot test) in order for carbon dioxide to diffuse 
from the blood across the membrane into the ventilating gas.  These processes occur 
simultaneously within the oxygenator unit.  The deoxygenator unit ventilating gas 
comprises carbon dioxide in balanced nitrogen utilising the same principles as the 
oxygenator.  Carbon dioxide within the ventilating gas passes across the membrane 
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entering the blood to create venous blood carbon dioxide tensions. The deoxygenator gas, 
devoid of oxygen, is set at an adequate flow rate (5 l/min determined in pilot test) for 
oxygen to diffuse from the blood across the membrane into the ventilating gas.  In order to 
complete the experimental protocol extra gases were added to the oxygenator ventilating 
gas.  Nitric oxide (NO), carbon monoxide (CO) and the inhaled anaesthetic Isoflurane 
were added as appropriate. 
 
3.1.1 Basic Circuit Set-Up 
The circuit described is based on the standard adult cardiopulmonary bypass circuit where 
one membrane oxygenator takes over from the lungs and the pump replaces cardiac 
function.  The deoxygenator in this circuit replaces the patient who ordinarily would be 
the generator of venous blood.  All lines were kept very short to aid the compactness of 
the circuit and to reduce the blood volume needed to run the circuit.  Monitors and 
analysers used for blood gas analysis, blood saturations and gas oxygen concentrations are 
all equipment used clinically. 
 
All hardware and disposables listed in Appendix 1 were required for this circuit set-up. 
PVC tubing can be cut with sterile scissors or a sterile blade using aseptic techniques.   
 
On both of the Cobe Duo Oxygenators with integral hardshell reservoirs (Sorin Group, 
Milano, Italy) the loose Luer Lock connections were tightened.  The ¼” red lockable cap 
by the oxygenator outlet port was closed.  To one of the Cobe Duo membrane oxygenators 
with integral reservoir (designated „deoxygenator‟ and „venous reservoir‟) a length of the 
⅜” PVC tubing was attached to the outlet port of the reservoir (located at the bottom).  
The ⅜” PVC tubing was directed through the Stockert pump raceway checking for correct 
direction of blood flow.  This ⅜” PVC tubing exiting from the Stockert pump outlet was 
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fed downwards towards the second Cobe Duo membrane oxygenator (designated 
„oxygenator‟) and attached to the oxygenator inlet port (top burgundy cap) (Figure 3.1).  
As the circuit only comprised one reservoir, the additional reservoir was removed as it was 
surplus, however the recirculation line from the oxygenator needed to be reattached to the 
venous reservoir.  The ⅜” PVC tubing between the Stockert pump outlet and the 
oxygenator inlet was cut centrally and a ⅜” x ⅜” connector with Luer Lock was used to 
reconnect this tubing.  A pressure dome was screwed on to this Luer Lock (Figure 3.2).  
Another length of ⅜” PVC tubing was attached to the „oxygenator‟ outlet port (lower red 
cap) and cut to length before the other end was attached to the „deoxygenator‟ inlet port 
(upper burgundy cap) (Figure 3.3).  This short section of tubing between the oxygenator 
and the deoxygenator was cut centrally and a ⅜” Cobe Sat/Hct Sensor connector was 
inserted into the tubing (Figure 3.4).   Further ⅜” PVC tubing was connected to the 
„deoxygenator‟ outlet port (lower red cap) and directed half way up towards the central 
inlet port located on top of the venous reservoir. A ⅜” x ½” Luer Lock connector was 
attached onto the end of the ⅜” PVC tubing (that had been cut to length) with a section of 
½” PVC tubing from the connector following through to attach to the venous reservoir 
central inlet port (Figure 3.5).  Calibrated CDI 500 sensors were screwed onto the purge 
lines from both the deoxygenator and the oxygenator before returning to the venous 
reservoir.  The „arterial‟ Cobe Sat/Hct sensor cable was connected to the ⅜” Cobe Sat/Hct 
Sensor connector between the oxygenator and the deoxygenator.  The „venous‟ Cobe 
Sat/Hct sensor cable was connected to the port on the venous reservoir inlet connection 
(Figure 3.6).  The Spectrum Medical M2 „arterial‟ wrap-around sensor was placed on the 
tubing between the oxygenator and the deoxygenator and the „venous‟ wrap-around sensor 
was located on the deoxygenator outlet tubing.   
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Figures 3.1-3.6  Step-By-Step Schematic Representation of the Basic Circuit Set-up.   
 
 
 
Figures 3.1 to 3.6 Step-By-Step Schematic Representation of the Basic Circuit Set-
up. 
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Finally a fluid administration line was added to one of the Luer Lock connections on the 
top of the reservoir and another one was screwed onto the ⅜” X ½” Luer Lock connector.  
This completed the basic circuit set-up. 
 
The ventilating gas tubing needed to be assembled using a series of ¼”x ¼” Luer Lock, 
¼” Y connectors and some ¼” tubing.  For the oxygenator a Y section of ¼” tubing was 
attached to the two gas inlet ports on the device.  A long length of ¼” tubing was cut close 
to the device to incorporate a ¼”x ¼” Luer Lock connector allowing for gas sampling.  
The ¼” tubing was cut further along to facilitate the anaesthetic vaporiser manifold (Isotec 
3, Datex-Ohmeda GE Healthcare, Chalfont Saint Giles, UK).  The final section of ¼” 
tubing was divided using a series of ¼” Y connectors and ¼” tubing to attach to the 
individual air, O2, N2, CO and NO regulators (Figure 3.7).  
   
 
Finally the oxygenator gas line was cut upstream of the anaesthetic regulator to 
accommodate the Teledyne AX300 O2 sensor.  The deoxygenator gas line was made in a 
similar way to the oxygenator line, with a gas sampling port made from a ¼” x ¼” Luer 
Lock connector and connection to 5% CO2 in balanced N2, CO2 and N2 regulators utilising 
a series of ¼” Y connectors.  For both oxygenator and deoxygenator, separate scavenging 
Figure 3.7 Schematic Diagram of the Oxygenator Gas Inlet Tubing. 
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tubing were made using ⅜” tubing and a ⅜” Y connector to allow passive removal of the 
exhaust gases to a safe atmosphere.  Gas sampling of the exhaust gases was facilitated by 
inserting a ⅜” x ⅜” Luer Lock connector into each of the exhaust lines close to the 
individual devices.  The oxygenator exhaust tubing was additionally cut near to the device 
to integrate a second Teledyne AX300 O2 sensor.   
 
The Medtronic heater/cooler unit (Medtronic, Minneapolis USA) outlet water pipe was 
pushed onto the heat exchanger inlet of the deoxygenator.  The heater/cooler inlet water 
pipe was attached to the deoxygenator heat exchanger outlet.  The water lines were 
unclamped and the heater/cooler switched to run, visually checking for a watertight 
connection.  The heater/cooler temperature was adjusted to 37 
◦
C and the heater enabled.  
During the experiments the circulating blood temperature was monitored via CDI 500 
sensors and the heater/cooler adjusted, if necessary, to maintain a circuit temperature of  
37 
◦
C.  
 
 3.1.2 Priming the Circuit 
The term „prime‟ is used to describe the addition of physiological fluid (priming fluid) to 
the circuit in order to displace air. 
 
Two litres of 0.9% sodium chloride (NaCl) was administered into the venous reservoir via 
the fluid administration line attached to the top.  One emptied 0.9% NaCl bag was placed 
onto the other fluid administration line with it clamped off.  The second emptied 0.9% 
NaCl bag was kept for later use.  The Stockert pump was set to a low flow (1 l/min flow 
rate) in order to control the de-airing process.  As fluid moved through the circuit the 
tubing was tapped with a clamp to dislodge bubbles.  Where a connector had been cut into 
the tubing it was gently manipulated to work the tubing further over the connector creating 
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a firm connection.  A 30ml syringe was pushed onto the end of the pressure dome and by 
gently using the plunger of the syringe, air from inside the dome was expelled.  Once 
visually de-aired the syringe was used to set the inner dome membrane to the middle.  The 
syringe was removed and the dome attached to a pressure gauge.  The circuit tubing was 
checked for air by following the flow pathway into the oxygenator, tapping the tubing and 
device to remove air via the purge line.  The connections between the oxygenator and the 
deoxygenator were checked for tightness and air bubbles trapped on the connector edges 
were dislodged.  The deoxygenator was de-aired by allowing expelled air to be vented 
through the purge line.  Finally the return line from the deoxygenator through to the 
venous reservoir was de-aired.   The pump flow was then turned up to 4 l/min to de-air the 
circuit under pressure (<300mmHg).  Once air was no longer seen exiting the oxygenator 
and deoxygenator purge lines these lines were closed off.   The pump flow was then 
switched off.   
 
The experiments that were run with equine blood in the circuit were initially primed with 
0.9% NaCl for ease of de-airing.  Clinical experience has highlighted that priming with 
whole blood makes de-airing difficult as blood is prone to frothing.  Once the circuit was 
fully primed with 0.9% NaCl, blood was added by displacement of the prime fluid.  The 
PVC tubing between the deoxygenator and the venous reservoir above the fluid 
administration line was clamped.  This fluid administration line was opened and the pump 
turned on slowly to gently pump prime fluid into the bag until the reservoir level reached 
minimum (i.e. 50ml).  The pump was stopped.  Two litres of equine blood was added to 
the reservoir via the administration line on top of the reservoir.  Once the blood was 
added, the pump was set on a slow flow to continue filling the fluid bag with prime until 
blood was seen entering the bag.  During this process the bag filled before blood was seen 
so the pump was stopped in order to replace the bag with the second empty 0.9% NaCl 
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fluid bag.  The procedure was continued until blood was seen entering the bag at which 
point the pump was stopped and the fluid administration line clamped off.  If there was 
less than 300ml of blood in the reservoir, additional fluid (equine blood or 0.9% NaCl) 
was added.   Finally, the clamp from the PVC tubing above the fluid administration line 
was removed and the pump restarted at a high flow (4 l/min) to allow mixing of the blood.  
The circuit was recirculated for five minutes with the CDI 500 sensor lines open to allow 
the CDI 500 analyser to reach equilibrium.  Gases for both the deoxygenator and 
oxygenator were switched on, tailoring the settings until optimum blood gas parameters 
were seen on the CDI 500 monitor.  Typical oxygenator gas settings were 5 l/min of air 
with 0.3 l/min oxygen resulting in an approximate FiO2 26%.  For the deoxygenator 
approximately 5l/min 5% CO2 in N2 with 0.2 l/min CO2 was used.   (Figure 3.8)   
 
 
Figure 3.8 Schematic Diagram of the Circuit Blood and Gas Phases 
 
3.1.3 Gas Mixtures 
All gases were obtained from British Oxygen, Manchester, UK.  For the oxygenator, stock 
cylinders of air and oxygen were connected via Y gas tubing to produce a FiO2 24-26% to 
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achieve normoxic blood gas parameters.  For experiments where the FiO2 was varied, 
stock cylinders of oxygen and nitrogen were connected to the oxygenator gas lines.  Stock 
cylinders of NO (1000ppm) in nitrogen and CO (0.3%) in oxygen (19%) and Helium 
(11%) were also connected to the oxygenator gas lines.  In the initial experiments this was 
via a therapeutic NO mixing device (Nomius 305, MTA Sahlgrewska, Goteburg, Sweden 
and Bronkhorst Hi Tech, 7261 AK Ruurlo, Netherlands).  The mixing device was set to 
give 5ppm of NO and 0.02% of CO and this gas was further diluted by the oxygenator gas 
mix as the CO and NO was added to the oxygenator gas line via a side arm downstream.  
In later experiments the NO and CO gases were connected into the oxygenator gas line via 
individual calibrated rotameters and the gases adjusted according to the inlet 
concentrations required.   
 
The volatile anaesthetic agent Isoflurane (Abbott Laboratories Ltd, Maidenhead, UK) was 
delivered via a calibrated Isotec 3 vaporiser (Datex-Ohmeda GE Healthcare, Chalfont 
Saint Giles, UK) located in the oxygenator gas line. 
 
For the deoxygenator a cylinder containing 5% CO2 in N2 and a stock cylinder of CO2 
were connected via Y gas tubing to provide adequate CO2 concentration (8%) in order to 
achieve normocapnia.  During the basic experiments where the test involved varying the 
FiCO2, stock cylinders of CO2 and N2 were connected to the deoxygenator gas lines. 
 
3.1.4 Blood 
Commercially available defibrinated horse blood (TCS Biosciences, Buckingham, UK) 
was used within twenty-eight days of collection.  No specification of gender or age was 
made for the preliminary experiments but was later specified as gelding age range 6-13 
years.  It was guaranteed free of haemolysis and adjusted by adding and withdrawing 
49 
 
serum to a constant haematocrit of between 40 to 50 % by the manufacturers.  It was 
refrigerated at 4°C prior to use. 
 
3.1.5 Equipment Details 
Blood gas analysis was made using the CDI Blood Parameter Monitoring System 500, an 
in-line optical fluorometric analyser which requires a minimum blood flow rate of 35 
ml/min (Terumo Cardiovascular Systems, Surrey, UK).  The blood sample shunt lines 
exiting the oxygenator and the deoxygenator were each connected to a calibrated shunt 
sensor which continually monitored pH, PO2, PCO2 and K.  The sensors used for each 
circuit were calibrated at the start of the session with manufacturer supplied calibration 
gases. 
 
Haemoglobin, methaemoglobin and carboxyhaemoglobin concentrations were measured 
using a bench-top analyser Rapidlab 800 (Bayer, Berks, UK).  This analyser was 
calibrated daily in accordance with the manufacturer‟s recommendations by a suitably 
trained member of hospital staff.   Blood samples (1.5ml) were withdrawn from the 
oxygenator sample shunt line (used for the CDI 500 sensor) into heparinised syringes and 
either analysed immediately or kept refrigerated prior to analysis at the end of the 
experimental run.   The concentration of methaemoglobin was less than 3% and 
carboxyhaemoglobin less than 7.5% in all experiments. 
 
Blood oxygen saturation was determined by either the Cobe Sat/Hct analyser (Cobe 
Cardiovascular, Arvada, USA) or the Spectrum Medical M2 analyser (Spectrum Medical 
Ltd, Cheltenham, UK).  Both of these devices automatically undertook an internal 
calibration run when switched on.  The Cobe Sat/Hct utilises infrared spectroscopy to 
determine blood saturation whereas the newer Spectrum Medical M2 uses white light 
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technology.  For the earlier work the Cobe Sat/Hct analyser was the available technology 
but for the later work the newer Spectrum Medical M2 was used in conjunction with the 
Cobe Sat/Hct analyser. 
 
The gas analysis was performed by different analysers. Oxygen in the gas phase (FiO2 and 
FeO2 measurements) was initially analysed using the Datex digital oxygen meter (5120, 
Datex Ohmeda, Louisville 80027-9560 USA) calibrated with 19%, 21% and 100% 
oxygen, and later a medical oxygen analyser AX300 (Teledyne Analytical Instruments, 
Cambridge, UK) calibrated with 100% or 21% oxygen.   The Teledyne AX300 was 
predominantly used due to its oxygen analysis range and sensitivity.  For all oxygen 
sensors, volatile anaesthetic agents can interfere with oxygen readings.  The manufacturers 
for the Teledyne AX300 quote a reading error of <1.5% in the presence of Isoflurane but 
that these performances meet or exceed the sensitivity requirements of ISO 7767: 1997 
(E).  The FiISO and FeISO were analysed using an in-built infrared analyser on the Datex 
anaesthetic monitor (Datex-Ohmeda, Hatfield, UK).  CO2, NO and CO were all analyzed 
using the chemiluminescent Logan LR 2000 analyser (Logan Research, Rochester, UK) to 
which a manufacturer custom-built CO analyser was bolted on in series “upstream.”  
 
Temperature, relative humidity and barometric pressure were recorded for each 
experimental session.  The humidity of the oxygenator outlet was determined by wet and 
dry bulb thermometer (Met-check, Milton Keynes, UK).  The barometric pressure was 
determined by the local weather station located at RAF Wittering. 
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3.2 Pilot Experiments With This Circuit Design  
 
Aim 
The focus of these initial experiments was to determine if a single oxygenator and a single 
deoxygenator were adequate to establish oxygenation and deoxygenation of the circulating 
equine blood.  The literature review demonstrated that either several membrane units or a 
linked but separately operating deoxygenating circuit was required.  The CDI 500 sensors 
were to be assessed for the time taken for equilibrium to be reached upon each 
experimental change to the circuit.   
 
The venous reservoir to be used was a hardshell type with vent holes around the top to 
allow for volume expansion within the holding device.  This allows blood to come into 
contact with air within the reservoir.  A blood/air interface is a potential source of oxygen 
transfer which may influence the results obtained for oxygenator gas transfer.  To 
determine the possible effects of a reservoir blood/air interface on gas transfer, a bypass 
loop was incorporated into the circuit allowing the venous reservoir to be bypassed.  Data 
was collected for comparison with and without the venous reservoir.  
 
3.2.1 Pilot Circuit Set-Up 
The circuit was assembled as described previously (3.1.1) but an extra recirculation loop 
was integrated to allow circulation of the venous blood from the venous reservoir via a 
second  stockert positive displacement pump to the deoxygenator (Figure 3.9). 
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If a single deoxygenator was not efficient at deoxygenating the blood, there was a facility 
available for venous conditioning as per previous published works (Van Meurs et al 1991, 
Rais-Bahrami et al 1992, Vocelka et al 1993, Griffiths et al 1994, Gourlay and Taylor 
1994, Beckley et al 1996, Matsuda and Sakai 2000, Maeda et al 2000, Kawahito et al 
2001 and Motomura et al 2003).  To facilitate this additional circuitry, two ⅜” Y 
connectors and an extra length of ⅜” tubing was required.  The circuit was primed as 
described previously (3.1.2) with the exception that prime fluid was recirculated through 
the loop and the secondary pump left switched off so that fluid did not pass through the 
loop.   
 
3.2.2 Pilot Methodology 
1. Gas Flow Test 
The circuit pump was set at 2.5 l/min.  The oxygenator received air (oxygen 21%).   
To determine the appropriate oxygenator gas flow for oxygenation of the blood, the 
flow was adjusted to 0.5, 1.0, 2.5 or 5.0 l/min of air.  The deoxygenator received 5 
l/min 5% CO2 in balanced N2. 
Figure 3.9 Schematic Diagram of the Venous Bypass Pumping Loop. 
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2. CDI 500 Sensor Equilibration Test 
The blood flow rate was set at 2.5 l/min.  The deoxygenator gas flow was 5l/min of 
5% CO2 in balanced N2.  The oxygenator gas flow was set from 0.5 l/min to 2.5l/min 
of air and the stopwatch started.  The pH, PO2 and PCO2 values from the CDI 500 
monitor for both venous and arterial blood were recorded at time 0, 1, 1.5, 2, 2.5, 3, 
3.5, 4, 4.5 and 5 minutes to assess the equilibration duration. 
 
3. Optimum Gas Settings 
To determine the optimal gas settings for both the oxygenator and the deoxygenator at 
a blood flow rate of 2.5 l/min, the standard gas was initially used for each device i.e. 5 
l/min air (determined in the Gas Flow Test) for the oxygenator and 5 l/min 5% CO2 in 
balanced N2 for the deoxygenator.  To these standard gases, oxygen was added to the 
oxygenator and carbon dioxide was added to the deoxygenator.  The blood gas 
changes were recorded until optimum arterial and venous blood gas parameters were 
observed.   
 
4. Open versus Closed Venous Reservoir 
A bypass loop was added between the deoxygenator outlet and the pump to bypass the 
venous reservoir.  The closed reservoir test incorporated clamping the venous 
reservoir out and the circuit continuously run utilising the bypass loop.  With the open 
reservoir test the bypass loop was clamped out allowing blood to pass through the 
reservoir with the blood/air interface.  The blood flow was set at 2.5 l/min.  The 
oxygenator gas flow was set to 5 l/min air with 0.3 l/min O2 and the deoxygenator gas 
flow was set to 5 l/min 5% CO2 in balanced N2 with 0.2 l/min CO2.   The pH, PO2 and 
PCO2 values from the CDI 500 monitor for both venous and arterial blood were 
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recorded for the open reservoir and closed reservoir circuit so that gas transfer data 
could be compared.  
 
3.2.3 Pilot Experimental Results 
1. Gas Flow Test 
With the blood flow set to 2.5 l/min the oxygenator gas flow required to adequately 
oxygenate the blood was 5 l/min (Table 3.1).  This produced a PaO2 81.00 mmHg with 
a P v O2 34.50 mmHg.  The deoxygenator gas flow of 5 l/min was sufficient to 
deoxygenate the blood.  Due to the low FiCO2 levels to the deoxygenator in this early 
experimental work it was not possible to determine the efficiency of the circuit with 
regards to CO2. 
 
Table 3.1 Preliminary Experimental Results for Optimal Oxygenator Gas Flows 
Oxy Gas Flow l/min pHa pHv PaO2 mmHg P v O2 
mmHg 
0.5 7.39 7.38 47.30 29.25 
1.0 7.42 7.41 63.76 33.75 
2.5 7.48 7.44 74.26 34.50 
5.0 7.53 7.48 81.00 34.50 
 
 
2. CDI 500 Sensor Equilibration Test 
During the first 4.5 minutes, PaO2 from the oxygenator outlet was seen to equilibrate 
from 47.25 mmHg to 70.50 mmHg after the air flow to the oxygenator was increased 
from 0.5 l/min to 2.5 l/min.  The CDI 500 analyser specification indicates a response 
time of 24 seconds to display 90% of a step change in PO2 so it is concluded that most 
of the equilibrium time was for the blood to stabilise rather than the sensors. 
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P c O2 took only 3.5minutes to reach equilibrium from 36.58 mmHg to 45.94 mmHg.  
DO2 mirrored this response time reaching 0.95 ml/min/mmHg.  The rate of oxygen 
uptake remained at 93.10 ml/min throughout from time 0 onwards indicating an 
instantaneous gas change. 
 
3. Optimum Gas Settings 
The oxygenator and deoxygenator gas settings were adjusted until more physiological 
arterial and venous readings were achieved.  The optimal oxygenator gas was 5 l/min 
air with 0.3 l/min O2 and the optimal deoxygenator gas was 5 l/min 5% CO2 in 
balanced N2 with 0.2 l/min CO2.  The blood gases are presented in Table 3.2. 
 
Table 3.2 Pilot Experimental Results for Optimum Gas Settings 
 Arterial Venous 
pH 7.27-7.29 7.13-7.15 
PO2 mmHg 76-86 36-38 
PCO2 mmHg 35-37 59-62 
 
 
4. Open versus Closed Venous Reservoir 
There were no changes in pH, PO2 or PCO2 when the venous reservoir was clamped 
out compared to the presence of the blood/air interface within the reservoir.  M O2 
and DO2 showed no difference between open or closed reservoir circuitry (Table 3.3). 
 
 
 
 
56 
 
Table 3.3 Pilot Experimental Results for Open and Closed Venous Reservoir 
Reservoir pHa pHv PaO2 
mmHg 
P v
O2 
mmHg 
PaCO2 
mmHg 
P v
CO2 
mmHg 
M O2 
ml/min 
DO2 
ml/min/mmHg 
Open 1 7.28 7.14 81 38 37 62 148.32 1.11 
Closed 1 7.28 7.15 83 39 36 60 119.61 0.88 
Open 2 7.28 7.15 83 39 37 61 119.61 0.88 
Closed 2 7.29 7.15 86 39 35 59 119.61 0.89 
Open 3 7.27 7.13 76 36 36 62 110.41 0.83 
Closed 3 7.28 7.14 78 37 36 60 110.41 0.84 
 
 
3.2.4 Pilot Experimental Outcomes 
For each experiment the CDI 500 sensors were left to equilibrate for 5 minutes prior to 
recording the monitor readings. 
 
A deoxygenator gas flow of 5 l/min was efficient in deoxygenating 2.5 l/min blood flow  
so the additional venous conditioning loop was not required in this circuit design.  
 
The optimal gas settings determined from the pilot test were set at the start of each 
experiment, i.e. 5 l/min air with 0.3 l/min O2 for the oxygenator and 5 l/min 5% CO2 in 
balanced N2 with 0.2 l/min CO2 for the deoxygenator.  From these initial settings, gases 
may need some slight adjustment to accommodate for small variations in the donated 
blood and membrane efficiency. Actual oxygenator and deoxygenator gas settings used for 
each experiment were recorded and reported in the methodology. 
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The open and closed reservoir test indicated that the blood/air interface present within the 
hardshell venous reservoir had no impact on gas transfer.  The circuit design retained the 
hardshell type venous reservoir as it adds flexibility with volume addition for varying Hb.  
 
3.3 Basic Gas Transfer Properties of this Circuit Design: Methodology 
 
To establish the gas transfer properties of this circuit, a series of basic experiments were 
conducted varying blood flow ( Q ), oxygenator gas flow (F), oxygenator inspired oxygen 
(FiO2), deoxygenator inspired carbon dioxide (FiCO2) and haemoglobin concentration 
(Hb).  The results of these experiments provided this model with baseline data.   Each 
experiment was duplicated with a different circuit each time (denoted as run 1, run 2 etc).  
The methodology for these experiments may have been modified on subsequent runs in 
order to rectify any issues raised during the first run, as described under each experimental 
heading.   
 
Each circuit was assembled and primed as previously described (3.1.1-3.1.2) for all but the 
varying Hb experiment.  For the varying Hb experiment once the circuit was primed with 
0.9% NaCl the test started with slow addition of equine blood to the circuit.  The pH, PO2 
and PCO2 values from the CDI 500 analyser for both venous and arterial blood were 
recorded for each experimental change after 5 minutes equilibration.  The oxygenator 
inspired and expired oxygen content was also established. 
 
3.3.1 Effects of Varying Blood Flow (Q ) and Surface Area (SA) 
The oxygenator gas flow was 5 l/min air (run 1) or 5 l/min air with 0.2-0.4 l/min O2 (runs 
2 and 3).  The deoxygenator gas flow was 5 l/min 5% CO2 in balanced N2 with addition of 
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0.2-0.4 l/min CO2. The blood flow was randomly varied to include 0.1, 0.2, 0.5, 1.0, 2.0 
and 2.5 l/min for one oxygenator cell and two oxygenator cells.   
 
3.3.2 Effects of Varying Oxygenator Gas Flow (F) 
The blood flow was set to 2.5 l/min. The deoxygenator gases were set to 5 l/min 5% CO2 
in balanced N2 (run 1) or 5 l/min 5% CO2 in balanced N2 with 0.2 l/min CO2 (run2).  The 
oxygenator received varying flows of air at 0.5, 1.0, 2.5, 5.0, 7.5, 10.0, 12.5 and 15.0 l/min 
in a randomized order.   
 
3.3.3 Effects of Varying Oxygenator FiO2 
The blood flow was set to 2.5 l/min. The deoxygenator gases were set to 5 l/min 5% CO2 
in balanced N2 with 0.2 l/min CO2.  The oxygenator received 5 l/min of a mixture of air, 
N2 and O2 to provide a range of FiO2 between 4.9% and 98% in a randomized order.  For 
the hypoxic gas mixtures, N2 was mixed with O2 at the following l/min ratios; 4.0+1.0, 
4.1+0.9, 4.2+0.8, 4.3+0.7, 4.4+0.6, 4.5+0.5, 4.6+0.4, 4.7+0.3, 4.8+0.2 and 4.9+0.1.  For 
the hyperoxic gas mixtures, air and O2 were mixed in the following l/min gas ratios; 
0+5.0, 0.5+4.5, 1.0+4.0, 1.5+3.5, 2.0+3.0, 2.5+2.5, 3.0+2.0, 3.5+1.5, 4.0+1.0, 4.5+0.5 and 
5.0+0.   
 
3.3.4 Effects of Varying Deoxygenator FiCO2  
The blood flow was set to 2.5 l/min.  The oxygenator gases were set to 5 l/min air with 
0.1-0.3 l/min O2.  The deoxygenator received approximately 5 l/min (4.7-5.3 l/min) of a 
mixture of 5% CO2 in balanced N2, 100% CO2 and N2 to achieve FiCO2 ranging between 
1.78% and 23.82%.  The deoxygenator inspired and expired carbon dioxide content was 
established for each change. 
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3.3.5 Effects of Varying Haemoglobin Concentration (Hb) 
The circuit was primed with 0.9% NaCl.  The pump flow was set to 2.5 l/min.  The 
oxygenator gases were 5 l/min air (run 1) or 5 l/min air with 0.3 l/min O2 (run 2 and 3).  
The deoxygenator gases were 5 l/min 5% CO2 in balanced N2 with 0.2 l/min CO2. 
 
For the first and second runs equine blood was held in a second reservoir with ⅜” tubing 
attached to the reservoir outlet directed through a second roller pump which pumped the 
blood into the top of the venous reservoir.  The second roller pump was set to 60 ml/min 
to facilitate a slow increase in Hb concentration.  The Hb achieved in runs 1 and 2 were 
2.4-10.3 g/dl and 2.2-9.0 g/dl, respectively.   
 
For the third run, equine blood was added in 25 ml aliquots via syringe into the top of the 
venous reservoir.  This approach was utilised to achieve results at the lower Hb 
concentrations where data appeared to be incomplete from the first two runs.  The Hb 
concentration range achieved was 0.26-2.29 g/dl.   
 
At one minute intervals or five minutes after every aliquot of equine blood data was 
recorded. 
 
3.3.6 Blood Shunt 
Using the data from the varying blood flow experiments, shunt fraction was calculated.  
Using the varying FiO2 data the calculated shunt was interpreted as diffusion or perfusion 
limiting. 
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3.3.7 Circuit Variation 
The same equine donation was divided and used to run two separate circuits comprising 
the same type of membrane oxygenators but of different batches.  Blood flow was set to 
2.5 l/min.  The same gas settings of 5 l/min air with 0.3 l/min oxygen for the oxygenator 
and 5 l/min 5% CO2 in balanced N2 with 0.2 l/min CO2 for the deoxygenator were applied 
to each circuit.  DO2, DNO and DCO were calculated and compared. 
 
3.3.8 Calculations 
Barometric pressure acquired in millibars was converted to mmHg.   
 
       
                
   
 
 
Calculations based on measurements of absolute amounts of gas were subjected to STPD 
conversion by correction for water vapour, pressure and temperature. 
 
                                            
 
                       
     
   
 
 
1. P c O2 
The mean pulmonary capillary oxygen partial pressure (P c O2)( mmHg) is derived from 
PaO2 and P v O2 using Bohr Integration method.  It is not possible to directly measure    
P c O2 therefore the value is calculated based on assumptions of the PO2 changes along 
the length of the pulmonary capillaries.  Bohr (1909) devised a method of calculating P c
O2 by assuming that the rate of oxygen diffusion is proportional to the PO2 difference 
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between the alveolar gas and the pulmonary capillary at that point.  A spreadsheet was 
created in Microsoft Excel, by C. Borland, recreating the Bohr integration to aid 
calculation of P c O2 from the circuit PaO2 and P v O2 data (Appendix 2). 
 
2. PAO2 
Alveolar oxygen partial pressure (PAO2) (mmHg) was calculated by taking the 
logarithmic mean of inlet and outlet gas oxygen concentrations.  This approach was based 
on an assumed semi-logarithmic decline in oxygen within the gas phase of the oxygenator 
mirroring the semi-logarithmic incline in blood uptake of oxygen within the blood phase. 
The equation was corrected for BP and water vapour. 
 
     
         
               
 
     
                
   
 –                            
 
3. M O2 
Rate of oxygen uptake by the oxygenator (ml/min) was calculated via the gas phase 
method (as previously described in chapter 1) by taking the difference between the 
oxygenator inlet and outlet oxygen concentrations.  The gas oxygen concentration 
difference was multiplied by the oxygenator gas flow to give a total uptake of oxygen, 
corrected for water vapour, pressure and temperature.   
  
                       
   
     
    
                
   
  –        
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4. DO2 
Oxygen diffusion (DO2) (ml/min/mmHg) was calculated using Lilienthal et al formula 
(1946) whereby oxygen uptake (M O2) is divided by the membrane oxygen partial 
pressure difference, determined as the difference between alveolar oxygen tension and 
capillary oxygen tension (PAO2-PcO2).  This method is not commonly used in clinical 
practice due to the calculation not accounting for uneven lung function.  For this method 
the simplicity of the oxygenator gas and blood pathways allow the use of direct DO2 
calculation.  
 
      
   
      c  
 
 
5. DO2 (Piiper method) 
Oxygen diffusion (ml/min/mmHg) using Piiper method (1980) was used to compare with 
the Lilienthal formula above in the DO2 calculation for the varying FiO2 experiment.  
Piiper‟s DO2 equation was a simplified version of the Lilienthal method as the pulmonary 
capillary O2 tension was omitted, however the simplification was only valid over the 
linear portion of the ODC.   
 
    
   
      v   
      
      v   
         
  
 
6. P c CO2 
Pulmonary capillary carbon dioxide partial pressure (P c CO2) (mmHg) was calculated as 
the mean of the inlet and outlet deoxygenator blood carbon dioxide tensions (PaCO2 and  
P v CO2 respectively).  Carbon dioxide reacts rapidly with blood therefore a simpler 
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formula was used assuming a linear increase in carbon dioxide from the gas phase of the 
deoxygenator. 
 
 c      
       v    
 
 
 
7. PACO2 
The alveolar carbon dioxide tension (mmHg) within the deoxygenator gas phase was 
calculated as the mean of the inlet and outlet gas carbon dioxide concentrations (FiCO2 
and FeCO2 respectively).  This was based on the assumption that carbon dioxide declines 
linearly within the gas phase of the deoxygenator due to the rapid reaction of carbon 
dioxide with the blood.  Correction for BP and water vapour was applied. 
  
        
           
 
    
                
   
  –                             
 
8. M CO2 
Carbon dioxide uptake (ml/min) via the deoxygenator was calculated using the M O2 
formula but substituting the inlet and outlet oxygen concentrations for inlet and outlet 
carbon dioxide concentrations.  The carbon dioxide inlet and outlet difference was 
multiplied by the deoxygenator gas flow, and corrected for water vapour, temperature and 
pressure. 
 
                            
   
     
    
                
   
 –        
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9. DCO2 
For consistency Lilienthal DO2 formula was modified for DCO2.   
 
       
    
       c   
 
 
10. Piiper „style‟ DCO2 
This is a modification of Piiper‟s DO2 method for calculating DCO2 to use as a 
comparison to the DCO2 described previously. 
 
     
    
 v          
      
           
       v    
  
 
11. Shunt Fraction 
This equation determines the venous admixture effect through the oxygenator, i.e. the 
blood not partaking in gas exchange that leaves the oxygenator deoxygenated.  The 
shunted blood (Q s) is taken as the difference between pulmonary capillary O2 content 
and arterial O2 content (CcO2-CaO2), divided by the total O2 content (Q t) achieved 
(CcO2-C v O2). 
 
               
Q  
Q  
 
         
      v   
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12. Respiratory Exchange Ratio 
The RER is the ratio of the rate of carbon dioxide leaving the oxygenator (FeCO2) to the 
rate of oxygen uptake in the oxygenator (FiO2-FeO2), thus making an allowance for 
movement of gas across the membrane or lungs.  RER in man at rest is typically 0.8.   
 
    
     
         
 
 
 
13. Circuit Haematocrit 
This calculation is used to predict the circuit haematocrit after blood addition to a 
crystalloid primed circuit.  Haematocrit was estimated in the varying haematocrit 
experiments due to difficulties in measuring such low values.  Haematocrit was calculated 
from the total volume in the circuit, the volume of blood added and the known haematocrit 
of the blood entering the circuit.   
 
             
                                           
                       
 
 
 
 
3.3.9 Statistical Analysis 
Statistical analysis has been detailed in Chapter 2, section 2.2. 
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3.4  NO and CO Gas Transfer Methodology 
 
3.4.1 NO and CO addition 
NO and CO were added to the circuit via a stock cylinder of NO (1000 ppm) in nitrogen 
and a stock cylinder of CO (0.3%) in oxygen (19%) and Helium (11%).  These two 
cylinders were incorporated into the oxygenator gas tubing via either a therapeutic NO 
mixing device or via individual rotameters.  NO and CO were diluted by the oxygenator 
gas mix so concentrations were titrated to give the desired amounts at the oxygenator inlet.  
NO was delivered at a concentration of 5000 ppb unless the outlet amount was likely to 
drop below the detectable limit and therefore the inlet concentration was increased to 
maintain uptake data.  CO was delivered at a concentration of 0.03%. 
 
3.4.2 Experiments 
The experiments for varying blood flow/surface area, oxygenator gas flow, oxygenator 
FiO2, deoxygenator FiCO2 and haemoglobin concentration, previously described (Section 
3.3), were conducted with NO and CO administration via the oxygenator gas mix.  
 
For each experimental change, NO and CO concentrations were established at the 
oxygenator gas inlet and oxygenator gas outlet, to be known as NOin, NOout, COin and 
COout. 
 
3.4.3 Calculations  
The DCO calculation is derived from the DLCO equation described by Marie Krogh 
(1915).  LN(COin/COout) is the membrane uptake rate constant multiplied by the 
oxygenator gas flow with STPD correction.  The DNO calculation was based on the same 
formula, replacing COin and COout with NOin and NOout.  DNO was further adjusted by 
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a membrane absorption correction factor (0.93 for half membrane) as minor NO uptake 
was noted in a saline primed membrane oxygenator (Borland, 2006). 
 
 
    
       
   
        
  
     
 
  
                                 
    
    
     
  
 
 
 
    
       
   
        
  
     
 
  
                                 
    
    
     
           
 
 
 
3.4.4 Statistical Analysis 
The statistical analysis is described in Chapter 2, section 2.2.  
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3.5  Basic Gas Transfer Properties of This Circuit Design: Results and Discussion 
 
3.5.1 Varying Blood Flow and Surface Area; Results  
At very low blood flows, the accuracy of the CDI 500 sensors was questioned due to the 
minimum blood flow of 35ml/min required.  Blood flow rates of 0.1 l/min highlighted 
sensor issues with lack of machine response to blood flow changes.  Later work 
incorporated a larger bore sample tubing for the sensors to optimise blood flow through 
them.   
 
Generally PaO2 showed a very slight decrease over the blood flow range 0.1- 2.5 l/min 
whereas P v O2 showed a very slight increase.  As a result P c O2 remained static 
throughout the blood flow range.  There were no differences in these trends when the 
surface area was halved (Figures 3.10 and 3.11, Figure section pg 191).  PaO2 averaged 
63.44 ±33.57 mmHg for 1 cell and 81.45 ±34.66 mmHg for 2 cells.  P v O2 averaged 
21.51 ±7.97 mmHg for 1 cell and 27.36 ±8.58 mmHg for 2 cells.  P c O2 calculated from   
P v O2 and PaO2 was 34.37 ±5.83 mmHg for 1 cell and 41.75 ±6.85 mmHg for 2 cells.  
Overall 2 cells resulted in slightly higher P v O2 (p=0.042), PaO2 (p=0.122) and resultant 
P c O2 (p=0.001) when compared to just 1 oxygenator cell. 
 
Increasing blood flow from 0.2 to 2.5 l/min for 1 cell and 2 cells corresponded with a 
linear increase in M O2 and DO2.  M O2 and DO2 for both 1 cell and 2 cells revealed inter-
run variations in data (Figures 3.12 and 3.13).  M O2 for 1 cell ranged 23.28 to 93.11 
ml/min (run 1, p=0.018), 229.46 to 321.24 ml/min (run 2, p=0.004) and 34.35 to 137.40 
ml/min (run 3, p=0.002).  The resultant DO2 for 1 cell ranged 0.21 to 0.90 ml/min/mmHg 
(run 1, p=0.011), 1.91 to 2.63 ml/min/mmHg (run 2, p=0.008) and 0.22 to 0.95 
ml/min/mmHg (run 3, p=0.002).  For two oxygenator cells the same inter-run variation 
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was noted with M O2 ranges of 23.28 to 93.11 ml/min (run 1, p=0.050), 183.57 to 275.35 
ml/min (run 2, p=0.032) and 49.07 to 161.93 ml/min (run 3, p=0.006).  The resultant DO2 
for 2 cells was calculated as 0.23 to 0.99 ml/min/mmHg (run 1, p=0.017), 1.54 to 2.36 
ml/min/mmHg (run 2, p=0.014) and 0.31 to 1.20 ml/min/mmHg (run 3, p=0.005).  The 
surface area size did not affect M O2 or DO2 (p=0.896 and p=0.927). 
 
CO2 data was only collected during run 3 as the analyser CO2 range was increased for this 
run.  Statistical analysis was not performed on this small sample size.  PaCO2 increased in 
a curvilinear manner with increasing blood flow from 10 mmHg at 0.1 l/min to a mean 
36.25 ± 2.22 mmHg at 1.0-2.5 l/min for 1 cell.  P v CO2 similarly decreased over the 
blood flow range from 63 mmHg at 0.1 l/min to a mean 48.25 ±2.36 mmHg over 1.0 – 2.5 
l/min for 1 cell. P c CO2 was calculated from P v CO2 and PaCO2 and averaged 40.83 
±2.48 mmHg for 1 cell (Figure 3.14).  Both M CO2 and DCO2 increased linearly from 
51.03 to 137.40 ml/min and 2.28 to 14.52 ml/min/mmHg respectively (Figures 3.16 and 
3.17). 
 
With two oxygenator cells the CO2 data showed very similar trends and results as that for 
1 cell concluding no effect of surface area on CO2.  PaCO2 increased curvilinearly with 
increasing blood flow from 10 mmHg at 0.1 l/min to a mean 31.75 ±5.38 mmHg at 1.0-2.5 
l/min for 2 cells.  P v CO2 similarly decreased over the blood flow range from 65 mmHg 
at 0.1 l/min to a mean 47.25 ±0.96 mmHg over 1.0-2.5 l/min for 2 cells. P c CO2 was 
calculated from P v CO2 and PaCO2 and averaged 39.00 ±2.28 mmHg (Figure 3.15).  
Both M CO2 and DCO2 increased linearly from 52.51 to 140.83 ml/min and 2.46 to 11.78 
ml/min/mmHg respectively (Figure 3.16 and 3.17).    
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Table 3.4 Effects of Blood Flow and Surface Area Data Summary 
Varying Blood Flow and Surface Area 
 Q  SA 
Parameter Trend  Statistical value d.f. or n p value Trend 
PaO2 Slight decrease 1 cell R
2
=0.249 
2 cells R
2
=0.098 
17 
17 
p=0.035 
p=0.207 
Slight 
increase 
t=-1.584 
d.f.=34 
p=0.122 
P v O2 Slight increase 1 cell R
2
=0.326 
2 cells R
2
=0.275 
17 
17 
p=0.013 
p=0.026 
Slight 
increase 
t=-2.118, 
d.f.=34 
p=0.042 
1 cell M O2 Linear increase R
2
=0.786, 0.894, 
0.928 
d.f.=5, 5, 5 p=0.018, 
0.004, 0.002 
No effect 
t=0.131 
d.f.=34 
p=0.896 
2 cell M O2 Linear increase R
2
=0.659, 0.722, 
0.873 
d.f.=5, 5, 5 p=0.050, 
0.032, 0.006 
1 cell DO2 Linear increase R
2
=0.831, 0.858, 
0.002 
d.f.=5, 5, 5 p=0.011, 
0.008, 0.002 
No effect 
t=-0.092 
d.f.=34 
p=0.927 
2 cell DO2 Linear increase R
2
=0.797, 0.811, 
0.890 
d.f.=5, 5, 5 p=0.017, 
0.014, 0.005  
 
 
Varying Blood Flow and Surface Area; Discussion 
The effect of blood flow on P v O2 and PaO2 showed increased arterial-venous oxygen 
tension difference at low flows which decreased as the blood flow increased.  This 
phenomenon was expected as low blood flow results in slower blood transit through both 
the oxygenator and the deoxygenator.  This provides more time to oxygenate and 
deoxygenate the blood, hence the results seen in this model at low flows.  As the blood 
flow through the circuit increases, transit time reduces through the devices thus the 
71 
 
arterial-venous difference decreases.  This same theory can be applied to the P v CO2 and 
PaCO2 as the blood flow through the circuit equally affects carbon dioxide transfer.  
 
The effect of increasing blood flow on M O2 and M CO2 is a linear increase with a slight 
plateau evident at higher flows (2-2.5 l/min).  Despite increased arterial-venous partial 
pressure difference in oxygen and carbon dioxide at low flow, the amount of blood 
circulating will restrict gas transfer.  Hence, the amount of deoxyhaemoglobin arriving at 
the oxygenator is very low thus limiting oxygen uptake via the oxygenator.  As the 
amount of deoxyhaemoglobin entering the oxygenator increases, as denoted by increased 
blood flow, oxygen uptake increases.  Similarly, increasing amounts of arterial blood 
entering the deoxygenator increases carbon dioxide transfer.  The potential M O2 and      
M CO2  plateau effect at higher blood flows through the circuit is likely to be related to the 
increasing P v O2 and PaCO2 thus less pressure gradient to drive oxygen and carbon 
dioxide transfer across the membrane.   DO2 and DCO2 showed the same trend as M O2 
and M CO2. 
 
Surface area did not affect M O2, M CO2, DO2 or DCO2.  Oxygen and carbon dioxide are 
considered perfusion limited gases (in resting healthy man) which is evident here in this 
apparatus.  Perfusion limited gases reach equilibrium quickly between the gas channel and 
blood channel.  Diffusion of a perfusion limited gas is affected by the blood available and 
blood partial pressures will readily increase in response to increasing gas concentrations.  
An effect on oxygen or carbon dioxide uptake associated with a reduction in membrane 
surface area would imply a diffusion limitation.  Carbon dioxide has a very quick reaction 
with blood due to its increased solubility so although the pressure gradient between the 
blood partial pressure and gas concentration is low, equilibrium is easily reached.  Oxygen 
however has a slower rate of reaction with blood but with a greater pressure gradient 
72 
 
between the alveolar gas and venous blood to drive the transfer, equilibrium is reached 
readily.   
 
The model circuit has shown expected trends in the effects of blood flow and surface area 
on oxygen and carbon dioxide transfer.  From this experiment the circuit has been 
validated for a blood flow of 2.5 l/min as a standard for all other experiments.  
 
3.5.2 Effects of Varying Oxygenator Gas Flow (F); Results 
Over the oxygenator gas flow range 0.5 to 15.0 l/min, the optimal gas flow was confirmed 
as 5 l/min coinciding with preliminary work. 
 
PaO2 increased initially from 47.25 mmHg (0.5 l/min) to 65.25 mmHg (2.5 l/min) after 
which the PaO2 averaged 69.88 ±5.46 mmHg over the gas flow range 5 to 15 l/min.   
Similarly P v O2 increased from 29.25 mmHg (0.5 l/min) to 37.5 mmHg (2.5 l/min) 
before averaging 36.63 ±1.10 mmHg over the 5 to 15 l/min gas flow range.  P c O2 
followed the same trend with increases from 37.00 mmHg (0.5 l/min) to 47.48 mmHg (2.5 
l/min) before averaging 48.19 ±0.29 mmHg for gas flows 5 to 15 l/min. (Figure 3.22) 
 
M O2 and DO2 both showed a positive linear relationship with increasing oxygenator gas 
flow. M O2 increased from 41.90 ml/min at 0.5 l/min to 139.67 ml/min at 15 l/min 
(p=0.004).  DO2 rose from 0.50 ml/min/mmHg at 0.5 l/min to 1.25 ml/min/mmHg at 15 
l/min (p=0.007). (Figures 3.23 and 3.24) 
 
PaCO2 was assessed as the increasing oxygenator gas flow would impact on the removal 
of CO2 from the „venous‟ blood.  PaCO2 was noted to slightly decrease curvilinearly with 
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increasing oxygenator gas flow.  In run 1, PaCO2 reduced from 30 mmHg at 0.5 l/min to 
15.75 mmHg at 5 l/min (p=0.042).  In run 2, PaCO2 reduced from 48 mmHg at 2.5 l/min 
down to 30 mmHg at 15 l/min (p=0.008). (Figure 3.25) 
 
Table 3.5 Varying Oxygenator Gas Flow Summary Table 
Varying oxygenator Gas Flow 0.5-15.0 l/min 
Parameter Trend Statistical value p value d.f. or n 
PaO2 Initial increase to 
plateau 
r=0.284 p=0.427 n=10 
P v O2 Initial increase to 
plateau 
r=0.567 p=0.087 n=10 
P c O2 Initial increase to 
plateau 
r=0.507 P=0.135 n=10 
M O2 Linear increase R
2
=0.661 p=0.004 d.f.=9 
DO2 Linear increase R
2
=0.614 p=0.007 d.f.=9 
PaCO2 Slight decrease r=-0.958 and r=-
0.928 
p=0.042, 
p=0.008 
n=5 and 6 
 
Effects of Varying Oxygenator Gas Flow (F); Discussion 
This experiment was designed to give information on the impact of gas flow on 
oxygenation within the circuit and to determine the ideal gas flow.  
 
PaO2 and P v O2 were seen to increase slightly with gas flows of 0.5-2.5 l/min before 
plateauing over the higher gas flows (5-15 l/min).  This indicated that gas flows up to 2.5 
l/min were limiting the oxygenation of the blood within the circuit.  At low gas flows the 
diffusion gradient between the gas channel and the blood channel was not great enough to 
drive diffusion to equilibrium.  At higher gas flows the fresh gas resulted in a higher 
diffusion gradient with equilibrium being reached between the gas and blood channels.  
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This was reflected in the M O2 and DO2 which showed a linear increase with increasing 
oxygenator gas flow. 
 
The oxygenator within the circuit not only oxygenates the blood but also removes carbon 
dioxide from the blood.  A change in oxygenator gas flow will impact on PaCO2 values as 
a higher oxygenator gas flow will remove more carbon dioxide from the blood.  This was 
demonstrated by a curvilinear decrease in PaCO2 with increasing oxygenator gas flows. 
 
From this experimental data, an oxygenator gas flow of 5 l/min was optimal for achieving 
the desired PaO2, P v O2 without compromising PaCO2.     
 
3.5.3 Effects of Varying Oxygenator FiO2; Results 
The oxygenator FiO2 range of 4.9% to 98.0% was achieved over two experimental runs. 
 
Over the FiO2 range achieved, PaO2 increased linearly from 19 mmHg up to 527 mmHg 
(p<0.0001).  In contrast P v O2 (p<0.0001) and P c O2 (p<0.0001) displayed a curvilinear 
increase.  P v O2 increased initially from 16 mmHg at FiO2 4.9% up to 40 mmHg at a 
FiO2 17.3% after which P v O2 averaged 48.98 ±3.64 mmHg.  P c O2 followed a similar 
trend with an initial increase from 17.5 mmHg at FiO2 4.9% up to 50.1 mmHg at FiO2 
21%, after which P c O2 averaged 72.80 ±4.58 mmHg. (Figure 3.27) 
 
M O2 when plotted against FiO2 displayed a statistically significant linear increase 
(p<0.0001) ranging from 18.48 ml/min at FiO2 4.9% up to 229.46 ml/min at FiO2 98% 
(Figure 3.28).   DO2 showed a more complex relationship with FiO2 (Figure 3.29).  DO2 
sharply increasing from 0.77 ml/min/mmHg at FiO2 7.4% up to 1.66 ml/min/mmHg at 
FiO2 8.9%.  The DO2 then followed a steep decrease down to 0.91 ml/min/mmHg at FiO2 
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21% before averaging 0.45 ±0.17 ml/min/mmHg at the higher FiO2 range 25 to 98%.  
Using Piiper‟s DO2 calculation the same trend was observed.  Piiper‟s DO2 increased 
sharply from 0.77 ml/min/mmHg at FiO2 7.4% up to 1.66 ml/min/mmHg at FiO2 8.9%.  
The DO2 then followed a steep decrease down to 0.97 ml/min/mmHg at FiO2 21% before 
averaging 0.67 ±0.13 ml/min/mmHg at the higher FiO2 range 25 to 98%.  At the lower 
FiO2 there was no significant difference between the two calculation methods (p=0.910) 
however at the higher FiO2 25-98% Piiper DO2 was slightly higher than the Lilienthal 
DO2 (p=0.012). 
 
Table 3.6 Varying Oxygenator FiO2 Data Summary Table 
Varying oxygenator FiO2 4.9% to 98% 
Parameter Trend Statistical value p value d.f. or n 
PaO2 linear increase R
2
=0.994 p<0.0001 d.f.=21 
P v O2 Curvilinear increase r=0.935 p<0.0001 n=21 
P c O2 Curvilinear increase r=0.945 p<0.0001 n=21 
M O2 Linear increase R
2
=0.896 p<0.0001 d.f.=20 
DO2 Unique trend - - - 
 
 
Effects of Varying Oxygenator FiO2; Discussion 
With increasing FiO2 a close linear correlation with increasing PaO2 was observed which 
is also expected in life.  This experiment provided reference data for the required FiO2 
needed to achieve a desired PaO2.  In this model the data has shown that a FiO2 of 26% 
was required to give P v O2 and PaO2 within a clinical range compared to 21% in life.  This 
can be attributed to the differences between the membrane oxygenator and the lungs 
which include smaller membrane surface area, larger diameter „pulmonary capillaries‟, 
thicker membrane and heterogeneity of blood and gas flow which all contribute to 
resistance to gas exchange. 
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The linear relationship seen between increasing FiO2 and resultant M O2 showed that as 
more oxygen was available in the gas phase, oxygen transfer increased corresponding with 
an increasing blood oxygen partial pressure (PaO2).  DO2 showed a unique trend with a 
steep rise over the lower FiO2 4.9-8.9% as the oxygen uptake rises rapidly over the 
corresponding steep portion of the ODC (β) where sO2 was approximately 45-85%.  The 
specific conductance of O2 (θ) per 1 ml blood is also increased at low PO2 due to the ease 
of O2 binding.  These findings are supportive of the historical diffusion resistance (1/D) 
equation published by Roughton and Forster (1957), modified by Cotes and Meade 
(1993), where membrane (DM), blood flow (Q ) and pulmonary capillary volume (Vc) 
remain unchanged in this model, attributing affects of O2 uptake to β and θ.   
 
 
 
 
 
  
 
 
      
 
 
FiO2 8.9% to 26% was associated with a less steep decline in DO2 covering the ODC sO2 
range 85-95% where the oxygen binding rate slows.  The plateau in the DO2 at FiO2 >26% 
corresponded with sO2 >98% so the transfer of oxygen based on the sigmoid shape of the 
ODC will be at its lowest.  This finding validates the requirement for FiO2 26% to achieve 
normoxia in this circuit. 
 
The DO2 calculation method used in this project was based on that described by Lilienthal 
(1946).  It is a simplistic calculation of gas uptake divided by the membrane partial 
pressure difference.  The difficulty with this equation is determining PAO2-Pc O2 with 
accuracy.  Bohr determined that PAO2-P c O2 increases non-linearly from PAO2-P v O2 to 
PAO2-PaO2.  He derived a method of calculating this from SaO2 and S v O2 of the ODC.  
This is thought to provide an accurate PAO2-P c O2.  Piiper‟s DO2 calculation is a more 
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complex calculation which simplifies the Bohr process.  However, Piiper uses            
PaO2-P v O2 for the partial pressure gradient difference which does not give the partial 
pressure gradient directly across the membrane as in Lilienthal DO2.  DO2 for varying 
FiO2 was calculated via both Lilienthal and Piiper methods and compared.  Over the 
hypoxic and normoxic conditions the results were virtually the same, however in the 
hyperoxic range Piiper‟s DO2 was significantly higher than the Lilienthal DO2.  The 
pressure gradient difference PaO2-P v O2 used in Piiper‟s DO2 equation will be affected 
by the venous admixture effect i.e. PaO2 will be lower than the end pulmonary capillary 
partial pressure.   At the lower FiO2 Piiper‟s use of PaO2-P v O2 will not be affected 
significantly by the venous admixture affect as at lower blood oxygen saturations the 
effect on PaO2 is less.  At higher FiO2 the lower blood oxygen saturations of the venous 
admixture will have a more diluting effect on the highly saturated blood exiting the 
pulmonary capillaries.  By dividing oxygen uptake by PaO2-P v O2 for the pressure 
gradient difference the overall DO2 will be overestimated particularly at higher FiO2. 
 
The varying oxygenator FiO2 experiment has demonstrated a reference range of PaO2 for a 
given FiO2.  From the data, FiO2 26% has been established as the standard oxygenator 
oxygen concentration required to achieve normoxic arterial blood in this circuit.  The DO2 
to be used for further experimental work will be that described by Lilienthal et al (1946) 
combined with the Bohr integration method.  
 
3.5.4 Effects of Varying Deoxygenator FiCO2; Results   
The FiCO2 range achieved via the deoxygenator in this apparatus was 1.78 to 23.8%.  
 
pH decreased with increasing FiCO2 over the range 1.78 to 23.8%.  pHa decreased from 
7.73 to 7.12 (p<0.0001) and pHv decreased from 7.71 to 6.93 (p<0.0001). (Figure 3.34) 
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Both P v CO2 (p<0.0001) and PaCO2 (p<0.0001) increased linearly in response to 
increasing FiCO2 (Figure 3.35).  At the lower FiCO2 1.78%, PaCO2 and P v CO2 was 
below the detection limit of the CDI 500 analyser at <10 mmHg.  For the FiCO2 range 
2.26 to 23.8%, P v CO2 was 12 to 125 mmHg and PaCO2 ranged 11 to 67 mmHg.  P c CO2 
was calculated from P v CO2 and PaCO2 so subsequently increased linearly from 11.5 to 
96 mmHg (p<0.0001). 
 
M CO2 increased linearly with increasing FiCO2 from 34.06 ml/min (at 2.26%) to 221.16 
ml/min (at 23.8%) (p<0.0001) (Figure 3.36).  DCO2 started high at 11.65 ml/min/mmHg 
at FiCO2 2.26% and then gradually decreased curvilinearly to 3.29 ml/min/mmHg at 
FiCO2 23.8% (p=0.031).  Comparing the modified Piiper method for calculating DCO2 
versus modified Lilienthal formula showed no significant difference (p=0.173) with 
modified Piiper DCO2 starting high at 11.76 ml/min/mmHg at FiCO2 2.26% and then 
gradually decreasing to 3.52 ml/min/mmHg at FiCO2 23.8%. (Figure 3.37) 
 
PaO2 was noted to curvilinearly (p<0.0001) decrease from 135 mmHg (P v CO2 13 
mmHg) to 96 mmHg (P v CO2 43 mmHg) in response to increasing P v CO2, plateauing 
at 90 ±2.89 mmHg (P v CO2 43 to 125 mmHg). P v O2 increased curvilinearly 
(p<0.0001) from 26 mmHg (P v CO2 12 mmHg) to 48 mmHg (P v CO2 125 mmHg). 
(Figure 3.38)  Despite the decrease in PaO2 there was a linear increase in M O2 with 
increasing P v CO2 (p<0.001) from 104.70 ml/min (P v CO2 15 mmHg) to 190.36 ml/min 
(P v CO2 125 mmHg). (Figure 3.39)  Similarly DO2 increased linearly with increasing     
P v CO2 (p<0.0001) from 0.74 ml/min/mmHg (P v CO2 15 mmHg) to 1.62 
ml/min/mmHg (P v CO2 125 mmHg). (Figure 3.40) 
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Table 3.7 Varying Deoxygenator FiCO2 Data Summary Table 
Varying deoxygenator FiCO2 1.78% to 23.8% 
Parameter Trend Statistical value p value d.f. or n 
pHa Linear decrease R
2
= -0.751 p<0.0001 d.f.=24 
pHv Linear decrease R
2
= -0.908 p<0.0001 d.f.=24 
PaO2 Curvilinear decrease r=-0.907 p<0.0001 n=22 
P v O2 Curvilinear increase r=0.992 p<0.0001 n=22 
M O2 Linear increase R
2
=0.872 p<0.001 d.f.=15 
FeO2 Linear decrease R
2
= -0.904 p<0.0001 d.f.=15 
DO2 Linear increase R
2
=0.872 p<0.0001 d.f.=15 
RER Linear increase R
2
=0.892 p<0.0001 d.f.=15 
PaCO2 Linear increase R
2
=0.959 p<0.0001 d.f.=22 
P v CO2 Linear increase R
2
=0.950 p<0.0001 d.f.=22 
P c CO2 Linear increase R
2
=0.962 p<0.0001 d.f.=22 
M CO2 Linear increase R
2
=0.715 p<0.0001 d.f.=23 
DCO2 Curvilinear decrease r=-0.466 p=0.031 n=23 
 
 
To investigate the apparent impact of P v CO2 on PaO2 the FeO2 was plotted against        
P v CO2 (Figure 3.41).  FeO2 decreased linearly with increasing P v CO2 (p<0.0001) from 
23.4% (P v CO2 12 mmHg) to 21.6% (P v CO2 125 mmHg).  The RER was seen to 
increase from 0.30 (P v CO2 12 mmHg) to 1.59 (P v CO2 125 mmHg) in response to 
increasing P v CO2 (p<0.0001) (Figure 3.42).    
 
Effects of Varying Deoxygenator FiCO2; Discussion 
The increase in FiCO2 corresponded with a linear rise in P v CO2 as the partial pressure 
gradient increased between the gas and blood channels, also driving a linear increase in  
M CO2.  Subsequently, pH was seen to decrease in response to the acidity in the blood 
80 
 
generated by the increased carbon dioxide partial pressures.  PaCO2 increased as 
oxygenator gas flows were not adjusted to remove the extra carbon dioxide in the venous 
blood.  The DCO2 decreasing curvilinear trend was consistent with a higher carbon 
dioxide uptake at the lower P v CO2 where the partial pressure difference would aid 
carbon dioxide transfer.  As the blood carbon dioxide levels increase the rate of carbon 
dioxide transfer will decrease.  
 
Hypercapnia is known to cause a right shift in the ODC resulting in increased P v O2 
which was evident in this experiment by the curvilinear increase in response to increasing 
deoxygenator FiCO2.  PaO2 was noted to decrease curvilinearly which caused some 
speculation.  M O2, and subsequently DO2, apparently increased with increasing 
deoxygenator FiCO2 which conflicted with the decrease in PaO2-P v O2 difference.  
During hypercapnia there is a resultant shift in the respiratory exchange ratio (RER) due to 
the extra carbon dioxide leaving the blood and entering the „alveolar‟ gas.  In this 
experiment, the oxygenator FeO2 was found to decrease with increasing deoxygenator 
FiCO2 which was a result of the increasing carbon dioxide moving across the membrane 
into the gas phase.  The decrease in FeO2 would account for the increase in M O2 and DO2 
by creating a calculation error.  An RER shift in man from the normal 0.8 can be at the 
expense of DO2 where hypercapnia occurs, which this model simulates.  If a correction 
factor is applied to the FiO2 values, corresponding to the increasing oxygenator FeCO2, 
the oxygenator FiO2 significantly decreases with increasing P v CO2 (R
2
=0.841, d.f.=14, 
p<0.0001) (Figure 3.44).  The reduced FiO2 would correspond with a decrease in PaO2, as 
the driving partial pressure gradient across the membrane reduces.  The resultant corrected 
M O2 shows no significant change with increasing P v CO2 (R
2
=0.217, d.f.=14, 
p=0.080)(Figure 3.45). 
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The varying deoxygenator FiCO2 experimental data provided a reference of the FiCO2 
required for a given P v CO2.  In further research where the deoxygenator FiCO2 is to be 
varied, correction would be needed for calculation of M O2 and DO2.  The data in this 
work has confirmed the initial deoxygenator FiCO2 8% as the standard gas setting for this 
circuit. 
 
3.5.5 Effects of Varying Haemoglobin Concentration (Hb); Results  
The haematocrit ranges achieved were 7.3-31.0% (run 1), 6.5-27.1% (run 2) and 0.66-
5.7% (run 3) (Figure 3.46).  Run 3 utilised a slower blood addition in order to achieve data 
in the lower Hct range <6% as this data was absent with the faster blood addition rates of 
runs 1 and 2.     
 
pHv (p<0.0001) and pHa (p<0.001) were seen to increase linearly during the blood 
addition for the experimental runs encompassing Hb 6.5 to 31.0 g/dl.  In the first run pHv 
ranged 6.66-7.10 and pHa ranged 6.73-7.13.  Similarly in the second run, pHv ranged 
6.64-7.17 and pHa ranged 6.84-7.31.  For the third run with lower Hct levels, the pHv 
values were below that detected by the analyser <6.5.  The pHa was initially out of range 
until a Hct of 2.5 was reached where the pH ranged 6.55-6.79 up to Hct 5.71.  (Figure 
3.47) 
 
PaO2 (p<0.0001) and P v O2 (p=0.023) when plotted against Hb concentration showed a 
curvilinear relationship (Figure 3.48).  The PaO2 was reading high initially with the saline 
prime (run 3 = 169mmHg) but reduced until the Hct was approximately 20% where the 
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PaO2 stabilised between 50 to 60 mmHg (run 1) or 80-90 mmHg (run 2).  The P v O2 was 
reading very low initially with the saline prime at 10 mmHg (run 3) but this increased as 
blood was added until a Hct of 15% where P v O2 stabilised between 35-38 mmHg (run 1) 
and 40-45 mmHg (run 2).  The resultant calculated P c O2 at the lower Hct range of 0-5.71 
showed a curvilinear increase from 34.56 to 45.31 mmHg.  In runs 1 and 2 where the Hct 
range was 7.3-31.0 and 6.5-27.1, P c O2 was stable at 43.86 ±4.42 mmHg and 56.70 ±2.64 
mmHg, respectively. 
 
The M O2 (p<0.0001) and DO2 (p<0.0001) showed a curvilinear increase over the Hct 
range where the values increased significantly from Hct 0 to 15% before plateauing 
(Figures 3.49 and 3.50).  In run 1, with lesser FiO2 (21%) M O2 and DO2 started at 71.7 
ml/min and 0.56 ml/min/mmHg at 0% rising to a mean of 252.43 ±46.47 ml/min and 2.51 
±0.58 ml/min/mmHg, respectively.  In run 2 with a FiO2 26.3%, M O2 and DO2 started at 
63.39 ml/min and 0.33 ml/min/mmHg at 0% increasing to a mean of 151.17 ±0 ml/min 
and 1.17 ±0.02 ml/min/mmHg, respectively.  Run 3 revealed a gradual increase in both  
M O2 and DO2 over the Hct range 0.66-5.71.  M O2 and DO2 rose from 63.66 ml/min and 
0.75 ml/min/mmHg to 146.92 ml/min and 0.98 ml/min/mmHg with an oxygenator FiO2 
26.5%. 
 
M CO2 data was only taken from runs 2 and 3 as the CO2 delivery for run 1 was 
interrupted during the experiment (Figure 3.51).  At lower Hct range 0.66-5.71 M CO2 
increased curvilinearly from 259.46 ml/min to 297.90 ml/min (p=0.004).  At the higher 
Hct range 6.5-27.1 M CO2 started at 119.34 ml/min at the start of the run (Hb=0) but 
maintained a mean M CO2 182.71 ±4.43 ml/min thereafter in the presence of RBC.  DCO2 
similarly increased from 6.77 ml/min/mmHg to 8.36 ml/min/mmHg over the Hct range 
0.66-5.71.  At the higher Hct range DCO2 was 4.94 ml/min/mmHg with the saline prime 
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and maintained a mean 8.82 ±0.66 ml/min/mmHg over the Hct range 6.45-27.1.  Across 
the whole Hct range 0.66-27.1 DCO2 increased curvilinearly (p=0.002) (Figure 3.52). 
 
Table 3.8 Varying Hb Concentration Data Summary Table 
Varying Hb concentration Hct 0.66% to 31.0% 
Parameter Trend Statistical Value p value d.f. or n 
pHa Linear increase R
2
=0.576 p<0.001 d.f.=19 
pHv Linear increase R
2
=0.870 p<0.0001 d.f.=19 
PaO2 Curvilinear decrease r= -0.913 p<0.0001 n=32 
P v O2 Curvilinear increase r=0.401 p=0.023 n=32 
M O2 Curvilinear increase r=0.726 p<0.0001 n=33 
DO2 Curvilinear increase r=0.699 p<0.0001 n=33 
M CO2 Curvilinear Increase 
at low Hb 
r=0.790 p=0.004 n=11 
DCO2 Increasing trend r=0.623 p=0.002 n=22 
 
 
Effects of Varying Haemoglobin Concentration (Hb); Discussion 
The varying haemoglobin experiment allowed gas transfer at very low haemoglobin 
concentrations to be examined.  This work could not be conducted in living species due to 
the extreme anaemic state.  The haematocrit range covered was conducted using three 
experimental runs which have shown some inter-run variations attributed to the different 
oxygenator circuits used.  The data trends were comparable even if the exact data values 
were not fully comparable. 
 
The prime used for the circuit was 0.9% NaCl which has a pH 5.5.  At very low Hct the 
pH was too acidotic and below the analyser limit (<6.5) but once the Hct reached 2.5% the 
pH showed a linear increase.  The undetectable pH was due to the acidotic prime 
influencing the pH and as blood entered the circuit the pH was buffered.  An alternative 
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prime of lactated ringers (pH 6.5) would have resulted in pH above the detection 
threshold. 
 
PaO2 was high at very low Hct concentrations whereas P v O2 was low.  Dissolved 
oxygen would be removed by the deoxygenator more readily than oxygen bound to 
haemoglobin.  As Hct levels increased the PaO2-P v O2 difference decreased as oxygen 
was liganded to haemoglobin.  At Hct 15-20% the oxygen partial pressures stabilised.   
 
M O2 and DO2 increased curvilinearly corresponding with increasing Hct, plateauing at 
Hct >15%.  As more haemoglobin became available in the circuit, more oxygen was taken 
up via the oxygenator.  Additionally, the haemoglobin being added to the circuit was 
deoxygenated.   Conversely, in this model the threshold Hct for a reduction in M O2 was 
15% (Hb 5 g/dl) which has been shown to cause an increase in cardiac output in acutely 
anaemic (human) volunteers (Weiskopf et al 1998).   In anaemic subjects, cardiac output 
would increase to maintain oxygen delivery thus M O2 and DO2 would not decrease but in 
this model the pump flow was not adjusted to compensate.  Additionally, in the first run a 
FiO2 21% was used in the oxygenator gas compared to 26.5% in the subsequent runs and 
it is noted that the M O2 and DO2 were higher in the lower oxygen gas mix than the higher 
mix.  This corresponded with the findings for the varying oxygenator FiO2 experiment. 
 
The CO2 data was limited due to a gas interruption in the initial experiment rendering the 
CO2 data unreliable.  The data available is small but shows good trends.  M CO2 and 
DCO2 were seen to gradually increase at the low Hct range (0.66-5.71) but then plateau 
after Hct >6.  The initial rise in M CO2 would be a result of the need for CO2 for buffering 
of the circulating blood until more clinical Hct and P v CO2 were achieved.  After this time 
85 
 
CO2 would still be taken up by the blood due to the concentration gradient across the 
membrane and utilised in the buffering reactions but at a slower uptake. 
 
From the increasing haemoglobin experiment the data showed that an Hct >15% was the 
threshold for stabilisation of the oxygen partial pressures and oxygen uptake.  The 
subsequent work in this research was to encompass Hct within the clinical range 27-36 
g/dl.  
 
3.5.6 Blood Shunt; Results 
The shunt fraction was seen to increase linearly with increasing blood flow (p=0.009).  
Shunt fraction ranged from 0.084% at 0.1 l/min up to 37% at 2.5 l/min (Figure 3.18). 
Shunt fraction for 1 cell and 2 cells was not significantly different (p=0.051). 
 
Shunt fraction was plotted against varying oxygenator FiO2 (Figure 3.33) for a standard 
blood flow rate (2.5 l/min) revealing a decreasing curvilinear relationship (p<0.0001).  At 
low FiO2 4.9% the shunt was calculated as 82.2% reducing to 18.5% at FiO2 21%.  At 
higher FiO2 (38-98%) the shunt fraction averaged 0.93 ±0.007%. 
 
Table 3.9 Shunt Fraction Data Summary 
Shunt Fraction 
Parameter Trend Statistical value p value d.f. or n 
Q  Linear increase R
2
=0.183 p=0.009 d.f.=35 
SA No statistical change t=2.021 p=0.051 d.f.=34 
FiO2 Curvilinear decrease r= -0.988 p<0.0001 n=22 
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Blood Shunt; Discussion 
Physiological blood shunting is due to venous blood from the bronchial artery supply 
draining into the left atrium and the coronary artery supply draining into the left ventricle.  
Pulmonary capillary blood from the lungs will be desaturated slightly by this venous blood 
to become the arterial blood.  The shunt fraction is usually 1-2% in healthy adults (Cotes, 
2006) but can increase with ventilation-perfusion mismatches and cardiac abnormalities.  
In the oxygenator, the shunt fraction is likely to be due to the wide blood channel and the 
laminar flow characteristics of the device.  With increasing blood flow, shunt fraction was 
seen to increase up to 37% which suggests there is a large amount of blood not in contact 
with the membrane.  The surface area change did not influence the shunt fraction which 
was expected, as the flow pathway through each side of the membrane is the same. 
 
To determine if the shunt fraction is attributed to poor ventilation-perfusion matching or is 
related to a blood flow pathway, shunt fraction was plotted against FiO2.  In this case the 
shunt fraction was seen to be extremely high (82%) at low FiO2 (4.9%) reducing steeply to 
18.5% at FiO2 21%.  In hyperoxia the shunt fraction reduced to 0.93% which is more 
comparable to the physiological shunt fraction.   The virtual elimination of the shunt 
fraction in hyperoxia indicates that the shunt seen with increasing blood flow can be 
attributed to blood not partaking in the gas exchange due to the blood flow characteristics 
through the device i.e. there is a substantial PO2 gradient decreasing from the immediate 
area of the membrane to the centre of the blood channel. 
 
Early work by Lilienthal (1946) detailed A-a (Alveolar-arterial) PO2 gradient and its 
impact on DLO2 during normoxic and anoxic conditions.  The shunt fraction was assumed 
to be equal during normoxia and anoxia.  Therefore any difference in A-a gradient would 
be attributed to the lung diffusion.  From this experimental work the theory appears to be 
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incorrect as in hypoxia the shunt fraction increases steeply.  Therefore a difference in the 
A-a gradient used in their work may actually be due to increasing shunt and may 
underestimate DLO2.   The original work went unchallenged until 1973 when questioned 
by Dr J B West, prompting Riley and Permutt (1973) to reinvestigate the assumption.  
They confirmed West‟s findings that the shunt fraction increases during low O2 breathing.  
This later publication confirms the findings in this experimental data. 
 
From this experiment, it was found that at FiO2 21% the shunt fraction is elevated which 
could cause a diffusion limitation in the experimental work.  At FiO2 26% the shunt 
fraction was comparable to that seen in life.  This coupled with the normoxic blood partial 
pressures achieved with FiO2 26% are evidence that this FiO2 should be the standard 
oxygenator gas setting.  
 
3.5.7 Circuit variation; Results 
DO2 results from two different circuits run with the same blood donation averaged 0.89 
±0.01 ml/min/mmHg (circuit 1) and 1.06 ±0.00 ml/min/mmHg (circuit 2).  There was a 
significant difference in DO2 (p<0.0001) which was attributed to membrane oxygenator 
variation. 
 
Similar variations were observed with DNO and DCO (p=0.001 and p<0.0001, 
respectively).  DNO averaged 13.52 ±4.76 ml/min/mmHg and 17.25 ±5.62 ml/min/mmHg.  
DCO averaged 1.20 ±0.00 ml/min/mmHg and 1.88 ±0.05 ml/min/mmHg. 
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Table 3.10 Circuit Variation Data Summary 
Circuit Variation 
Parameter Trend Statistical value p value d.f. or n 
DO2 Significant difference t=-5.107 p<0.0001 d.f.=19 
DNO Significant difference t=-3.755 p=0.001 d.f.=19 
DCO Significant difference t=-9.614 p<0.0001 d.f.=19 
 
 
Circuit variation; Discussion 
The membrane oxygenators used were manufactured by perforating the polypropylene in 
order to create a microporous membrane through which gas transfers.  The process is a 
mechanical one which is likely to elicit some variation.  The circuit variation test has 
quantified this as a significant variation which may have an impact on between-run 
comparative experiments.   
 
The marked between-run variation observed with blood from a single horse donor used in 
two circuits shows that the variation observed is between oxygenators.  To limit this 
variation impact, any comparative work would need to be conducted during the same 
experimental run, i.e. using the same circuit set-up and blood donation.  Repeated 
experimental runs can be conducted using a different circuit and blood donation. 
   
 
3.6  NO and CO Gas Transfer Data in This Circuit Design: Results and Discussion  
 
3.6.1 Effects of Varying Blood Flow (Q ) and Surface Area (SA) 
DNO was not affected by changes in blood flow from 0.1 to 2.5 l/min (p=0.333).  There 
was a significant increase in DNO with increasing surface area (p=0.002).  DNO for 1 cell 
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averaged 5.72 ±1.61 ml/min/mmHg and for 2 cells averaged 9.71 ±3.62 ml/min/mmHg. 
(Figure 3.19) 
 
DCO was not significantly affected by changes in blood flow from 0.1 to 2.5 l/min 
(p=0.079).  DCO was significantly affected by changes in surface area with 1 cell 
averaging 1.07 ±0.21 ml/min/mmHg and 2 cells averaging 1.46 ±0.35 ml/min/mmHg for 
run 1 (p=0.039).  In run 2 DCO for 1 cell averaged 0.81 ±0.17 ml/min/mmHg and for 2 
cells averaged 1.13 ±0.25 ml/min/mmHg (p=0.026). (Figure 3.20) 
 
3.6.2 Effects of Varying Oxygenator Gas Flow (F) 
DNO increased linearly with increasing oxygenator gas flow 2.5 to 15.0 l/min (p<0.001).  
DNO increased from 4.76 ml/min/mmHg at 2.5 l/min gas flow up to 11.19 ml/min/mmHg 
at 15 l/min gas flow. (Figure 3.26) 
 
DCO showed no change in response to increasing oxygenator gas flow (p=0.932).  DCO 
averaged 1.36 ±0.28 ml/min/mmHg over the oxygenator gas flow range 2.5 to 15.0 l/min. 
(Figure 3.26) 
 
3.6.3 Effects of Varying Oxygenator FiO2 
DNO was unaffected by increasing FiO2 in the hyperoxic range 21-98% with DNO 
averaging 10.00 ±0.94 ml/min/mmHg (p=0.639) (Figure 3.32).  Similarly DNO was 
unaffected by FiO2 in the hypoxic range 4.9-20% with DNO averaging 5.08 ±0.30 
ml/min/mmHg (p=0.617) (Figure 3.31).  The hypoxic and hyperoxic data were achieved 
with two separate experimental runs so inter-run variation was noted. 
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DCO significantly decreased linearly from 1.98 ml/min/mmHg to 0.50 ml/min/mmHg 
with increasing FiO2 over the range 4.9-98% (p=0.011) (Figure 3.30). 
 
Table 3.11 DNO and DCO Data Summary Table 
Parameter DNO 
Trend Statistic p value d.f. or n 
Blood Flow No change R
2
=0.043 p=0.333 d.f.=23 
Surface 
Area 
Increased t=3.491 p=0.002 d.f.=22 
Oxy gas 
Flow 
Linear increase R
2
=0.978 p<0.001 d.f.=5 
Oxy FiO2 No change R
2
=0.025 
R
2
=0.033 
p=0.639 
p=0.617 
d.f.=10 
d.f.=9 
Deoxy 
FiCO2 
No change R
2
=0.116 p=0.509 d.f.=5 
Hct Linear increase R
2
=0.964 p<0.0001 d.f.=19 
Parameter DCO 
Trend Statistic p value d.f. or n 
Blood Flow No change R
2
=0.134 p=0.079 d.f.=23 
Surface 
Area 
Increased t=-2.369 
t=-2.602 
p=0.039 
p=0.026 
d.f.=10 
d.f.=10 
Oxy gas 
Flow 
No change R
2
=0.002 p=0.932 d.f.=5 
Oxy FiO2 Linear decrease R
2
=0.295 p=0.011 d.f.=21 
Deoxy 
FiCO2 
Linear increase R
2
=0.767 p=0.022 d.f.=5 
Hct Curvilinear increase r=0.782 p<0.0001 n=22 
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3.6.4 Effects of Varying Deoxygenator FiCO2 
DNO was unaffected by increasing deoxygenator FiCO2 ranging 7.8-23% with DNO 
averaging 6.19 ±0.89 ml/min/mmHg (p=0.509) (Figure 3.43). 
 
DCO increased linearly with increasing deoxygenator FiCO2 ranging 7.8-23% with DCO 
increasing from 0.45 ml/min/mmHg to 3.24 ml/min/mmHg (p=0.022) (Figure 3.43). 
 
3.6.5 Effects of Varying Haemoglobin Concentration (Hb) 
DNO significantly increased with rising Hct (p<0.0001) from 0.68 ml/min/mmHg at Hct 
0.66 up to 7.08 ml/min/mmHg at Hct 27.1 (Figure 3.53).   
 
DCO significantly increased curvilinearly with increasing Hct (p<0.0001) from 0.34 
ml/min/mmHg (saline prime) up to 1.09 ml/min/mmHg at Hct 27.1 (Figure 3.53). 
 
3.6.6 DNO and DCO Discussion 
NO and CO are both diffusion limited gases as evident from the data in this series of 
experiments.  Both NO and CO were unaffected by blood flow whereas surface area did 
influence NO and CO uptake which was expected with diffusion limited gases.   
 
Carbon monoxide is a competitive inhibitor to haemoglobin binding oxygen (Roughton et 
al 1957).  Both gases will compete for the same haemoglobin binding site but carbon 
monoxide is preferentially bound as the affinity is greater.  Although the affinity for 
carbon monoxide is greater the reaction with haemoglobin is slower than that for oxygen.  
When the oxygenator FiO2 was increased DCO was seen to decrease.  The high amount of 
oxygen was successfully competing with carbon monoxide and the displacement of this 
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bound oxygen makes the reaction rate with carbon monoxide much slower.  More 
interestingly, DCO increased with increasing deoxygenator FiCO2.  As carbon monoxide 
is delivered via the oxygenator, this seemed an odd finding.  Reviewing the experimental 
data for oxygen, it was noted that PaO2 decreased due to an increase in the oxygenator 
respiratory quotient which suggested a dilutionary effect on O2 as the CO2 transfers from 
the blood into the oxygenator gas.  This would account for the increase in DCO as the 
respiratory quotient shifts favouring the competitive binding of carbon monoxide by 
haemoglobin.  In future work where the respiratory quotient may be varied from the 
clinical 0.7-0.75 range, data must be interpreted with this consideration. 
 
Increasing gas flow through the oxygenator resulted in an increase in DNO but not DCO.  
The reaction rate of NO with haemoglobin is very rapid compared to CO.  When the inlet 
and outlet NO concentration data were compared, it revealed a decrease in NO inlet 
concentration with increasing gas flow, while the outlet concentrations increased as the 
bulk flow carries NO through the gas pathway.  The inlet-outlet difference significantly 
decreased with increasing gas flow to a minimal difference.  The increasing DNO was 
therefore attributed to a mathematical enhancement as the NO concentration difference is 
multiplied by gas flow.  Increasing gas flow through the oxygenator results in quicker gas 
transit time that mathematically enhances DNO but limits DCO.   
 
Rising haemoglobin concentrations increased both DNO and DCO curvilinearly.  The 
prominent increase in diffusion corresponded with the preclinical Hct range <15g/dl.   As 
CO binds to the haemoglobin molecule it is evident that an increase in haemoglobin will 
increase DCO at such low haemoglobin concentrations.  NO binds to the β globin chain of 
haemoglobin but the decreased DNO in low haemoglobin concentrations has been 
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attributed to diffusion resistance of RBCs or plasma (Chapter 5).  Low haemoglobin levels 
provide chemical limitation to DCO and diffusion resistance to DNO.   
 
From this battery of NO and CO experiments, both gases responded to the changing 
conditions with expected results given historical data.  The circuit provides an insight into 
the diffusion of NO and CO under varying conditions where one parameter may be studied 
in isolation.  With this flexibility of the circuit the next phase was to determine the effects 
of haemolysis on DNO and DCO as speculation grows regarding RBC resistance to DNO. 
 
3.7  Model Suitability; Overall Discussion 
 
From the data it is evident that a reliable model of gas exchange over physiological blood 
partial pressure ranges can be achieved with two commercially available oxygenators.  
This model has demonstrated that a deoxygenator membrane surface area of equal size to 
the oxygenator is adequate to provide deoxygenation. 
 
These experiments revealed some inter-run variations in the data so that some 
experimental data taken on different days were not wholly comparable.  However, the 
trends of the data were significant which adds validity to the circuit design.  The inter-run 
variations were considered to be a result of either the initial broad blood donor pool or the 
membrane oxygenator manufacturing process.  Subsequently, the donor selection was 
narrowed to geldings aged 5-12 years rather than including younger or female donors that 
seemed to have skewed earlier data.  The membrane oxygenators used were from clinical 
stock so they will have imposed manufacturing tolerances.  Experiments to clarify the 
differences in gas diffusion across the membrane oxygenators within the circuit added a 
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significant inter-run variation.  Based on this unexpected finding, work involving 
comparative experiments was subsequently conducted using the same blood and circuitry.   
 
Carbon dioxide transfer is less widely investigated probably due to the complex way in 
which carbon dioxide is present within the blood and red blood cell.  In patients, tissues 
produce carbon dioxide and the transfer across the lungs is purely an elimination process.  
In this model, carbon dioxide is actively added to the blood via a membrane deoxygenator 
in order to provide venous blood to the circuit.  Data regarding influences upon carbon 
dioxide transfer is integral to these investigations.   
 
The model can be used to investigate gas transfer with regards to diffusion laws.  Vapour 
density and water solubility denotes the diffusion ratio DCO2>DNO>DO2>DCO.  This 
was demonstrated during the varying blood flow experiment (graph 3.21).  The limiting 
mechanisms of gas transfer were established in this experimental model which reflected 
that previously reported.  Oxygen and carbon dioxide were both considered perfusion 
limited with NO and CO exhibiting diffusion limited characteristics.   
  
A wide range of gas exchange data can be extrapolated from this model and adaptations of 
the methodology can be made for investigating both clinical and non-clinical parameters.  
This circuit has been used to model gas exchange in the presence of nitric oxide and 
carbon monoxide with publication of results (Borland et al 2006 and 2010).  The 
methodology of this model has been previously described (Dunningham et al 2007) but in 
this work the methodology has been extended to enable investigations into the effects of a 
volatile anaesthetic agent (Isoflurane) and a blood substitute (Oxyglobin) on gas diffusion.  
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CHAPTER 4: Effects of the Volatile Anaesthetic Isoflurane on Gas Transfer 
 
Aims 
To test the hypothesis, that a volatile anaesthetic agent (Isoflurane) affects oxygen uptake 
in the membrane oxygenator.  Isoflurane is commonly added to the oxygenator gas flow 
during cardiopulmonary bypass, to provide either anaesthetic to the patient or to control 
hypertension.  It is important to establish if the presence of Isoflurane results in altered gas 
exchange properties of the oxygenator. There is limited data on the impact of Isoflurane 
on oxygen transfer in the membrane oxygenator and most studies are confined to the 
adequacy of anaesthesia to avoid patient awareness during cardiopulmonary bypass 
(Henderson et al 1988, Hickey et al 1996, Philipp et al 2002 and Wiesenack et al 2002).  
In this study, the effects of Isoflurane on oxygen transfer and the oxygen dissociation 
curve (ODC) within the membrane oxygenator were investigated, using a continuously 
running oxygenator and deoxygenator model circuit.  
 
 
4.1 Addition of Isoflurane to the Oxygenator: Circuit Set-Up.  
 
Isoflurane is a volatile anaesthetic in liquid form at room temperature.  The molecules of 
the liquid have low cohesion (poor attraction to other molecules) and a high kinetic energy 
which enable the molecules to pass across the surface of the liquid, known as vaporisation.  
A liquid is considered volatile if it vaporises easily.  A large surface area of the Isoflurane 
liquid will enable rapid vaporisation until equilibrium is reached between the liquid and 
gas.  Therefore, if fresh gas is passed over the surface area of the Isoflurane liquid, vapour 
will be carried away enabling more vapour to form.  Vaporisation is proportional to the 
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gas flow across the surface.  An anaesthetic vaporiser is designed to use these properties to 
mix the volatile agent with a carrier gas such as air and oxygen. 
  
4.1.1 Isoflurane Vaporiser 
The vaporiser type used for this research was the Ohmeda Isotec 3 (Ohmeda, Hatfield, 
UK).  Fresh gas passes through this vaporiser via two channels controlled by an integrated 
flow-splitting valve.  A proportion of the gas is diverted to be exposed to vapour given off 
from the Isoflurane saturated wicks, whilst the remainder of the gas passes through a 
bypass channel.  This design safely regulates the amount of Isoflurane administered into 
the gas flow.  If all of the gas were to pass through the vaporiser the end concentration 
would be too potent.  The concentration setting on the vaporiser controls the flow-splitting 
valve.  Isoflurane liquid is affected by temperature whereby the amount of vapour 
increases with rising temperature.  A temperature-compensating valve is incorporated 
which generates resistance to flow through the vapour chamber with varying temperature.  
The temperature-compensating valve provides a constant concentration of Isoflurane in 
the carrier gas despite temperature fluctuations.    
 
4.1.2 Incorporation of Isoflurane into the Circuit 
The Isoflurane vaporiser was situated in the oxygenator gas inlet tubing (Figures 3.7 pg 44 
and 3.8 pg 47), sited on a mounting bracket that had specifically sized reducing connectors 
to fit into the ¼” gas inlet tubing.  The vaporiser was located initially downstream of the 
FiO2 analyser but was relocated upstream of the FiO2 analyser following the preliminary 
experiments.  In the preliminary work (Borland et al 2007b) Isoflurane was associated 
with an increased oxygen uptake across the membrane oxygenator.  The calculation relies 
upon FiO2 and FeO2 differences, which increased when the vaporiser was switched on due 
to an increase in FiO2.  To verify the data, the FiO2 pre vaporiser and at the oxygenator gas 
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inlet were compared (section 4.2.3).  This work showed that the vaporiser setting switch 
increased the FiO2 of the oxygenator pre vaporiser gas for 1-5% compared to 0% 
Isoflurane.  The FiO2 analyser positioning post vaporiser represented actual oxygen 
concentrations delivered to the oxygenator.    
 
The Isoflurane concentration within the oxygenator gas flow was set to 0.5, 1, 2, 3, 4 and 
5% for the preliminary work or 1% for the main experimental work, using the percentage 
setting dial on the vaporiser.  The circuit was otherwise assembled as described in chapter 
3, section 3.1. 
 
4.1.3 Isoflurane Analyser 
Isoflurane concentrations are analysed via gas chromatography or infrared technology.  
Clinically, the latter has emerged as the current standard analyser due to the compact size, 
rapid response to concentration changes and reliability. The inspired gas Isoflurane 
concentration (FiISO) and expired gas Isoflurane concentration (FeISO) in this work were 
analysed using an in-built infrared analyser on the Datex anaesthetic monitor (Datex-
Ohmeda, Hatfield, UK).    
 
 
4.2 Pilot Experiments With Isoflurane 
 
Aims 
The pilot experiments were designed to clarify the experimental protocol.   
 
The anaesthetic agent was administered via a vaporiser so the initial test was to clarify the 
actual concentration achieved for a particular percentage setting.  This would verify the 
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accuracy of the calibrated vaporiser used in this work.  Then, the actual Isoflurane 
concentration passing across the oxygenator membrane was determined to establish that 
the membrane was permeable to Isoflurane.   Following some initial preliminary tests on 
oxygen transfer in the presence of Isoflurane (Borland et al 2007b) a non dose related 
increase in M O2 was observed which raised concerns over the circuitry.  The FiO2 and 
FeO2 difference appeared to be the determining factor in the M O2 increase so the location 
of the vaporiser to the FiO2 analyser within the gas tubing was investigated.  These tests 
were performed on a circuit assembled dry (without priming). 
 
During a preliminary experimental run with Isoflurane, the time to wash-out was 
determined.  This would be of importance in following experiments where the Isoflurane 
concentration was to be randomised.  Knowledge of the time needed to allow the 
Isoflurane to be removed from the circuit would be critical where 0% Isoflurane followed 
an Isoflurane group. 
 
4.2.1 Pilot Circuit Set-up and Methodology 
1. Isoflurane Vaporiser Test – Concentration versus Setting 
The circuit was set up dry (Chapter 3, section 3.1).  The oxygenator gas flow was set 
to 5 l/min with a FiO2 26%.  The Isoflurane vaporiser was randomly set at 1, 2, 3, 4 or 
5% and the concentration delivered into the gas line determined via analyser.  This 
was repeated five times. 
 
2. Isoflurane Concentrations Pre and Post Oxygenator Membrane 
The circuit was set up dry (Chapter 3, section 3.1).  The blood inlet tubing was 
clamped so that gas passing across the membrane could exit via the blood outlet tubing 
(arterial line) only.  Gas flowing into the oxygenator gas channel would either pass 
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through the gas channel and exit via the exhaust or pass across the membrane exiting 
via the arterial line.  FiO2 was set to 26% and the gas flow randomised to 1, 2, 3, 4 or 5 
l/min.  The Isoflurane vaporiser concentration was randomly set to 0.5, 1, 2 or 3%.  
The Isoflurane concentration was measured pre (FiISO), post oxygenator membrane 
(arterial line) and in the oxygenator exhaust (FeISO). 
 
3. FiO2 Analyser Positioning With Isoflurane 
The circuit was set up dry (Chapter 3, section 3.1).  Two FiO2 analysers (AX300) were 
placed into the oxygenator gas inlet tubing, one pre and another post Isoflurane 
vaporiser.  The oxygenator gas was set to 5.5 l/min with a FiO2 27%.  The Isoflurane 
vaporiser setting was randomly adjusted to 0, 1, 2, 3, 4 or 5% and the pre and post 
vaporiser FiO2 recorded for each change.  This was repeated five times. 
 
4. Isoflurane Wash-out 
The circuit was set-up and primed with equine blood (Chapter 3, section 3.1).  The 
oxygenator gas settings were 5 l/min air with 0.3 l/min O2.  The deoxygenator gas 
settings were 5 l/min 5% CO2 in balanced N2 with 0.2 l/min CO2.  The blood flow of 
the circuit was 2.5 l/min.  The Isoflurane vaporiser was set to 1% (based on the 
outcomes from the FiO2 Analyser Positioning Experiment section 4.2.3) and this was 
confirmed by FiISO and FeISO measurements.  The Isoflurane vaporiser was turned to 
0% and the FeISO recorded at 5, 25, 30, 35, 40, 45, 60, 70 and 80 seconds.  The 
Isoflurane washout time for 1% concentration was calculated from this data.    
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4.2.2 Pilot Experimental Results 
1. Isoflurane Vaporiser Test – Concentration versus Setting 
The actual mean Isoflurane concentrations versus the vaporiser settings are given in 
Table 4.1.  There was good correlation between the Isoflurane concentration achieved 
versus the Isoflurane concentration setting (Figure 4.1, R
2
=0.998).   For each change in 
Isoflurane concentration it was noted to take three minutes for the concentration 
reading to stabilise on the Datex analyser. 
 
Table 4.1 Isoflurane Concentration Setting Versus Analyser Concentration 
Isoflurane Vaporiser 
Conc. % 
Analyser Isoflurane 
Conc. % 
Mean (SD) 
% 
Difference 
1.0 0.93 (0.00) 7% 
2.0 1.8 (0.00) 10% 
3.0 2.9 (0.00) 3.3% 
4.0 3.8 (0.00) 5% 
5.0 5.0 (0.00) 0% 
 
 
 
Figure 4.1 Isoflurane oxygenator inlet concentration versus the vaporiser setting; 
There was a good correlation between the Isoflurane concentration achieved versus the 
Isoflurane vaporiser concentration setting (R
2
=0.998).    
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Table 4.2 Pre and Post Membrane Isoflurane Concentrations. 
The FeISO and arterial line Isoflurane concentrations were compared (t-test) to the 
FiISO for each concentration setting to determine significant differences in Isoflurane 
distribution within the circuit.  No differences in distribution were observed  
 Mean SD t-test value p value d.f. 
0.5% FiISO 0.46 0.001 - - - 
0.5% FeISO 0.44 0.001 0.955 p=0.352 18 
0.5% 
Arterial line 
0.44 0.002 1.197 p=0.247 18 
1% FiISO 0.90 0.004 - - - 
1% FeISO 0.89 0.004 0.412 p=0.686 18 
1% Arterial 
line 
0.88 0.007 0.684 p=0.504 18 
2% FiISO 1.91 0.010 - - - 
2% FeISO 1.88 0.006 0.747 p=0.464 18 
2% Arterial 
line 
1.86 0.009 1.140 p=0.269 18 
3% FiISO 2.91 0.028 - - - 
3% FeISO 2.84 0.012 1.187 p=0.251 18 
3% Arterial 
line 
2.81 0.017 1.504 p=0.150 18 
 
2. Isoflurane Concentrations Pre and Post Membrane 
The FiISO, FeISO and arterial line Isoflurane concentrations were unaffected by the 
gas flow.  There was no notable difference in the inlet gas Isoflurane concentrations 
compared to both the outlet gas and arterial line concentrations (Table 4.2).   
 
3. FiO2 Analyser Positioning With Isoflurane 
The difference between pre vaporiser and post vaporiser FiO2 was 0.4% at 0% 
Isoflurane up to 2.3% at 4% Isoflurane.  The data showed statistically significant pre 
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and post vaporiser FiO2 differences in the Isoflurane concentration range 1-5%.  The 
actual mean pre and post vaporiser values are presented in Table 4.3. 
 
 
Table 4.3 Pre and Post Isoflurane Vaporiser FiO2 Data 
FiO2 was measured pre and post vaporiser to determine effects of vaporiser positioning 
within the gas line.  The pre vaporiser FiO2 increased when Isoflurane (1-5%) was 
switched on.  Post vaporiser values decreased with Isoflurane presence with t-test 
values highlighting the pre-post vaporiser FiO2 significance.   
Isoflurane 
Conc. % 
Pre 
Vaporiser 
FiO2 
Post 
Vaporiser 
FiO2 
Pre-Post 
% 
Difference 
t-test 
value 
p value d.f. 
0 0.265 
 (SD 0.006) 
0.261  
(SD 0.004) 
0.4% 1.233 p=0.252 8 
1 0.273 
(SD 0.005) 
0.259  
(SD 0.005) 
1.4% 4.185 p=0.003 8 
2 0.272  
(SD 0.004) 
0.254  
(SD 0.005) 
1.8% 6.114 p<0.001 8 
3 0.271  
(SD 0.004) 
0.254  
(SD 0.006) 
1.7% 5.743 p<0.001 8 
4 0.272  
(SD 0.003) 
0.249  
(SD 0.003) 
2.3% 11.387 p<0.0001 8 
5 0.272  
(SD 0.003) 
0.250  
(SD 0.003) 
2.2% 12.080 p<0.0001 8 
 
 
4. Isoflurane Wash-out 
With the Isoflurane vaporiser set to 1%, the FiISO and FeISO were 1.30% and 1.00% 
respectively.  The time to completely wash out 1% Isoflurane from the circuit was 80 
seconds.   The t⅟2 was calculated as 25.4 seconds. (Figure 4.2) 
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Figure 4.2 Oxygenator wash out time for 1% Isoflurane; The time to completely wash 
out 1% Isoflurane from the circuit was 80 seconds.   The t⅟2 was calculated as 25.4 
seconds. 
 
4.2.3 Pilot Experimental Outcomes 
The Isoflurane concentration measured in the gas was lower than the vaporiser 
concentration setting for all but the 5% setting.  According to the manufacturer‟s 
specifications, the Isotec 3 vaporiser has an acceptable calibration tolerance of 10% of the 
percentage dial setting.  The vaporiser used in this experiment was within the acceptable 
tolerances.  Whilst this test has highlighted a reduction in Isoflurane concentrations the 
relevance would be negligible as inlet and outlet concentrations were subsequently 
analysed for each experiment.  The time taken for Isoflurane concentrations to stabilise on 
the Datex analyser was 3 minutes.  In the circuit pilot tests (Chapter 3, section 3.2) PaO2 
on the CDI 500 analyser took 4.5 minutes to reach equilibrium resulting in a 5 minute run 
after each experimental change before recording data.  
 
The Isoflurane concentrations measured in the outlet gas (FeISO) and arterial line were 
found to be marginally less than the inlet gas (FiISO) although not significantly different.  
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The gas inlet and outlet were continuous with little resistance to flow so no variation in 
Isoflurane concentration between FiISO and FeISO was expected or observed.  For 
Isoflurane to pass into the arterial line it had to cross the microporous membrane and there 
was potential for the membrane to cause a degree of resistance to the gas flow.  However, 
as indicated by the Isoflurane concentration difference between FiISO and the arterial line, 
a membrane resistance to the varying gas flow was not observed.  This result also 
demonstrated that Isoflurane was not absorbed by the membrane material polypropylene. 
 
The difference in FiO2 pre and post vaporiser was marked with a notable increase (2.6%) 
in pre vaporiser FiO2 when Isoflurane was switched on (1-5%).  Manufacturers of oxygen 
sensors state that volatile anaesthetic agents can interfere with the oxygen reading.  The 
manufacturer of this oxygen analyser (Teledyne AX300) stated a reading error of <1.5% 
in the presence of Isoflurane but in this test we found greater reading errors of up to 2.6%.  
For subsequent work the FiO2 analyser was placed post Isoflurane vaporiser to ensure 
accurate FiO2 data collection at oxygenator inlet.  If the FiO2 was measured prior to the 
vaporiser, it would always be higher than the actual FiO2 delivered to the oxygenator as 
the Isoflurane concentration itself would reduce the FiO2.  The Isoflurane was 
subsequently used at 1% throughout this work in order to represent a clinical 
concentration.  At 1% Isoflurane there was minimal FiO2 reading error based on this work. 
 
The Isoflurane 1% wash out t½ was calculated as 25.4 seconds which was much quicker 
than that cited by Henderson et al (1988) at 12.2 minutes in normothermic conditions.  
The work carried out by Henderson et al was conducted in patients on cardiopulmonary 
bypass.  The times will be increased in vivo due to retention and release of the anaesthetic 
agent by tissues (Eger 2004).  This in vitro work was not subjected to these influential 
factors hence the much quicker clearance of Isoflurane.  The t½ for this in vitro circuit was 
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important for experiments conducted in the absence and presence of Isoflurane in a 
random order to ensure adequate recirculation time was applied for the anaesthetic to be 
removed.  In the following experiments where Isoflurane was discontinued, a minimum 
period of ten minutes elapsed prior to further experimental work commencing. 
 
 
4.3 Effects of Isoflurane on O2 Transfer: Methodology 
 
The experimental circuit was set-up and primed as described in Chapter 3, section 3.1.  
For each experimental change, the pH, PO2 and PCO2 values from the CDI 500 monitor 
for both venous and arterial blood were recorded after 5 minutes equilibration.  Venous 
and arterial blood saturations were noted from the Spectrum Medical M2 analyser.  The 
oxygenator FiO2 and FeO2 were established for each change.  Inspired Isoflurane and 
expired Isoflurane concentrations were also measured via the Datex analyser in either the 
oxygenator or the deoxygenator gases as appropriate. 
 
4.3.1 Effects of Oxygenator Isoflurane on DO2 
The blood flow was set at 2.5 l/min.  The oxygenator was ventilated with 5 l/min mixture 
of N2 and O2 giving FiO2 ranging 5.9 to 34.7%.  Isoflurane was administered via the 
oxygenator gas line at 0% or 1% for each FiO2 range.  The deoxygenator was ventilated 
with 5 l/min 5% CO2 in balanced N2 and 0.2 l/min CO2.   The test was repeated five times 
on different days using a new circuit and equine donor each time. 
 
4.3.2 Effects of Deoxygenator Isoflurane on DO2 
The blood flow was set at 2.5 l/min.  The oxygenator gas was 5 l/min N2 and O2 at varying 
mixtures to give a FiO2 ranging 3.3 to 31.8%.  Isoflurane was initially delivered via the 
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oxygenator at 1% concentration for the FiO2 range.  The deoxygenator received 5 l/min 
5% CO2 in balanced N2 with 0.2 l/min CO2.  The circuit was run for a period of 15 
minutes without Isoflurane administration prior to switching the Isoflurane vaporiser to 
the deoxygenator gas inlet line.  The oxygenator and deoxygenator received the same gas 
regime as previously stated with the deoxygenator gas delivering 1% Isoflurane, via the 
deoxygenator membrane, to the circuit blood.  
 
4.3.3 Effects of Isoflurane on ODC 
The blood flow was set to 2.5 l/min.  The deoxygenator gas was 5 l/min 5% CO2 in 
balanced N2 with 0.2 l/min CO2.  The oxygenator was ventilated with a total gas flow of 5 
l/min comprising O2 and N2 mix achieving FiO2 ranging 5.9 to 34.7%.  Isoflurane was 
administered via the oxygenator gas inlet line and was set to 0% or 1%.  For each 
Isoflurane setting, ten FiO2 concentrations within the range 5.9 to 34.7% were randomly 
tested.   
 
4.3.4 Calculations 
The calculations are detailed in Chapter 3, section 3.3.8.  Details of Hills Plots are given in 
Chapter 2, section 2.1. 
 
4.3.5 Statistical Analysis 
The statistical analysis has been described in Chapter 2, section 2.2.   
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4.4 Effects of Isoflurane on the Membrane Diffusion Ability: Methodology 
 
To determine if Isoflurane has an effect on the diffusion ability of the membrane, tests 
were conducted in the presence of NO and CO.  NO and CO are both diffusion limited 
gases so if Isoflurane exerted an effect on the diffusion capabilities of the membrane, a 
change in DNO and DCO would be evident. 
 
4.4.1 Effects of Isoflurane on DNO and DCO 
The circuit was run with varying blood flow of 0.5, 1.0, 2.0 and 3.0 l/min.  The 
deoxygenator received 5 l/min 5% CO2 in balanced N2 with 0.3 l/min CO2.  The 
oxygenator gas was set to 5 l/min air with 0.3 l/min O2 resulting in FiO2 24.8%.  NO and 
CO were added to the oxygenator gas at 5000 ppb and 0.03% respectively.  The Isoflurane 
was randomly set to 0, 1, 2, 3, 4 and 5% in the oxygenator gas and for each of these 
Isoflurane settings the blood flow was randomly tested at the flow rates detailed above.  
Inspired and expired NO and CO were established for each change of Isoflurane 
concentration and blood flow. 
 
4.4.2 Calculations 
The DNO and DCO calculations are detailed in Chapter 3, section 3.4.3. 
 
 
4.5 Effects of Isoflurane on O2 Transfer: Results 
 
Isoflurane was taken up by the blood as indicated by a reduction in FeISO concentrations 
compared to FiISO concentrations (Figure 4.3). 
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Figure 4.3 FiISO and FeISO values for each vaporiser setting; Reduction of FeISO ■ 
for each corresponding FiISO ■ demonstrates the uptake of Isoflurane across the 
membrane oxygenator.  
 
4.5.1 Effects of Oxygenator Isoflurane on DO2 
There was no significant change in PaO2 (p=0.380) and P v O2 (p=0.475) in the presence 
of 1% Isoflurane when compared to the control (0% Isoflurane).  PaO2 averaged 50.60 
±24.12 mmHg at 0% Isoflurane compared to 46.64 ±21.33 mmHg at 1% Isoflurane 
(Figure 4.4).  P v O2 averaged 33.77 ±7.06 mmHg with 0% Isoflurane compared to 32.78 
±6.99 mmHg in the presence of 1% Isoflurane (Figure 4.5). 
 
The addition of Isoflurane to the oxygenator gas flow did not affect M O2 (p=0.981).  At 
0% Isoflurane M O2 was 136.83 ±85.40 ml/min compared to 137.24 ±88.12 ml/min at 1% 
over the FiO2 range.  (Figure 4.6) 
 
The addition of Isoflurane to the oxygenator gas flow did not affect DO2 (p=0.605).  DO2 
was calculated as 2.09 ±1.09 ml/min/mmHg at 0% Isoflurane compared to 2.20 ±1.18 
ml/min/mmHg for 1% Isoflurane.  (Figure 4.7) 
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Figure 4.4 Effects of Isoflurane on PaO2 at varying FiO2; There was no significant 
change in PaO2 (p=0.380) in the presence of 1% Isoflurane ■ when compared to 0% 
Isoflurane ♦.  PaO2 averaged 50.60 ±24.12 mmHg (range 20 to 117 mmHg) at 0% 
Isoflurane compared to 46.64 ±21.33 mmHg (range 20 to 114 mmHg) at 1% Isoflurane.   
 
 
 
Figure 4.5 Effects of Isoflurane on P v O2 with varying FiO2; There was no significant 
change in P v O2 (p=0.475) in the presence of 1% Isoflurane ■ when compared to 0% 
Isoflurane ♦.  P v O2 averaged 33.77 ±7.06 mmHg (range 21 to 44 mmHg) with 0% 
Isoflurane compared to 32.78 ±6.99 mmHg (range 21 to 45 mmHg) in the presence of 1% 
Isoflurane. 
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Figure 4.6 Effects of Isoflurane on M O2 at varying FiO2; Addition of Isoflurane to the 
oxygenator gas flow did not affect M O2 (p=0.981).  At 0% Isoflurane ♦ M O2 was 136.83 
±85.40 ml/min compared to 137.24 ±88.12 ml/min at 1% ■ over the FiO2 range. 
 
 
   
Figure 4.7 Effects of Isoflurane on DO2 at varying FiO2; Addition of Isoflurane to the 
oxygenator gas flow did not affect DO2 (p=0.605).  DO2 was calculated as 2.09 ±1.09 
ml/min/mmHg at 0% Isoflurane ♦ compared to 2.20 ±1.18 ml/min/mmHg for 1% 
Isoflurane ■. 
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4.5.2 Effects of Deoxygenator Isoflurane on DO2 
There was no significant difference in DO2 when Isoflurane (1%) was delivered via the 
oxygenator or the deoxygenator (p=0.405).  DO2 ranged 0.93 to 2.80 ml/min/mmHg 
(mean 1.68 ±0.35 ml/min/mmHg) for the oxygenator Isoflurane and ranged 0.92 to 2.95 
ml/min/mmHg (mean 1.91 ±0.40 ml/min/mmHg) for the deoxygenator Isoflurane. 
 
4.5.3 Effects of Isoflurane on ODC 
SaO2 was plotted against PaO2 to highlight the arterial ODC (Figure 4.8). The arterial 
ODC presented as a Hills plot (Figure 4.9) showed good correlation between log PaO2 and 
SaO2 (S/1-S) (p<0.0001).  The arterial ODC showed no significant shift in the presence of 
1% Isoflurane compared to the control group (0% Isoflurane) (p=0.311).  
 
S v O2 was plotted against P v O2 to form the venous ODC (Figure 4.10).  When plotted 
as a Hills plot (Figure 4.11) there was good correlation between the log P v O2 and S v O2 
(S/1-S) (p<0.0001).  There was no significant shift of the ODC in the presence of 1% 
Isoflurane compared to the control group (0% Isoflurane) (p=0.751). 
 
The P50 was calculated from the venous ODC Hills plot as 24.23 mmHg for blood exposed 
to 0% Isoflurane compared to 24.00 mmHg for blood exposed to 1% Isoflurane.  
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Figure 4.8  Effects of Isoflurane on the Arterial ODC; The arterial ODC showed no 
significant shift in the presence of 1% Isoflurane ■ compared to the control group ♦ (0% 
Isoflurane) (p=0.311).  
 
 
Figure 4.9 Effects of Isoflurane on the arterial ODC – Hills plot; The arterial ODC 
presented as a Hills plot showed good correlation between log PaO2 and SaO2 (S/1-S) 
(p<0.0001).  The arterial ODC showed no significant shift in the presence of 1% 
Isoflurane ■ compared to the control group ♦ (0% Isoflurane) (p=0.311).  
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Figure 4.10 Effects of Isoflurane on the Venous ODC; There was no significant shift of 
the ODC in the presence of 1% Isoflurane ■ compared to the control group ♦ (0% 
Isoflurane) (p=0.751). 
 
 
 
Figure 4.11  Effects of Isoflurane on the Venous ODC – Hills plot; When plotted as a 
Hills plot there was good correlation between the log P v O2 and S v O2 (S/1-S) 
(p<0.0001).  There was no significant shift of the ODC in the presence of 1% Isoflurane ■ 
compared to the control group ♦ (0% Isoflurane) (p=0.751). 
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Table 4.4 Effects of Isoflurane on DO2 Data Summary 
Effects of Isoflurane on DO2 
Parameter Trend Statistical value p value d.f. or n 
PaO2 No change t=0.881 p=0.380 d.f.=101 
P v O2 No change t=0.718 p=0.475 d.f.=101 
M O2 No change t=-0.024 p=0.981 d.f.=101 
DO2 No change t=-0.518 p=0.605 d.f.=101 
Deoxy Iso 
DO2 
No change t=-0.852 p=0.405 d.f.=18 
Art ODC Hills Correlation 
No ODC shift 
R
2
=0.762 
t=1.019 
p<0.0001 
p=0.311 
d.f.=99 
d.f.=99 
Ven ODC Hills Correlation 
No ODC shift 
R
2
=0.729 
t=-0.318 
p<0.0001 
p=0.751 
d.f.=102 
d.f.=102 
 
 
 
4.6 Effects of Isoflurane on the Membrane Diffusion Ability: Results  
 
4.6.1 Effects of Isoflurane on DNO and DCO 
DNO (p=0.001) and DCO (p<0.0001) increased curvilinearly in the presence of Isoflurane 
0% to 5% (Figure 4.12).  Table 4.5 shows the mean and SD values for DNO and DCO for 
each Isoflurane concentration.  The effect was predominantly seen at the 4% and 5% 
Isoflurane concentrations.  If the test was conducted on the 0 to 3% „clinical‟ Isoflurane 
concentration range neither DNO (p=0.622) or DCO (p=0.340) were significantly 
increased. 
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Table 4.5 Effects of Isoflurane Concentration on Mean DNO and DCO 
Mean DNO and DCO values for each Isoflurane concentration showed a curvilinear 
increase statistically significant over the range 0-5% but not the clinical range 0-3%. 
Isoflurane 
Concentration 
% 
DNO 
ml/min/mmHg 
Mean (SD) 
DCO  
ml/min/mmHg  
Mean (SD) 
0 % 4.50 (1.42) 0.74 (0.14) 
1 % 3.76 (0.30) 0.76 (0.14) 
2 % 3.83 (0.16) 0.82 (0.17) 
3 % 3.96 (0.20) 0.83 (0.16) 
4 % 5.35 (0.25) 1.07 (0.16) 
5 % 6.15 (0.44) 1.22 (0.08) 
0-5% stats r=0.620, n=24 
p=0.001 
r=0.721, n=24 
p<0.0001 
0-3% stats r=0.133, n=16 
p=0.622 
r=0.255, n=16 
p=0.340 
 
 
 
Figure 4.12 Effects of Isoflurane on DNO and DCO; DNO ♦ (p=0.001) and DCO ■ 
(p<0.0001) increased curvilinearly in the presence of Isoflurane 0% to 5%.  The effect 
was predominantly seen at the 4% and 5% Isoflurane concentrations.  In the 0 to 3% 
„clinical‟ Isoflurane concentration range neither DNO (p=0.622) or DCO (p=0.340) 
were significantly increased. 
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4.7 Implications of Isoflurane Use in the Membrane Oxygenator: Discussion. 
 
During cardiopulmonary bypass, Isoflurane is added to the oxygenator gas providing 
either anaesthetic to the patient or hypertension treatment (Alston 1989).  Oxygenator 
manufacturers discourage the use of volatile anaesthetic agents in their devices yet the 
practice is commonplace.  It is important to establish if Isoflurane may result in altered gas 
exchange properties of the oxygenator.  This study investigated the effects of Isoflurane on 
oxygen transfer within a membrane oxygenator using a continuously running oxygenator 
and deoxygenator model.   
 
Previously, preliminary results indicated that Isoflurane in the oxygenator gas caused an 
increase in oxygen uptake (M O2), significant at all concentrations but not dose related    
(1 to 5%).  The data showed a venous ODC left shift although the arterial ODC was 
unaffected.  The apparent left shift of the venous ODC corresponded with the observed 
increase in oxygen uptake (Borland et al 2007b).  Further investigation in this work 
suggested that the FiO2 analyser was affected by Isoflurane vaporiser interference.  The 
M O2 equation is based upon the FiO2 and FeO2 difference, multiplied by gas flow.  
Therefore, any interference of FiO2 analysis may inadvertently affect M O2.  
Manufacturers of the FiO2 analyser (AX300) have cited an interference rate of <1.5% 
however in this work it was seen to increase to 2.6% at 1-5% Isoflurane concentrations.  
Following the pilot study, the AX300 was repositioned downstream of the vaporiser to 
minimise interference and to establish accurate FiO2 delivery at the oxygenator.  After this 
change no effects on M O2 were evident.  The results of the experiments detailed in this 
chapter were repeated with consistency validating these findings rather than the presented 
preliminary work (Borland et al 2007b).  Muhle et al (2001) conducted a similar study in a 
hollow fibre microporous polypropylene membrane oxygenator concluding no effect of 
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Isoflurane on M O2.  Muhle‟s study involved venous conditioning of bovine blood before 
passing through the test oxygenator exposed to gas containing Isoflurane.  It was a single-
pass experiment of thirty seconds duration.  Based on this work, the circuit run time for 
Muhle‟s study was not adequate for Isoflurane to equilibrate between the blood and gas 
phases.  In this experiment, the washout phase t½ was calculated as 25.4 seconds and 
therefore five minutes were allowed to elapse after each settings change.  Despite this, the 
conclusions reached by Muhle and this group are the same.  The FiO2 analyser placement 
was a significant influence in this work.  Clinically, these analysers are often placed prior 
to the vaporiser so patients will receive less inspired oxygen than the analyser displays.  
 
There was no significant change in PaO2 or P v O2 in the presence of Isoflurane compared 
to controls.  This coupled with an absence of an Isoflurane effect on M O2 adds validity to 
the conclusion that Isoflurane does not affect oxygen transfer in the membrane 
oxygenator.  An ODC experiment was conducted to determine if Isoflurane affected the 
carriage of oxygen in blood.  The circuit equipment was modified to simulate a tonometer, 
a novel approach not published by any other group.  By simultaneously measuring arterial 
and venous PO2 and arterial and venous sO2, the ODC was determined.  Addition of 1% 
Isoflurane had no significant effect on arterial or venous PO2 or sO2 in the membrane 
oxygenator.  Subsequently, the venous and arterial ODCs were unaffected by 1% 
Isoflurane.  This finding concluded that 1% Isoflurane did not affect oxygen carriage in 
the blood. 
 
To determine if Isoflurane affected gas transfer properties of the membrane oxygenator, 
the circuit was run with nitric oxide (NO) and carbon monoxide (CO) present in the 
oxygenator gas.  NO and CO are both diffusion limited gases which could indicate 
changes in membrane porosity or permeability.  In this work, there was no statistically 
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significant difference in DNO or DCO between control and Isoflurane groups for clinical 
concentrations of 1 to 3%.  This concluded that the membrane gas transfer properties are 
unaffected by 1-3% Isoflurane, corresponding with the lack of effect in oxygen transfer 
across the membrane where 1% Isoflurane was used.  1% Isoflurane was selected as it 
represented the clinical Isoflurane concentration for the membrane oxygenator (Rhodia 
NZ Ltd 1999).  At higher Isoflurane concentrations (4 and 5%) DNO and DCO both 
significantly increased.  The reason for this apparent membrane effect exerted by high 
Isoflurane concentrations remains unclear.  It is speculated that in higher Isoflurane 
concentrations the membrane pores are surrounded by a vapour barrier rather than a water 
barrier which may aid NO and CO transfer.  Although DNO and DCO increases observed 
at higher Isoflurane concentrations suggest an effect on the membrane, this does not 
account for the DO2 increase in the preliminary data at all concentrations.  The FiO2 
analyser placement in relation to the Isoflurane vaporiser was deemed accountable for the 
enhanced DO2 rather than a membrane effect.  In this work, clinical Isoflurane 
concentrations did not affect the membrane oxygenator gas transfer ability.  
 
An interaction between the membrane and Isoflurane (4 and 5%) was considered.  FiISO 
and FeISO data demonstrated uptake of Isoflurane from the gas.  Hickey et al (1996) 
investigated the effects of uptake and elimination of Isoflurane in different membrane 
oxygenators, concluding that microporous polypropylene membranes have low affinity for 
Isoflurane.  A FiISO concentration of 1.15% administered via the oxygenator gas resulted 
in bovine blood concentrations of 2.6-2.9mg/dl after five minutes of exposure (Hickey et 
al 1996).  FiISO 1% would achieve similar Isoflurane blood concentrations in this study.  
The pilot work showed the same Isoflurane concentrations present in the oxygenator inlet 
gas, in the exhaust gas and arterial line.  If the membrane absorbed Isoflurane a reduction 
in Isoflurane concentration in the arterial line would have been observed.  Based on this 
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work and previously reviewed studies (Crosbie et al 1998 and Lanquetot et al 2002), it is 
concluded that Isoflurane does not interact with the polypropylene membrane.  
 
The circuit developed for this work can be used to investigate the effects of a volatile 
anaesthetic agent on gas transfer.  Manufacturers of membrane oxygenators would need to 
seek approval from the regulatory bodies to permit use of volatile anaesthetic agents in 
their devices.  Extensive tests would have to be conducted, with this work being an 
example of that requirement.  This work demonstrates that Isoflurane used within the 
clinical range has no effect on oxygen transfer in polypropylene microporous membrane 
oxygenators or oxygen carriage in the blood.  Administration of Isoflurane via 
polypropylene microporous membrane oxygenators during cardiopulmonary bypass will 
not adversely affect patient care.   
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Chapter 5:  Effects of Haemolysis on DO2 DCO2 DNO and DCO 
 
Aims 
To test the hypothesis that haemolysis of whole blood does not affect DO2, DCO2, DNO 
and DCO in the membrane oxygenator circuit.  There is little data on the effects of 
haemolysis on DO2 and DCO2 due to ethical issues of inducing gross haemolysis in living 
species.  Patients exhibiting clinical haemolysis are likely to have secondary effects such 
as altered lung physiology which may preclude reliable gas transfer data.  The membrane 
oxygenator model designed in this work facilitates the investigation into the effects of 
haemolysis on gas transfer.  NO is used in conjunction with CO for lung function testing 
whereby DNO is considered to reflect alveolar-capillary diffusion (Heller and Schuster 
1998).  NO is a diffusion limited gas which has an instantaneous reaction with 
oxyhaemoglobin in contrast to CO.  Based on this DLNO would be equal to DMNO 
(Guenard et al 1987).  There has been speculation that the specific conductance of NO 
within the blood (θNO) may not be infinite as previously assumed (Borland 1990, 2003, 
2005, 2006, 2010).  If this is the case then the values for DLNO do not represent DMNO as 
the NO reaction with blood may influence the results.  To determine the effects of gross 
haemolysis on DO2, DCO2, DNO and DCO the circuit was primed with equine blood and 
gradually haemolysed by addition of water to the circuit volume.  To reflect clinical levels 
of haemolysis (up to 2.1 g/dl in long term dialysis patients, Rother et al 2005) a free Hb 
solution was prepared and gradually added to the circuit blood where DO2, DNO and 
DCO were evaluated. 
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5.1 Altering the Circuit Blood via Gross Haemolysis: Circuit Set-Up.  
 
To achieve haemolysis, a quantity of water was to be added to the circuit blood to cause 
the RBC to swell and lyse.  The venous reservoir facilitates the addition of volume to the 
circuit via access ports on the top.  Three types of port were available, Luer lock, ¼” and 
⅜”.  The Luer lock allows attachment of a syringe or a fluid administration line whereas 
the ¼” and ⅜” ports attach appropriate sized tubing.  In the first pilot experiment, water 
was added via a fluid administration line attached to a Luer lock on top of the reservoir.  A 
500 ml tap water aliquot was measured using a measuring cylinder and added via the fluid 
administration line.  A second 500 ml aliquot of tap water was added in the same way.  In 
total, 1000 ml of water was added which achieved visual haemolysis, also confirmed by a 
potassium increase from 5.4 to 9.5 mmol/l measured via the CDI 500 analyser.  The 
volume to be added in subsequent experiments was likely to be 1000 ml but over a slower 
flow rate such as 60 ml/min so a gradual haemolysis would occur.  Therefore, a more 
consistent volume addition methodology was required.  
 
A second reservoir was added to the circuit.  ⅜” PVC tubing was attached to the reservoir 
outlet, directed around a second calibrated stockert positive displacement pump (water 
pump) and attached to the available ⅜” access port on the venous reservoir.  The second 
reservoir was filled with 1500 ml of tap water via a fluid administration line.  The second 
(water) pump was utilised to administer the water to the circuit at a designated flow rate 
i.e. 60 ml/min. 
 
Haemolysis in the circuit blood was determined by an increase in blood potassium levels 
as potassium is released from the red blood cell (RBC) when lysed by water.  Potassium 
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levels were analysed using the CDI 500 analyser with a potassium range 1.0 to 10.0 
mmol/l (bias 0.12 mmol/l). 
 
 
5.2 Free Hb Solution Addition to the Circuit Blood: Circuit Set-Up.  
 
5.2.1 Free Hb Solution Preparation 
For preparation of free Hb solution, 500 ml of horse blood (PCV 50% and 44%, Hb 17.0 
and 15.2 g/dl) was stored upright overnight, refrigerated, to allow the separation of RBCs 
from the plasma.  The following morning, plasma was expressed from the top of the blood 
bag by a separating clamp leaving the RBCs in the bottom of the bag. Tap water was 
added to a total volume of 500ml to achieve complete haemolysis.  The blood bag 
containing the free Hb solution was agitated by hand prior to removal of the free Hb 
solution into a syringe. 
 
5.2.2 Addition of the Free Hb Solution to the Circuit 
The circuit was set-up and primed (Chapter 3, section 3.1).  A single equine blood 
donation was used to prime the circuit and to create the free Hb solution for that circuit.  
While the circuit was operating, free Hb solution was added into the top of the venous 
reservoir via syringe in measured aliquots of 25 or 30 ml.  In the first experiment, 330 ml 
total free Hb solution was added to ensure adequate DNO data was accomplished.  After 
data examination, subsequent experiments received 250 ml total free Hb solution to allow 
for comparisons with an Oxyglobin transfusion (250 ml).  The free Hb solution added to 
the circuit was calculated to give a free Hb concentration of between 0.19 to 2.4 g/dl in the 
circulating blood. 
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5.3 Pilot Experiments With Gross Haemolysis 
 
Aims 
The pilot experiments were designed to clarify the experimental protocol.  The initial 
preliminary experiment was conducted to assess what amount of water addition to the 
circuit was necessary to create haemolysis as determined by an increase in K
+
.   
 
The second pilot test was conducted to establish methodology for a gradual haemolysis to 
fully investigate the effects on gas transfer.  A set amount of water was to be pumped into 
the circuit reservoir at a low flow rate per minute to achieve gradual haemolysis of the 
circuit blood. 
 
5.3.1 Pilot Circuit Set-up and Methodology 
Following all experimental changes to the circuit, the blood was allowed to recirculate for 
5 minutes to allow equilibrium to occur between the blood and analysers as discussed in 
Chapter 3, section 3.2. 
 
1. Quantifying the Total Water Addition for Haemolysis Induction 
The circuit was set up and primed with equine blood (Chapter 3, section 3.1).  The blood 
pump was set at 2.5 l/min.  The oxygenator gases were set to 5 l/min air with 0.3 l/min O2 
and the deoxygenator gases were set to 5 l/min 5% CO2 in balanced N2 with 0.2 l/min 
CO2.  500 ml of circuit blood was removed by pumping out via a giving line attached to 
the venous reservoir return tubing.  This was replaced by 500 ml of water into the top of 
the venous reservoir via another fluid administration line.  After 5 minutes of recirculation 
the CDI 500 results were recorded before another 500 ml of water was added to the circuit 
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via the venous reservoir.  The CDI 500 results were recorded after five minutes of 
circulation.      
 
2. Verification of Gradual Water Addition Methodology for Inducing Haemolysis 
The circuit was set-up and primed with equine blood (Chapter 3, section 3.1).  The blood 
pump was set at 2.5 l/min.  A second reservoir was filled with water, which was pumped 
via a second Stockert roller pump (water pump) into the top of the venous reservoir.  The 
water pump was set to 60 ml/min to achieve a gradual addition of 1500 ml of water into 
the circuit over 25 minutes.  The oxygenator gases were set to 5 l/min air and the 
deoxygenator gases were set to 4.5 l/min 5% CO2 in balanced N2 with 0.1 l/min CO2.    
 
For each pilot run the potassium levels were monitored as they indicated the level of 
haemolysis within the circuit.  The pH, PO2, PCO2 and K
+
 values from the CDI 500 
monitor for both venous and arterial blood were recorded at 5 minute intervals during the 
volume addition.  The oxygenator inspired and expired oxygen content was also 
established. 
 
5.3.2 Pilot Experimental Results 
 
1. Quantifying the Total Water Addition for Haemolysis Induction 
The starting Hb of the circuit blood was 11.3 g/dl.  The potassium level was 5.4 mmol/l 
prior to water addition.  After the first 500 ml of water was added to the circuit via 
displacement the potassium rose to 7.2 mmol/l.  The second aliquot of 500 ml water 
increased potassium to 9.5 mmol/l.  The pHa and pHv both decreased with addition of 
water to the circuit from 7.41 to 7.19 and 7.34 to 7.08 respectively.  PaO2, P v O2, PaCO2 
and P v CO2 all remained stable during haemolysis averaging 89.33 ±5.69 mmHg, 30.67 
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±1.15 mmHg, 31.33 ±0.57 mmHg and 46.33 ±0.57 mmHg, respectively.  M O2 and        
M CO2 showed no change, averaging 111.25 ±14.17 ml/min and 137.89 ±4.37 ml/min, 
respectively.  DO2 and DCO2 followed the same trend and averaged 0.77 ±0.12 
ml/min/mmHg and 10.76 ±0.58 ml/min/mmHg respectively.  No statistics were performed 
on this data as the sample size (n=3) was too small. 
 
2. Verification of Gradual Water Addition Methodology for Inducing Haemolysis 
The Hb at the start of the experiment was 10.1 g/dl.  1500ml of water was added to the 
circuit at 60 ml/min over 25 minutes duration.  Haemolysis was indicated by a curvilinear 
rise in potassium levels (r=0.986, n=6, p<0.001) from 6.5 mmol/l up to 10 mmol/l 
achieved after 1200 ml of water addition.  At 1200 ml water addition, the upper limit of 
the CDI 500 sensors (10 mmol/l) was reached with this level indicating a significant 
presence of haemolysis.   
 
The pHv (R
2
=0.962, d.f.=5, p<0.01) and pHa (R
2
=0.945, d.f.=5, p<0.01) were seen to 
decrease linearly with increasing addition of water to the circulating blood from 7.09 to 
6.91 and 7.12 to 6.95, respectively. 
 
PaO2 was seen to slightly decrease from 58.5 mmHg to 48.0 mmHg over the duration of 
the experiment.  Similarly P v O2 decreased from 39.5 mmHg to 24.75 mmHg.  Both 
PaCO2 and P v CO2 remained stable at 56.36 ±2.34 mmHg and 66.50 ±0.61 mmHg, 
respectively. 
 
M O2 increased from 215.22 ml/min with no water addition to a mean of 272.62 ±21.39 
ml/min throughout the haemolysis.  DO2 was initially 2.02 ml/min/mmHg with no 
addition of water but then averaged 2.52 ±0.10 ml/min/mmHg during haemolysis.  Piiper 
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DO2 showed the same trend as Lilienthal DO2 at 2.05 ml/min/mmHg with no water added 
and then averaged 2.58 ±0.10 ml/min/mmHg during haemolysis.  M CO2 remained stable 
throughout the addition of water to the circuit at 101.94 ±0.95 ml/min.  DCO2 similarly 
stabilised at 17.71 ±3.56 ml/min/mmHg throughout. 
 
5.3.3 Pilot Experimental Outcomes 
From the pilot experiments, the methodology was adequate in providing significant 
haemolysis in the circuit blood as determined by an increase in K
+
.  The maximum 
threshold for K
+
 analysis by the CDI 500 was 10 mmol/l and the water addition needed to 
achieve this was approximately 1000 ml.  The circuit blood volume was usually 2000 ml 
so to achieve gross haemolysis 1000 ml of water was added to give a total circulating 
volume of 3000 ml.  The addition of water via the second reservoir and water pump 
worked well.  The results showed a curvilinear rise in K
+
 indicating a gradual lysis leading 
to gross haemolysis.  This methodology was easy to execute with consistency in results.  
For the main experiments, the water was to be added via a second „water‟ pump or via 
individual syringe aliquots at a slow flow rate.   
 
For the free Hb solution addition, the methodology would incorporate syringe aliquots 
followed by 5 minutes recirculation, facilitating a slow increase in free Hb.  Based on the 
previous haemolysis pilot work no specific experiments were required for free Hb.  
 
 
5.4 Effects of Haemolysis on O2 Transfer: Methodology 
The circuit was set up and primed with equine blood (Chapter 3, section 3.1).  For each 
experimental change, the circuit was allowed to run for 5 minutes for equilibrium to be 
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achieved as discussed in Chapter 3, section 3.2.  Following this, the pH, PO2 and PCO2 
values from the CDI 500 analyser were noted.  Venous and arterial blood saturations were 
recorded from the Spectrum Medical M2 analyser.  The oxygenator FiO2 and FeO2 were 
established for each change.  Potassium levels were recorded from the CDI 500 analyser 
as an indicator for haemolysis.  
 
5.4.1 Effects of Gross Haemolysis on O2 Transfer 
The blood flow was set at 2.5 l/min.  A second reservoir was filled with water and pumped 
via a second Stockert roller pump (water pump) into the top of the main venous reservoir.  
The oxygenator gases were 5 l/min air with 0.3 l/min O2 and the deoxygenator received 5 
l/min 5% CO2 in balanced N2 with 0.2-0.3 l/min CO2.  In the first circuit set-up the water 
pump was set to 30 ml/min in order to investigate a slower rate of haemolysis. Data from 
the analysers was noted every 5 minutes.  In the subsequent circuit set-up, water was 
added in 60 ml syringe aliquots into the top of the venous reservoir.   
 
5.4.2 Effects of Free Hb Solution on O2 Transfer 
The blood flow was set at 2.5 l/min.  The oxygenator received 5 l/min air with 0.3 l/min 
O2.  The deoxygenator gases were set to 5 l/min 5% CO2 in balanced N2 with 0.2 l/min 
CO2.  At five minute intervals 25 or 30 ml aliquots of free Hb Solution were added into 
the top of the venous reservoir up to a total of 250 or 330ml, respectively. 
 
5.4.3 Effects of Free Hb Solution on ODC 
The blood flow was set at 2.5 l/min.  The oxygenator was ventilated with 5 l/min N2 and 
O2 at varying mixtures to give a FiO2 ranging 5.0 to 43.5%.  The deoxygenator gases were 
set to 5 l/min 5% CO2 in balanced N2 with 0.2 l/min CO2.  The ODC experiment was 
conducted with whole equine blood in the absence or presence of 250 ml free Hb solution.  
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The blood saturations were plotted against the blood oxygen partial pressures for both the 
venous and arterial blood to achieve the venous and arterial ODCs.   
 
5.4.4 Shunt Fraction in Gross Haemolysis 
Using the same methodology as that described for the effects of gross haemolysis on O2 
transfer (section 5.4.1), the shunt fraction was calculated from the data achieved. 
 
5.4.5 Calculations 
The calculations used for the data generated in this chapter were those detailed in Chapter 
3, section 3.3.8.  Hills plots are described in Chapter 2, section 2.1. 
 
5.4.6 Statistical Analysis 
Statistical analysis is described in Chapter 2, section 2.2.   
 
 
5.5 Effects of Haemolysis on DNO and DCO: Methodology 
 
5.5.1 Effects of Gross Haemolysis on DNO and DCO 
The same methodology was used as that described in section 5.4.1.  NO was added to the 
oxygenator gas at 4500-5000 ppb for the first experimental run, rising to 6100-6300 ppb 
for the second experimental run.  The increase in NO addition was to ensure that the 
NOout concentration did not drop below a detectable amount so that DNO was calculable.  
The CO was also added to the oxygenator gas at a concentration of 0.03%.  At five minute 
intervals NOin, NOout, COin and COout were established.  
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5.5.2 Effects of Free Hb Solution on DNO and DCO 
The same methodology as that described in section 5.4.2 was used.  NO was added to the 
oxygenator gas at 7200, 14700, 12300 and 17900 ppb for each run to ensure that the inlet 
concentration exceeded that crossing the membrane.  CO was added to the oxygenator gas 
at 0.03%.  Five minutes after each aliquot of free Hb solution, the NOin, NOout, COin and 
COout were determined. 
  
5.5.3 Effects of DNO on the ODC 
The same methodology as that described in section 5.4.3 was used.  NO was added to the 
oxygenator gas at 10000 ppb.  The ODC in the absence and presence of NO was plotted 
and compared.  
 
5.5.4 Calculations 
The DNO and DCO calculations are detailed in Chapter 3, section 3.4.3. 
 
 
5.6 Effects of Haemolysis on O2 Transfer: Results 
 
5.6.1 Effects of Gross Haemolysis on O2 Transfer 
The initial Hb concentrations of the two circuits were 8.9 g/dl and 10.6 g/dl.  In run 1, 
1300 ml of water was added at a flow rate of 30 ml/min over fifty minutes.  In the second 
run, 800 ml of water was added using 60 ml aliquots over sixty minutes.  K
+
 was seen to 
increase curvilinearly with increasing water addition to the circuit for both experimental 
runs (p<0.0001).  K
+
 increased from 3.3 up to 9.9 mmol/l where the upper threshold of the 
CDI 500 analyser was exceeded after 900ml of water addition (Figure 5.1). 
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Figure 5.1 Effects of Water Addition on Potassium; K
+
 increased from 3.3 up to 9.9 
mmol/l where the upper threshold of the CDI 500 analyser was exceeded after 900ml of 
water addition. 
 
 
pHv and pHa gradually decreased with water addition and potassium increase (p=0.005 
and p=0.023, respectively).  In the first circuit, pHa reduced from 7.27 to 7.12 and pHv 
decreased from 7.13 to 6.95.  In the second circuit, pHa was reduced from 7.42 to 7.31 and 
pHv decreased from 7.24 to 7.16.  
 
PaO2 remained stable (p=0.070) which differed to that seen in the pilot work where a 
slight decrease was observed (section 5.3.2.2).  P v O2 slightly decreased over the 
haemolysis (p=0.046).  PaO2 averaged 79.54 ±3.49 mmHg and P v O2 averaged 29.63 
±3.65 mmHg (Figure 5.2).  There was no significant change in PaCO2 and P v CO2 during 
the haemolysis (p=0.298 and p=0.601, respectively).  PaCO2 was 35.00 ±5.19 mmHg and  
P v CO2 was 60.50 ±2.93 mmHg (Figure 5.3). 
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Figure 5.2 Effects of Haemolysis on PO2; PaO2 ■ averaged 79.54 ±3.49 mmHg and        
P v O2 ♦ averaged 29.63 ±3.65 mmHg. 
 
 
Figure 5.3 Effects of Haemolysis on PCO2; There was no significant change in PaCO2 ■ 
and P v CO2 ♦ during haemolysis (p=0.298 and p=0.601, respectively).  PaCO2 was 35.00 
±5.19 mmHg and P v CO2 was 60.50 ±2.93 mmHg. 
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There was no significant difference in M O2 (p=0.699 and p=0.605) or M CO2 (p=0.219 
and p=0.153) during the water addition for these experiments although significant inter-
run variation was noted.   M O2 was 121.91 ±7.96 ml/min and 209.87 ±13.39 ml/min 
(inter-run p<0.0001) (Figure 5.4).  M CO2 was 168.49 ±4.29 ml/min and 221.65 ±8.63 
ml/min (inter-run p<0.001) (Figure 5.5). 
 
Subsequently, no significant change was seen in DO2 (p=0.588 and p=0.714) or DCO2 
(p=0.051 and p=0.128) during the water addition.  DO2 was 0.90 ±0.06 ml/min/mmHg and 
1.60 ±0.12 ml/min/mmHg (Figure 5.6) while DCO2 was 8.95 ±2.48 ml/min/mmHg and 
3.24 ±0.54 ml/min/mmHg (Figure 5.7).  Inter-run variation was significant for both DO2 
and DCO2 (p<0.0001 and p<0.001). 
 
 
Figure 5.4 Effects of Haemolysis on M O2; M O2 averaged ♦ 121.91 ±7.96 ml/min and ■ 
209.87 ±13.39 ml/min (inter-run p<0.0001) with no change during haemolysis (p=0.699 
and p=0.605). 
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Figure 5.5 Effects of Haemolysis on M CO2; M CO2 was ♦ 168.49 ±4.29 ml/min and ■ 
221.65 ±8.63 ml/min (inter-run p<0.001) with no change during haemolysis (p=0.219 and 
p=0.153). 
 
 
Figure 5.6 Effects of Haemolysis on DO2; No significant change was observed in DO2 
(p=0.588 and p=0.714) averaging 0.90 ±0.06 ml/min/mmHg and 1.60 ±0.12 
ml/min/mmHg. 
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Figure 5.7 Effects of Haemolysis on DCO2; No significant change was observed in 
DCO2 during haemolysis (p=0.051 and p=0.128) averaging ♦ 8.95 ±2.48 ml/min/mmHg in 
run 1 and ■ 3.24 ±0.54 ml/min/mmHg in run 2. 
 
Table 5.1 Increasing Gross Haemolysis Data Summary 
Increasing Gross Haemolysis 
Parameter Trend Statistical value p value d.f. or n 
K
+
 Curvilinear increase r=0.872 p<0.0001 n=20 
pHa Linear decrease R
2
=0.359 p=0.023 d.f.=19 
pHv Linear decrease R
2
=0.464 p=0.005 d.f.=19 
PaO2 No change R
2
=0.171 p=0.070 d.f.=19 
P v O2 Slight decrease R
2
=0.203 p=0.046 d.f.=19 
M O2 No change R
2
=0.014, 0.031 p=0.699, 0.605 d.f.=12, 10 
DO2 No change R
2
=0.027, 0.016 p=0.588, 0.714 d.f.=12, 10 
PaCO2 No change R
2
=0.060 p=0.298 d.f.=19 
P v CO2 No change R
2
=0.016 p=0.601 d.f.=19 
M CO2 No change R
2
=0.134, 0.213 p=0.219, 0.153 d.f.=12, 10 
DCO2 No change R
2
=0.304, 0.238 p=0.051, 0.128 d.f.=12, 10 
Shunt 
Fraction 
Curvilinear decrease r=-0.985 p<0.0001 n=13 
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5.6.2 Effects of Free Hb Solution on O2 Transfer 
There was a linear increase in potassium levels with gradual addition of free Hb solution 
to the circuit blood (p=0.001).  Potassium rose from 5.6 ±1.43 mmol/l to 8.3 ±1.57 
mmol/l. 
 
There was no change in pHa or pHv on addition of free Hb solution to the circuit (p=0.690 
and p=0.080, respectively).  pHa averaged 7.27 ±0.06 and pHv averaged 7.18 ±0.05 
(Figure 5.8). 
 
 
Figure 5.8 Effects of Free Hb Solution Addition on pH;  pHa ■ averaged 7.27 ±0.06 
and pHv ♦ averaged 7.18 ±0.05. 
 
There was a slight decrease in both PaO2 and P v O2 with addition of free Hb solution to 
the circuit (p=0.025 and p<0.001, respectively).  The data distribution for P v O2 is small 
so a slight decrease gives rise to a more prominent statistical significance.  PaO2 averaged 
78.10 ±5.85 mmHg and P v O2 averaged 35.88 ±2.22 mmHg (Figure 5.9). 
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PaCO2 and P v CO2 did not change with increasing addition of free Hb solution to the 
circuit (p=0.816 and p=0.778 respectively).  PaCO2 averaged 40.46 ±6.02 mmHg and        
P v CO2 averaged 59.17 ±4.92 mmHg (Figure 5.10). 
 
 
Figure 5.9 Effects of Free Hb Solution Addition on PO2; There was a slight decrease in 
both PaO2 and P v O2 (p=0.025 and p<0.001) where PaO2 ♦ averaged 78.10 ±5.85 mmHg 
and P v O2 ■ averaged 35.88 ±2.22 mmHg. 
 
 
Figure 5.10 Effects of Free Hb Solution Addition on PCO2; There was no change in 
PaCO2 and P v CO2 (p=0.816 and p=0.778) where PaCO2 ■ averaged 40.46 ±6.02 mmHg 
and P v CO2 ♦ averaged 59.17 ±4.92 mmHg. 
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M O2 and DO2 remained stable when free Hb solution was added to the circuit blood 
(p=0.554 and p=0.792, respectively).  M O2 averaged 164.87 ±17.63 ml/min (Figure 5.11) 
and DO2 averaged 1.22 ±0.16 ml/min/mmHg (Figure 5.12). 
 
 
Figure 5.11 Effects of Free Hb Solution Addition on M O2; There was no change in   
M O2 (p=0.554) averaging 164.87 ±17.63 ml/min. 
 
 
Figure 5.12 Effects of Free Hb Solution Addition on DO2; There was no change in DO2 
(p=0.792) averaging 1.22 ±0.16 ml/min/mmHg. 
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5.6.3 Effects of Free Hb Solution on ODC 
SO2 was plotted against PO2 for both the arterial and venous blood data to achieve the 
respective ODCs.  The data underwent logarithmic transformation to achieve Hills plots 
for both arterial and venous ODCs.  The arterial ODC showed a significant correlation 
between SaO2 (S/1-S) and log PaO2 (p<0.0001) and a left shift in the presence of 250 ml 
free Hb solution when compared to the control (p<0.001) (figures 5.13 and 5.14).   
 
The venous Hills plot showed good linear correlation between the S v O2 (S/1-S) and log 
P v O2 (p<0.0001) and a significant left shift in the presence of 250 ml free Hb solution 
(p<0.0001) (Figures 5.15 and 5.16).  P50 was calculated from the venous Hills plot data as 
22.15 mmHg for the circuit equine blood and 15.50 mmHg after addition of 250 ml free 
Hb solution.  
 
 
Figure 5.13 Effects of Free Hb Addition on the Arterial ODC; A left shift was apparent 
after 250 ml free Hb solution addition ■ compared to the control ♦.  
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Figure 5.14 Effects of Free Hb Addition on the Arterial ODC – Hills plot; A 
significant correlation was observed between SaO2 (S/1-S) and log PaO2 (p<0.0001) and a 
left shift in the presence of 250 ml free Hb solution ■ when compared to the control ♦ 
(p<0.001). 
 
 
Figure 5.15 Effects of Free Hb Addition on the Venous ODC; A significant left shift in 
the presence of 250 ml free Hb solution ■ (p<0.0001) was evident compared to the control 
♦. 
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Figure 5.16 Effects of Free Hb Addition on the Venous ODC – Hills plot; A good 
linear correlation between the S v O2 (S/1-S) and log P v O2 (p<0.0001) and a significant 
left shift in the presence of 250 ml free Hb solution ■ (p<0.0001) was evident compared to 
the control ♦.   
 
Table 5.2 Effects of Free Hb Solution Addition Data Summary 
Effects of Free Hb Solution Addition 
Parameter Trend Statistical value p value d.f. or n 
K
+ 
Linear increase R
2
=0.268 p=0.001 d.f.=37 
pHa No change R
2
=0.003 p=0.690 d.f.=51 
pHv No change R
2
=0.060 p=0.080 d.f.=51 
PaO2 Slight decrease R
2
=0.097 p=0.025 d.f.=51 
P v O2 Slight decrease R
2
=0.242 p<0.001 d.f.=51 
PaCO2 No change R
2
=0.001 p=0.816 d.f.=51 
P v CO2 No change R
2
=0.002 p=0.778 d.f.=51 
M O2 No change R
2
=0.007 p=0.554 d.f.=51 
DO2 No change R
2
=0.001 p=0.792 d.f.=51 
Art Hills 
plot 
Correlation 
Left Shift 
R
2
=0.783 
t=3.925 
p<0.0001 
p<0.001 
d.f.=102 
d.f.=102 
Ven Hills 
plot 
Correlation 
Left Shift 
R
2
=0.594 
t=6.611 
p<0.0001 
p<0.0001 
d.f.=109 
d.f.=109 
No Haem y = 1.7426x - 2.3443 250 ml Haem y = 1.3566x - 1.6149
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5.6.4 Shunt Fraction in Gross Haemolysis 
The shunt fraction significantly decreased in a curvilinear trend with increasing water 
addition to the circuit blood (p<0.0001).  The shunt fraction reduced from 18.7% to 6.8% 
over the addition of 1300 ml water to the circuit blood (Figure 5.17). 
 
 
Figure 5.17 Effects of Haemolysis on Shunt Fraction; With increasing haemolysis, 
shunt fraction decreased curvilinearly from 18.7% to 6.8% (p<0.0001). 
 
 
5.7 Effects of Haemolysis on DNO and DCO: Results  
 
5.7.1 Effects of Gross Haemolysis on DNO and DCO 
Haemolysing the circuit blood did not affect DCO (p=0.052).  DCO averaged 1.17 ±0.21 
ml/min/mmHg in run 1 and averaged 0.69 ±0.14 ml/min/mmHg in run 2 during 
haemolysis (Figure 5.18). There was a significant inter-run variation between the two 
circuits for DCO (p<0.001) 
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DNO was seen to significantly increase curvilinearly with water addition from 4.66 
ml/min/mmHg to 24.24 ml/min/mmHg in run 1 and from 3.60 ml/min/mmHg to 9.98 
ml/min/mmHg in run 2 (p<0.001) (Figure 5.19).  There was a significant inter-run 
variation between the two circuits (p<0.001). 
 
 
Figure 5.18 Effects of Haemolysis on DCO; DCO was unaffected by haemolysis 
(p=0.052) averaging 1.17 ±0.21 ml/min/mmHg in run 1♦ and 0.69 ±0.14 ml/min/mmHg in 
run 2 ■. 
 
Figure 5.19 Effects of Haemolysis on DNO; DNO increased curvilinearly with 
haemolysis (p<0.001) from 4.66 ml/min/mmHg to 24.24 ml/min/mmHg in run 1 ♦ and 
from 3.60 ml/min/mmHg to 9.98 ml/min/mmHg in run 2 ■. 
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Table 5.3 Effects of Gross Haemolysis on DNO and DCO 
DNO and DCO Increasing Gross Haemolysis 
Parameter Trend Statistical value p value d.f. or n 
DCO No change R
2
=0.293 p=0.052 d.f.=19 
DNO Curvilinear increase r=0.881 p<0.001 d.f.=24 
Inter-run 
Variation 
Observed DCO t=6.341 
DNO t=5.980 
p<0.001 
p<0.001 
d.f.=22 
d.f.=22 
 
 
 
5.7.2 Effects of Free Hb Solution on DNO and DCO 
DCO was not affected by addition of free Hb solution to the circuit blood (p=0.061).  
DCO averaged 1.57 ±0.24 ml/min/mmHg throughout free Hb solution addition (Figure 
5.20). 
 
 
Figure 5.20 Effects of Free Hb Addition on DCO; DCO was unaffected by free Hb 
addition (p=0.061) averaging 1.57 ±0.24 ml/min/mmHg. 
 
DNO increased curvilinearly with increasing addition of free Hb solution to the circuit 
blood (p<0.0001).  DNO increased from 11.79 ±3.48 ml/min/mmHg with 0 ml free Hb 
solution up to 22.25 ±8.03 ml/min/mmHg after 250 ml free Hb solution addition (Figure 
5.21), an overall increase of 91% compared to baseline.  After just 25 or 30 ml free Hb 
0.5
1
1.5
2
2.5
3
0 50 100 150 200 250 300 350
D
C
O
 m
l/
m
in
/m
m
H
g
Free Hb Solution Addition ml
144 
 
solution addition to the circuit blood, DNO had increased to 13.40 ±3.31 ml/min/mmHg, 
an increase of 14% compared to baseline.  DNO showed some inter-run variation 
(p<0.0001). 
 
 
Figure 5.21 Effects of Free Hb Addition on DNO; DNO increased curvilinearly with 
free Hb addition (p<0.0001) increasing from 11.79 ±3.48 ml/min/mmHg with 0 ml free 
Hb up to 22.25 ±8.03 ml/min/mmHg after 250 ml free Hb solution. 
 
5.7.3 Effects of NO on ODC 
There were no significant effects of NO on the arterial ODC (t=-1.176, d.f.=14, p=0.267).  
The Hills plot demonstrated good correlation between log PaO2 and SaO2 (S/1-S) 
(R
2
=0.896, d.f.=14, p<0.0001).  
 
The Hills plot of the venous ODC demonstrated significant correlation between log          
P v O2 and S v O2(S/1-S) (R
2
=0.925, d.f=29, p<0.0001).  The venous ODC was shifted 
leftwards in the presence of NO when compared to the control (t=7.425, d.f.=19, 
p<0.0001).  When free Hb solution was added in the presence of NO this further shifted 
the venous ODC to the left (t=6.063, d.f.=19, p<0.0001).  P50 was calculated as 29.41 
mmHg for the circuit blood, 26.12 mmHg for the circuit blood exposed to NO and      
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21.59 mmHg for the combined NO and free Hb addition to the circuit blood (Figures 5.22 
and 5.23). 
 
 
Figure 5.22 Effects of Free Hb and NO on the Venous ODC; A leftward ODC shift was 
observed following NO exposure ■ (p<0.0001) and a further left shift was seen with 
250ml free Hb addition ▲ (p<0.0001) compared to equine blood ♦. 
 
 
Figure 5.23 Effects of Free Hb and NO on the Venous ODC – Hills plot; P50 was 
calculated as 29.41 mmHg for equine blood ♦, 26.12 mmHg for equine blood exposed to 
NO ■ and 21.59 mmHg for the combined NO and free Hb addition ▲ to equine blood. 
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Table 5.4 Effects of Free Hb Solution on DNO and DCO  
Effects of Free Hb Solution Addition on DNO and DCO 
Parameter Trend Statistical value p value d.f. or n 
DCO No change R
2
=0.112 p=0.061 d.f.=31 
DNO Curvilinear increase r=0.654 p<0.0001 n=46 
Inter-run 
variation 
Observed for DNO t=7.119, 5.411 p<0.0001, 
p<0.0001 
d.f.=20, 19 
 
 
 
5.8  Implications of Haemolysis on Gas Transfer in the Membrane Oxygenator: 
Discussion. 
Adding water to the circuit induced gradual haemolysis indicated by increasing potassium 
levels leached out of ruptured RBCs.  A curvilinear increase in potassium was detectable 
by the CDI 500 analyser (up to 10mmol).  The pH decreased, but as the water was pH 7.1-
7.9, the acidity was attributed to leaching of RBC contents further indicating successful 
haemolysis.  Latterly, free Hb solution was added to the circuit giving levels encountered 
clinically by shear stress with long-term dialysis or ventricular assist devices.  Haemolytic 
anaemia (i.e. Thalassemia, Sickle-cell anaemia, hereditary Spherocytosis) can cause 
elevated free Hb in plasma and resultant abdominal pain, pulmonary hypertension, 
systemic hypertension and renal dysfunction have been linked to nitric oxide scavenging 
by free Hb (Rother et al 2005).  
 
From this data, haemolysing blood or addition of free Hb solution did not alter carbon 
dioxide partial pressures or uptake.  It is concluded that plasma, red cell membrane and 
haemoglobin packing within the red cell have limited effect on carbon dioxide transfer.  
CO2 is carried in the blood as dissolved CO2, bound to haemoglobin and plasma protein 
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amino acids or as bicarbonate ions.  Due to the complex way in which the gas is carried in 
plasma and red cells, the lack of effect of red cell disruption is unsurprising. 
 
The transfer of oxygen comprises several components.  Initially, oxygen diffuses across 
the membrane.  It then moves through plasma before crossing the RBC membrane to bind 
with Hb.  Free Hb reduces the distance between the alveolar membrane and Hb as the red 
cell is bypassed.  In the membrane oxygenator, shunt fraction reduced with haemolysis 
indicating less boundary effect.  An increased oxygen uptake would be expected.  Several 
factors resulting from the haemolysis were considered to be limiting to M O2.  
Haemodilution of haemoglobin concentrations by water addition (minimum circuit Hb 6.4 
g/dl) should reduce M O2 but work on varying Hb (Chapter 3) did not affect M O2 at 
concentrations >5g/dl.  Decreasing pH should cause right ODC shifting, reducing Hb 
oxygen binding.   In this data, a leftward venous ODC shift was observed after 250 ml free 
Hb solution addition to the circuit (P50 22 to 15.5 mmHg).  Stroma free Hb has a P50 of 12-
14 mmHg (Grethlein et al 2007) compared to 26.5 mmHg (whole blood).  This is because 
stroma free Hb dissociates into α and β chains which have a high oxygen affinity.  A 
leftward ODC shift results in increased oxygen uptake but poor tissue offloading.  It 
appears that the effects described above act in opposition so that there is no net effect of 
haemolysis on M O2. 
 
In this circuit, NO caused a significant leftward shift of the venous ODC.  When oxyHb is 
exposed to NO the O2 is displaced by NO and the iron atom oxidises to form 
methaemoglobin.  The iron oxidates to a ferric state (Fe
+++
) which limits the Hb oxygen 
binding compared to the usual ferrous state (Fe
++
) (normal oxygen binding).  Bound-NO 
causes the Hb molecule to remain in the high oxygen affinity R-state conformation 
limiting oxygen offloading. NO therapy is a potential therapy for sickle cell crisis patients 
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where sickle RBCs have impaired oxygen carrying capacity resulting in arterial hypoxia.  
Low dose NO (80 ppm) can induce a leftward shift of the ODC, increasing oxygen uptake 
during a crisis (Head et al 1997, Martinez-Ruiz et al 2001).  
 
Haemolysis did not affect DCO but DNO increased significantly during gross haemolysis 
and addition of free Hb solution suggesting that the RBC membrane, interior or its 
surrounding creates resistance to its transfer (Borland et al 2006, 2010).  The level of 
DNO increase was less with low amounts of free Hb present in the circuit blood compared 
to that seen with gross haemolysis.  This finding corresponds with uptake of NO via free 
Hb present in the circuit.  The increase in DNO with low levels of free Hb present in the 
circuit blood has implication for DLNO in lung function testing.  Some authorities believe 
that DLNO in patients is a measure solely of NO transport across the alveolar membrane 
(Heller and Schuster 1998).  The specific conductance of NO with the blood (θNO) was 
thought to be infinite (Guenard et al 1987).  Therefore due to the instantaneous reaction 
rate of NO with Hb, DLNO would equal DMNO.  This experiment demonstrates that 
DLNO does not reflect DMNO as the RBC membrane, interior or its surrounding plays a 
significant role in DNO resistance and θNO is not infinite (Borland et al 2006).    Increased 
DNO during haemolysis of the circuit blood or addition of free Hb solution can be 
attributed to three areas of resistance; RBC membrane, RBC interior and surrounding 
plasma.  RBC membrane resistance to DNO is obviously lost when the RBC membrane is 
lysed.  Release of tightly packed Hb within the RBC may also increase DNO on 
haemolysis.  Free Hb within the circulating blood will reduce the diffusion distance and 
plasma resistance to DNO.  This work (gross haemolysis or free Hb solution addition) 
does not differentiate between these three potential resistances to DNO.  To establish if 
DNO resistance can be attributed to plasma, a Haemoglobin-Based-Oxygen-Carrier 
(HBOC) was added to the circulating blood to increase free Hb without disruption of the 
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RBCs.  After gradual Oxyglobin addition to the circuit, haemolysis will be induced in the 
circuit to test for DNO resistance as a result of the RBC membrane and interior.     
 
From this work, gross circuit haemolysis and addition of free Hb solution resulted in a 
significant DNO increase.  Whilst gross haemolysis was not clinically representative, a 
similar increase in DNO was observed at lower levels of free Hb which could be more 
clinically attributed.  Presence of free Hb in the circuit blood alters the carriage of oxygen 
via a leftward shift of the venous ODC.  Further work will investigate the factors 
responsible for DNO resistance and to examine the potential for the HBOC Oxyglobin to 
scavenge NO from the circuit. 
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CHAPTER 6 Effects of Oxyglobin Solution Addition on DO2 DNO and DCO 
 
Aims 
The aim was to determine if the Haemoglobin-Based-Oxygen-Carrier (HBOC) Oxyglobin 
affected DO2, DNO and DCO in the membrane oxygenator circuit.  Chapter 5 concluded 
that haemolysis and addition of free Hb solution to the circuit results in increased DNO.  
Whole blood resistance to DNO was attributed to one of three areas; the RBC membrane, 
the RBC interior or the plasma surrounding the RBC.  To determine if plasma provided 
DNO resistance, Oxyglobin was added to the circuit blood.  Oxyglobin is free bovine Hb 
modified to give a larger molecular weight (increasing half-life) and adjusted for oxygen 
affinity.  The RBCs within the circuit blood would remain intact thus eliminating the 
influence of both RBC membrane and interior which were present in the haemolysis work 
(Chapter 5).  Subsequently, the circuit blood was haemolysed post Oxyglobin addition to 
determine if further increases in DNO would occur consistent with  RBC membrane or 
interior resistance to DNO.  Concurrent with this work, the HBOC Oxyglobin was 
assessed for its NO scavenging potential, a potential contributing factor in HBOC related 
vasoconstriction.   
 
 
6.1  Addition of Oxyglobin Solution to the Circuit Blood: Circuit Set-Up.  
 
6.1.1 Oxyglobin 
Oxyglobin is polymerised bovine Hb with a P50 34 mmHg (Driessen et al 2001).  The 
elevated P50 decreases oxygen affinity of Oxyglobin thus enhancing oxygenation of the 
tissues.  During the experimental phase, Oxyglobin was the only licensed HBOC available 
for veterinary or human use.  This product was licensed for use in dogs for improving the 
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clinical signs of anaemia independent of the underlying cause (Arnolds, Shrewsbury, UK).  
Oxyglobin solution was provided as a 130 mg/ml solution with a recommended dosage of 
30 ml/kg.  Each box contained two 125 ml intravenous infusion packs, totalling 250 ml 
per box.   The Oxyglobin solution infusion packs accommodated a standard infusion 
giving set allowing removal into a syringe for repeated administration of known volume 
aliquots.   
 
In dogs, Oxyglobin solution can cause mild to moderate discoloration of the mucous 
membranes and urine due to metabolism and excretion of free Hb.  Advisory notes state 
that colorimetric tests may be affected by this discoloration.  sO2 monitoring in blood is 
determined by spectrophotometric techniques, typically infrared light.  Infrared light of a 
known wavelength is directed at the blood which is refracted back at different 
wavelengths depending on the deoxyhaemoglobin and oxyhaemoglobin ratio.  To 
determine if Oxyglobin affects sO2 analysis, two different spectrophotometric analysers 
were compared.  The Cobe Sat/Hct monitor utilises infrared light technology compared to 
the Spectrum Medical M2 which utilises white light technology.          
 
6.1.2 Addition of Oxyglobin Solution to the Circuit 
The circuit was set up and primed with equine blood (Chapter 3, section 3.1).  The circuit 
was run for a minimum of 30 minutes at normoxic conditions while control data was 
collected.  Oxyglobin solution was added via a Luer Lock connection on the top of the 
venous reservoir in syringed aliquots of 25 or 30 ml.  A total transfusion volume of 240 ml 
(30 ml aliquots in run 1) or 250 ml (25 ml aliquots in subsequent runs) Oxyglobin solution 
was added to the circuit blood (2000 ml) giving a total circulating volume of 2240-2250 
ml.  The circuit Oxyglobin concentration achieved during the gradual addition was 
calculated as 1.60 to 14.44 mg/ml, added to a circuit Hb range 11.7 to 13.5 g/dl. 
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6.2 Pilot Experiments With Oxyglobin Solution 
Based on the free Hb addition work (Chapter 5) no methodology related pilot studies were 
considered necessary for the Oxyglobin solution addition work.  Experiments on sO2 
measurements were conducted concurrently with the first two experimental runs due to 
limited availability of Oxyglobin.  
 
 
6.3 Effects of Oxyglobin Solution on O2 Transfer: Methodology 
Each circuit was set-up and primed with equine blood (Chapter 3, section 3.1).  Each 
aliquot or change in circuit settings was allowed 5 minutes circulation for equilibrium to 
be achieved (Chapter 3, section 3.2).  pH, PO2 and PCO2 values from the CDI 500 
analyser were noted.  Venous and arterial blood saturations were recorded from the 
Spectrum Medical M2 analyser and the Cobe Sat/Hct analyser.  The oxygenator FiO2 and 
FeO2 were established for each change. 
 
6.3.1 Effects of Oxyglobin Solution on sO2 Analysis 
The blood flow was set at 2.5 l/min. The oxygenator gases were set to 5 l/min air with 0.3 
l/min O2.   The deoxygenator gases were set to 5 l/min CO2 in balanced N2 with 0.2 l/min 
CO2.  Oxyglobin solution was added to the circuit in ten 25 ml aliquots, totalling 250 ml.  
sO2 were recorded on both the Spectrum Medical M2 and the Cobe Sat/Hct analysers for 
each 25 ml Oxyglobin aliquot.  In the second run, blood flow was set at 2.5 l/min. The 
oxygenator gases were a mixture of N2 and O2 giving a FiO2 range of 5.3 to 26.4 %.  The 
deoxygenator gases were set to 5 l/min CO2 in balanced N2 with 0.2 l/min CO2.  sO2 was 
recorded for the circuit blood at a range of FiO2 and repeated post 250 ml Oxyglobin 
addition. 
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6.3.2 Effects of Oxyglobin Solution on O2 Transfer 
The circuit was run at a blood flow of 2.5 l/min.  The oxygenator received 5 l/min air with 
0.3 l/min O2.  The deoxygenator gases were set to 5 l/min 5% CO2 in balanced N2 with 
0.1-0.3 l/min CO2.  At five minute intervals, 30 ml (run 1) or 25 ml (subsequent runs) 
aliquots of Oxyglobin Solution were added into the top of the venous reservoir, totalling 
240 or 250 ml, respectively. 
 
6.3.3 Effects of Oxyglobin Solution on ODC 
The blood flow was set to 2.5 l/min.  The oxygenator was ventilated with 5 l/min N2 and 
O2 at varying mixtures to give a FiO2 ranging 9.1 to 35.2%.  The deoxygenator gases were 
set to 5 l/min 5% CO2 in balanced N2 with 0.2 l/min CO2.  The ODC experiment was 
conducted with whole equine blood and repeated in the presence of 250 ml Oxyglobin 
solution.   
 
6.3.4 Calculations 
The calculations used for the data generated in this chapter are those detailed in Chapter 3, 
section 3.3.8.  Hills plots are described in Chapter 2, section 2.1. 
 
6.3.5 Statistical Analysis 
The statistical analysis tests used for the data generated in this chapter are described in 
chapter 2, section 2.2. 
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6.4 Effects of Oxyglobin Solution on DNO and DCO: Methodology 
 
Five minutes after each aliquot of Oxyglobin solution or water, the NOin, NOout, COin 
and COout were determined 
 
6.4.1 Effects of Oxyglobin Solution on DNO and DCO 
The same methodology as that described in section 6.3.2 was used.  NO was added to the 
oxygenator gas at 4000, 6600 and 8000 ppb for each run to ensure that the inlet 
concentration exceeded that crossing the membrane.  CO was added to the oxygenator gas 
at 0.03%. 
 
6.4.2 Effects of Oxyglobin Solution combined with NO on ODC 
The blood flow was set at 2.5 l/min.  The oxygenator was ventilated with 5 l/min N2 and 
O2 at varying mixtures to give a FiO2 ranging 5.3 to 34.7%.  The deoxygenator gases were 
set to 5 l/min 5% CO2 in balanced N2 with 0.1-0.2 l/min CO2.  The ODC experiment was 
conducted with whole equine blood in the absence of Oxyglobin solution.  250 ml 
Oxyglobin solution was added to the circuit.  The ODC experiment was repeated with 
whole equine blood in the presence of 250 ml Oxyglobin solution while being exposed to 
6600 (run 1) or 8000 (run 2) ppb NO.   
 
6.4.3 Effects of Haemolysis post Oxyglobin Solution Addition on DNO and DCO 
The circuit was run at a blood flow of 2.5 l/min.  The oxygenator received 5 l/min air with 
0.3 l/min O2 with NO 16000 ppb and CO 0.03%.  The deoxygenator gases were set to 5 
l/min 5% CO2 in balanced N2 with 0.2 l/min CO2.  At five minute intervals 25 ml aliquots 
of Oxyglobin Solution were added into the top of the venous reservoir, totalling 250 ml.  
Once 250 ml Oxyglobin solution had been added, the circuit was recirculated for a further 
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5 minutes.  To haemolyse the circuit blood, tap water was added to the venous reservoir in 
150ml aliquots (run 1) until 750 ml had been added and the K
+
 had exceeded the analyser 
limit (>10 mmol/l).  In subsequent runs, 100 ml aliquots of water were added to a total of 
700 ml.  
 
6.4.4 Calculations 
The calculations for DNO and DCO are detailed in Chapter 3, section 3.4.3. 
 
 
6.5 Effects of Oxyglobin Solution on O2 Transfer: Results 
 
6.5.1 Effects of Oxyglobin Solution on sO2 Analysis 
SaO2 and S v O2 both decreased with a gradual addition of Oxyglobin to the circuit for 
both analysers.  The M2 analyser decrease in SaO2 and S v O2 were significant (p<0.001 
and p=0.0001) but less pronounced graphically than the Cobe SaO2 and S v O2 (p<0.001 
and p=0.049) (Figure 6.1).  SaO2 and S v O2 achieved with the varying FiO2 test showed a 
good linear correlation between the two analysers (R
2
=0.976 and R
2
=0.920, respectively) 
(Figure 6.2). 
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Figure 6.1 Effects of Oxyglobin Addition on sO2 Analysers; SaO2 and S v O2 
decreased for both the M2 (♦ SaO2 p<0.001 and ▲ S v O2 p=0.0001) and Cobe (■ SaO2 
p<0.001 and ● S v O2 p=0.049) analysers. 
 
 
 
Figure 6.2 M2 versus Cobe sO2 Correlation; Both SaO2 ■ and S v O2 ♦ showed good 
correlation between the two analysers (SaO2 R
2
=0.976 and S v O2 R
2
=0.920). 
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Table 6.1 Effects of Oxyglobin Solution Addition on sO2 
Effects of Oxyglobin Solution Addition on sO2 
Parameter Trend Statistical value p value d.f. or n 
M2 SaO2 Decrease R
2
=0.134 p<0.001 d.f.=96 
M2 S v O2 Decrease R
2
=0.153 p=0.0001 d.f.=96 
Cobe SaO2 Decrease R
2
=0.450 p<0.001 d.f.=23 
Cobe        
S v O2 
Decrease R
2
=0.165 p=0.049 d.f.=23 
SaO2 
Analyser 
Correlation 
Significant R
2
=0.976 p<0.001 d.f.=23 
S v O2 
Analyser 
Correlation 
Significant R
2
=0.920 p<0.001 d.f.=23 
 
 
 
6.5.2 Effects of Oxyglobin Solution on O2 Transfer 
There was no change in potassium levels with gradual addition of Oxyglobin solution to 
the circuit blood (p=0.964).  Potassium averaged 6.02 ±0.33 mmol/l. 
 
There was no change in pHa or pHv on addition of Oxyglobin solution to the circuit blood 
(p=0.465 and p=0.766, respectively).  pHa averaged 7.35 ±0.07 and pHv averaged 7.21 
±0.34. 
 
There was no change in PaO2 or P v O2 with addition of Oxyglobin solution to the circuit 
blood (p=0.098 and p=0.591, respectively).  PaO2 averaged 79.33 ±6.91 mmHg and P v
O2 averaged 40.88 ±3.27 mmHg (Figure 6.3).  PaCO2 and P v CO2 did not change with 
increasing addition of Oxyglobin solution to the circuit (p=0.605 and p=0.267, 
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respectively).  PaCO2 averaged 39.80 ±7.18 mmHg and P v CO2 averaged 58.16 ±11.27 
mmHg (Figure 6.4). 
 
 
Figure 6.3 Effects of Oxyglobin Addition on PO2; PaO2 and P v O2 were unaffected by 
Oxyglobin addition (p=0.098 and p=0.591).  PaO2 ♦ averaged 79.33 ±6.91 mmHg and      
P v O2 ■ averaged 40.88 ±3.27 mmHg. 
 
 
Figure 6.4 Effects of Oxyglobin Addition on PCO2; PaCO2 and P v CO2 were 
unaffected by Oxyglobin addition (p=0.605 and p=0.267) where PaCO2 ■ averaged 39.80 
±7.18 mmHg and P v CO2 ♦ averaged 58.16 ±11.27 mmHg. 
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M O2 and DO2 remained stable with gradual addition of Oxyglobin solution to the circuit 
(p=0.066 and p=0.051, respectively).  M O2 averaged 196.10 ±64.11 ml/min (Figure 6.5) 
and DO2 averaged 1.55 ±0.56 ml/min/mmHg (Figure 6.6).  Inter-run variation was evident 
for both M O2 and DO2 graphically and from the standard deviations presented. 
 
 
Figure 6.5 Effects of Oxyglobin Addition on M O2; M
 O2 was unaffected by Oxyglobin 
addition (p=0.066) averaging 196.10 ±64.11 ml/min. 
 
 
Figure 6.6 Effects of Oxyglobin Addition on DO2; DO2 was unaffected by Oxyglobin 
addition (p=0.051) averaging 1.55 ±0.56 ml/min/mmHg. 
 
 
0
50
100
150
200
250
300
350
400
450
0 50 100 150 200 250 300
M
O
2
m
l/
m
in
Oxyglobin Solution ml
0
0.5
1
1.5
2
2.5
3
3.5
0 50 100 150 200 250 300
D
O
2
m
l/
m
in
/m
m
H
g
Oxyglobin Solution ml
160 
 
6.5.3 Effects of Oxyglobin Solution on ODC 
The data demonstrated good curvilinear relationships between sO2 and PO2 for both the 
venous and arterial ODCs (Figures 6.7 and 6.9). 
 
The Hills plot showed a good correlation between log PaO2 and SaO2 (S/1-S) (p<0.0001).  
A significant right shift of the arterial ODC in the presence of 250 ml Oxyglobin was 
evident when compared to the circuit blood (p<0.0001) (Figure 6.8). 
 
The Hills plot of the venous ODC demonstrated significant correlation between log           
P v O2 and S v O2(S/1-S) (p<0.0001).  The venous ODC was shifted to the right in the 
presence of 250 ml Oxyglobin when compared to the circuit blood (p<0.0001) (Figure 
6.10).   
 
P50 was calculated from the venous ODC data as 30.50 mmHg for the circuit blood and 
35.20 mmHg for the 250 ml Oxyglobin solution addition to the circuit blood. 
 
 
Figure 6.7 Effects of Oxyglobin Addition on the Arterial ODC; Oxyglobin ■ addition 
resulted in a right shift of the ODC (p<0.0001) compared to equine blood ♦. 
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Figure 6.8 Effects of Oxyglobin Addition on the Arterial ODC – Hills plot; A 
significant right shift of the arterial ODC in the presence of 250 ml Oxyglobin ■ was 
evident when compared to equine blood ♦ (p<0.0001). 
 
 
 
 
Figure 6.9 Effects of Oxyglobin Addition on the Venous ODC; A significant right shift 
of the ODC was observed after Oxyglobin ■ addition to equine blood ♦ (p<0.0001). 
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Figure 6.10 Effects of Oxyglobin Addition on the Venous ODC – Hills plot; Oxyglobin 
■ addition to the equine blood ♦ resulted in a significant right ODC shift (p<0.0001).  
 
6.6 Effects of Oxyglobin Solution on DNO and DCO: Results 
 
6.6.1 Effects of Oxyglobin Solution on DNO and DCO 
DNO increased curvilinearly with gradual addition of Oxyglobin solution to the circuit 
blood (p<0.0001) (Figure 6.11).  DNO for the circuit blood averaged 7.41 ±2.77 
ml/min/mmHg.  After a 25 ml Oxyglobin solution aliquot to the circuit blood, DNO 
increased by 29% to a mean 9.59 ±3.90 ml/min/mmHg.  After 250 ml Oxyglobin addition 
to the circuit blood, DNO had increased by 143% to an average 17.97 ±1.83 
ml/min/mmHg. 
 
DCO increased curvilinearly with gradual addition of Oxyglobin solution to the circuit 
blood (p=0.005) (Figure 6.12).  DCO increased from 1.16 ±0.19 ml/min/mmHg prior to 
Oxyglobin addition up to 1.29 ±0.18 ml/min/mmHg after 225 ml Oxyglobin addition. 
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Figure 6.11 Effects of Oxyglobin Addition on DNO; DNO increased curvilinearly with 
Oxyglobin addition (p<0.0001) from 7.41 ±2.77 ml/min/mmHg (0 ml) to 17.97 ±1.83 
ml/min/mmHg after 250 ml Oxyglobin. 
 
 
 
Figure 6.12 Effects of Oxyglobin Addition on DCO; DCO increased curvilinearly with 
Oxyglobin addition (p=0.005) from 1.16 ±0.19 ml/min/mmHg (0 ml) up to 1.29 ±0.18 
ml/min/mmHg after 225 ml Oxyglobin. 
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6.6.2 Effects of Oxyglobin Solution combined with NO on ODC 
The data demonstrated good curvilinear relationships between sO2 and PO2 for both the 
venous and arterial ODCs (Figures 6.13 and 6.15). 
 
The Hills plot showed a good correlation between log PaO2 and SaO2 (S/1-S) (p<0.0001).  
A right shift of the arterial ODC in the presence of 250 ml Oxyglobin combined with NO 
was evident when compared to the circuit blood (p=0.007)(Figure 6.14). 
 
Hills plot of the venous ODC demonstrated significant correlation between log P v O2 and 
S v O2(S/1-S) (p<0.0001).  The venous ODC was shifted to the left in the presence of 250 
ml Oxyglobin exposed to NO when compared to the circuit blood (p=0.003) (Figure 6.16).  
P50 was calculated from the venous ODC data as 25.34 mmHg for the circuit blood and 
22.71 mmHg for the NO exposed Oxyglobin solution added to the circuit blood. 
 
 
Figure 6.13 Effects of Oxyglobin and NO on the Arterial ODC; Oxyglobin combined 
with NO ■ resulted in a right shift of the arterial ODC compared to control ♦ (p=0.007). 
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Figure 6.14 Effects of Oxyglobin and NO on the Arterial ODC – Hills plot; A right 
shift of the arterial ODC in the presence of 250 ml Oxyglobin combined with NO ■ was 
evident when compared to equine blood ♦ (p=0.007). 
 
 
 
Figure 6.15 Effects of Oxyglobin and NO on the Venous ODC; 250 ml Oxyglobin 
combined with NO ■ resulted in a left venous ODC shift compared to equine blood ♦ 
(p=0.003). 
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Figure 6.16 Effects of Oxyglobin and NO on the Venous ODC – Hills plot; The venous 
ODC was shifted to the left in the presence of 250 ml Oxyglobin exposed to NO ■ when 
compared to equine blood ♦ (p=0.003).    
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Table 6.2 Effects of Oxyglobin Solution on Gas Transfer 
Effects of Oxyglobin Solution Addition on Gas Transfer 
Parameter Trend Statistical value p value d.f. or n 
K
+ 
No change R
2
=0.000 p=0.964 d.f.=36 
pHa No change R
2
=0.007 p=0.465 d.f.=82 
pHv No change R
2
=0.001 p=0.766 d.f.=82 
PaO2 No change R
2
=0.033 p=0.098 d.f.=82 
P v O2 No change R
2
=0.004 p=0.591 d.f.=82 
PaCO2 No change R
2
=0.003 p=0.605 d.f.=82 
P v CO2 No change R
2
=0.015 p=0.267 d.f.=82 
M O2 No change R
2
=0.041 p=0.066 d.f.=82 
DO2 No change R
2
=0.046 p=0.051 d.f.=82 
Oxyglobin  
Art ODC 
Hills plot 
Correlation 
Right Shift 
R
2
=0.865 
t=14.689 
p<0.0001 
p<0.0001 
d.f.=38 
d.f.=38 
Oxyglobin 
Ven ODC 
Hills plot 
Correlation 
Right Shift 
R
2
=0.980 
t=-16.235 
p<0.0001 
p<0.0001 
d.f.=40 
d.f.=40 
DCO Curvilinear increase r=0.359 p=0.005 n=61 
DNO Curvilinear increase r=0.704 p<0.0001 n=83 
Oxygobin+NO 
Art ODC  
Hills plot 
Correlation 
Right shift 
R
2
=0.853 
t=-2.787 
p<0.0001 
p=0.007 
d.f.=78 
d.f.=78 
Oxygobin+NO 
Ven ODC  
Hills plot 
Correlation 
Left Shift 
R
2
=0.941 
t=3.112 
p<0.0001 
p=0.003 
d.f.=79 
d.f.=79 
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6.6.3 Effects of Haemolysis post Oxyglobin Solution Addition on DNO and DCO 
The results from this experiment were published and are presented in Appendix 9 
(Borland et al 2010).  Following publication, the calculations for DNO and DCO were 
modified to incorporate laboratory temperature and barometric pressure correction.  
Presented here are the modified results. 
 
Addition of Oxyglobin to the oxygenator circuit increased DNO from 5.22 ±1.98 to 17.17 
±3.86 ml/min/mmHg (p<0.0001), while DCO increased from 1.02 ±0.05 to 1.37 ±0.19 
ml/min/mmHg (p<0.0001).  No significant further increase in DNO (mean 19.31 ±4.08 
ml/min/mmHg) or DCO (mean 1.30 ±0.23 ml/min/mmHg) was observed after haemolysis 
was induced in the oxygenator circuit (p=0.398 and p=0.600, respectively) (Figures 6.17 
and 6.18).  Potassium levels rose from an average 6.03 ±0.33 (Oxyglobin phase) to >10 
mmol/l during the haemolysis phase. 
 
 
Figure 6.17 Effects of Oxyglobin and Subsequent Haemolysis on DNO; Addition of 
Oxyglobin ♦ ■ ▲ increased DNO from 5.22 ±1.98 to 17.17 ±3.86 ml/min/mmHg 
(p<0.0001) with no further increase in DNO during haemolysis Χ Ӿ ● (p=0.398) (mean 
19.31 ±4.08 ml/min/mmHg).   
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Figure 6.18 Effects of Oxyglobin and Subsequent Haemolysis on DCO; DCO 
increased from 1.02 ±0.05 to 1.37 ±0.19 ml/min/mmHg (p<0.0001) with Oxyglobin 
addition ♦ but no further increase was seen during the haemolysis ■ (p=0.600) (mean 1.30 
±0.23 ml/min/mmHg). 
 
 
Table 6.3 Effects of Oxyglobin Solution Addition and Haemolysis on DNO and DCO 
Effects of Oxyglobin Solution Addition and Haemolysis on DNO and DCO 
Parameter Trend Statistical value p value d.f. or n 
Oxyglobin 
DNO  
Curvilinear 
increase 
r=0.778 p<0.0001 n=36 
Oxyglobin 
DCO 
Curvilinear 
increase 
r=0.712 p<0.0001 n=36 
Post Oxyglobin 
Haemolysis 
DNO  
No change t=0.859 p=0.398 d.f.=25 
Post Oxyglobin 
Haemolysis 
DCO 
No change t=-0.531 p=0.600 d.f.=25 
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6.7 Implications of Oxyglobin Solution on Gas Transfer in the Membrane 
Oxygenator: Discussion 
 
The aim was to determine if the Haemoglobin-Based-Oxygen-Carrier (HBOC) Oxyglobin 
affected DO2, DNO and DCO in the membrane oxygenator circuit.  It was previously 
concluded that haemolysis of circuit blood and addition of free Hb solution to the circuit 
resulted in an associated increase in DNO (Chapter 5).  DNO resistance was attributed to 
one of three areas; RBC membrane, RBC interior or the plasma surrounding the RBC.   To 
determine DNO resistance exerted by plasma, Oxyglobin was added to the circuit blood.  
Oxyglobin would reduce the boundary effect thus reducing plasma resistance.   After 
HBOC addition, circulating RBCs were haemolysed to determine if the RBC membrane or 
interior was influential to DNO.  The work in this chapter was extended to determine the 
NO scavenging potential of Oxyglobin.  HBOCs have been linked to pulmonary 
hypertension, systemic hypertension, myocardial infarctions and strokes (Natanson et al 
2008) due to the theoretical scavenging of endothelial NO in the vasculature (Irwin 2008).   
 
Oxyglobin is a licensed HBOC for canine use and was the only available licensed product 
at the time of conducting this work.  Oxyglobin can cause discolouration of blood during 
metabolism and excretion.   Whilst Oxyglobin was not undergoing metabolic 
transformation within the circuit, an interference check was made of the 
spectrophotometric blood saturation analysers.  A similar experiment in dogs pre and post 
Oxyglobin transfusion concluded that blood saturation equipment was unaffected by 
Oxyglobin (Jahr et al 2001).   In this work, the Cobe Sat/Hct analyser (infrared light) and 
the Spectrum Medical M2 (white light) were comparably consistent in their results. There 
was no significant difference in sO2 between the two analysers: a decrease in SvO2 and 
SaO2 was noted with gradual addition of Oxyglobin to the circuit blood.  This was 
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considered an accurate result as it was evident in both analysers.  The Oxyglobin 
manufacturing process increases P50 to enhance oxygen offloading to the tissues.  The 
ODC experiments in this circuit showed a right ODC shift in the presence of Oxyglobin, 
increasing P50 from 32.50 mmHg for circuit blood to 35.20 mmHg.  A right ODC shift 
would result in a reduction in SaO2 and SvO2 further supporting the Cobe and Spectrum 
Medical analyser results.  Additionally, uptake of oxygen in the membrane would be 
reduced however in this circuit M O2 remained stable throughout the Oxyglobin.  The lack 
of M O2 effect is due to the reduction in M O2 from the right ODC shift being masked by 
oxygen taken up by Oxyglobin. 
 
DCO increased slightly with gradual addition of Oxyglobin to the circuit blood, whereas 
DNO increased up to 143%.  This result confirms that RBC surroundings provide 
resistance to DNO.  In flowing whole blood, a boundary layer effect occurs whereby the 
distance between the alveolar membrane and RBC is increased.  Oxyglobin reduces the 
boundary effect as free Hb penetrates plasma surrounding the RBC and that between the 
RBC and the endothelial layer.  Oxyglobin reduces DNO resistance by partaking in NO 
uptake which effectively bypasses the RBC membrane and interior.  This finding was 
substantiated in three dogs undergoing DLNO tests before and after three successive equal 
volume-exchange transfusions with Oxyglobin.  DLNO rose 57 ±16% after the Oxyglobin 
transfusions.  The canine experiments were conducted and published in collaboration with 
this in vitro laboratory work (Borland et al 2010).  Significant plasma resistance may also 
affect DNO at low Hb concentrations.  In Chapter 3, a curvilinear increase in DNO was 
observed at lower Hb concentrations (<5 g/dl) which may be due to the spatial dispersion 
of RBC with increased unstirred RBC plasma layers or a lack of Hb availability.  At 
clinical levels Hb has not affected DLNO in anaemic patients‟ pre and post transfusion 
(van der Lee et al 2005).   
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To determine RBC membrane and interior resistance to DNO (post Oxyglobin addition), 
the RBCs were lysed by progressive water addition to the circuit.  DNO did not 
significantly increase further with circuit haemolysis although a slight increase from a 
mean 17.17 ml/min/mmHg (250 ml Oxyglobin) to 19.31 ml/min/mmHg (haemolysis) was 
observed.  It was considered that RBC membrane or interior resistance to DNO would 
result in a further DNO increase during the haemolysis phase.   However, if the RBC 
membrane and interior effect was small it would be masked by the uptake of NO by 
Oxyglobin and liberated Hb.  To clarify RBC membrane resistance, further work would 
need to be devised i.e. investigating DNO in normal compared to altered or reduced RBC 
membrane surface area.  Despite this, the study has suggested that the traditional lung 
transfer equation for DNO, as detailed by Roughton and Forster (1957), may not be fully 
representative of the specific resistances encountered.   
 
 
    
 
 
    
  
 
      
 
 
In this equation (above) DLNO is the overall gas transfer for NO, DMNO is membrane 
transfer for NO, θNO is the blood conductance for NO and Vc is the pulmonary capillary 
blood volume.  With data from this work, plasma has been isolated as an important source 
of DNO resistance.  In patients with significant clinical haemolysis or post HBOC 
transfusion, lung function impairment may not be highlighted with current DLNO lung 
function testing.  Presence of circulating free Hb or HBOC may enhance DNO in these 
patients.  To rectify this, the calculation of DNO resistance should be modified to 
incorporate plasma resistance.  
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The combination of Oxyglobin and NO has not been documented.  HBOCs scavenging 
endothelial NO have been widely accepted as the cause for HBOC induced pulmonary and 
systemic hypertension.  The risk of HBOC associated MIs and increased mortality has 
halted licensing of such products for clinical use (Natanson et al 2008).  The mechanism 
for HBOC induced MIs and increased mortality has been speculated as reduced coronary 
blood flow due to coronary vasoconstriction (Yu 2009) or inadequate organ perfusion due 
to systemic vasoconstriction (Winslow 2003).  In this work, Oxyglobin has demonstrated 
NO scavenging potential and when Oxyglobin was administered to dogs, an increase in 
DLNO was observed (Borland et al 2010).   Oxyglobin, as an HBOC example, readily 
binds NO supporting HBOC hypertension as a result of endothelial NO binding in the 
vasculature.   To combat NO induced hypertension Yu et al (2009) suggested NO therapy 
prior to and during HBOC transfusion.  In this study, Oxyglobin addition to the circuit 
blood when combined with NO resulted in a left venous ODC shift.  Whole blood exposed 
to NO in this circuit also resulted in a left shift of the ODC (Chapter 5) so influence of 
Oxyglobin is unclear.  Neya et al (1998) found that a Biopure HBOC oxidates to 
methaemoglobin readily over five hours in an extracorporeal circuit, associated with 
decreasing P50.  Oxyglobin in whole blood enhances P50 to increase oxygen offloading but 
when combined with NO, the P50 significantly reduced.  Reduction in P50 results in poorer 
oxygen offloading in the tissues.  It appears that HBOCs readily oxidate to 
methaemoglobin and NO enhances the oxidation rate.  Oxidation rate was less with whole 
blood presence indicating antioxidant effects of whole blood upon HBOCs (Neya et al 
1998).  NO scavenging by the HBOC Oxyglobin could be coupled with a reduced P50 
resulting in poorly perfused and poorly oxygenated organs.  This work concludes that the 
HBOC Oxyglobin has NO scavenging properties with potential for increased oxygen 
affinity of the NO-bound HBOC.    
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CHAPTER 7 Discussion 
 
In this work, a novel in vitro membrane oxygenator circuit was developed to test gas 
exchange.  Circuit tests have shown that the RBC surroundings (plasma) provide 
significant resistance to nitric oxide diffusion, therefore in lung function testing DMNO 
cannot equal DLNO as the reaction rate of nitric oxide with blood does not equal infinity.  
The work has demonstrated a significant uptake of nitric oxide by the HBOC Oxyglobin, 
supporting its potential to scavenge endothelial nitric oxide in vivo, resulting in 
vasoconstriction.  NO binding to Oxyglobin shifts the circuit blood ODC to the left 
resulting in poorer oxygen delivery to the tissues.    
 
 
7.1 Circuit Design 
 
The oxygenator circuit developed for this work is a unique model for testing gas exchange 
in vitro (Dunningham 2007).  The circuit comprises two commercially available 
membrane oxygenators connected to form a continuous blood circuit resembling venous 
and arterial blood conditions.  The work conducted in this circuit has demonstrated that 
particular elements of gas exchange can be examined whilst keeping other variables 
constant, so that the circuit can be manipulated to test theories previously devised.  For 
example, in the diffusion resistance equation described by Roughton and Forster (1957), 
modified by Meade and Cotes (Cotes 1993), changes in gas exchange can be reliably 
attributed to specific resistance factors by changing each factor independently.   
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In this equation, the overall resistance to lung diffusion (DL) is made up of two 
components, the resistance of the membrane (DM) and the resistance of the interaction of 
gas with the blood, where    is the influence of the ODC slope and blood flow and     is 
the specific conductance of the gas with 1 ml blood and the volume of pulmonary 
capillary blood.   
 
This membrane oxygenator circuits allows examination of these individual diffusion 
resistances.  The membrane oxygenator selected was a dual chamber device, enabling DM 
and Vc to be tested by halving the membrane without altering blood flow.  Blood flow 
could be adjusted from 0.1 to 2.5 l/min without affecting DM.  Varying FiO2 experiments 
facilitated examination of β and θ elements of the reaction.  Finally, varying Hct and 
haemolysis enabled diffusion resistances of the RBC to be investigated.  In man, 
respiratory tests for gas exchange are subject to many clinical consequences i.e. a 
significant reduction in haematocrit results in increased cardiac output to compensate for 
reduced oxygen carrying capacity (Varat et al 1972).  In this circuit, these consequences 
are not encountered so allowing for consistent experimental conditions.  The scope of 
experiments undertaken for this work would not be suitable in vivo as some changing 
conditions would be detrimental to life i.e. hypoxia, low haematocrit and haemolysis.  The 
experimental circuit has given insight into gas transfer for clinical and sub-clinical 
conditions.  Such a circuit has not been developed previously for this type of investigation.  
 
A commercial membrane oxygenator used as a deoxygenator is unusual as there is no 
clinical necessity.  Several other researchers have cited varying deoxygenator unit 
numbers, membrane sizes and gas regimes (Gourlay et al 1990 and 1994, Van Meurs et al 
1991, Rais-Bahrami et al 1992, Vocelka et al 1993, Griffiths et al 1994, Beckley et al 
1996, Matsuda et al 2000, Kawahito et al 2001, Walczak et al 2005).  This study used a 
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single deoxygenator unit with approximately 5 l/min (5.1-5.3 l/min) 8-10% CO2 in N2 to 
deoxygenate 2.5 l/min blood flow (Dunningham et al 2007).  Similar deoxygenator 
circuits are now being described in Ex-Vivo-Lung-Perfusion (EVLP) circuits where 
harvested marginal donor lungs are maintained on a circuit for organ evaluation and re-
conditioning prior to transplantation with good outcomes (Cypel et al 2009, Pego-
Fernandes et al 2010, Okamoto et al 2010).  These studies use 7% CO2 in N2 for the 
deoxygenator gas and ventilated lungs for arterialising the blood.      
 
The blood used in this circuit was of equine origin rather than human due to ethical 
considerations.  Several human donors of a compatible blood group would be required for 
each circuit (1500-2000 ml) leading to greater variation.  Human blood from out-dated 
blood bank supply was considered inappropriate for gas transfer testing due to storage 
conditions that appear to induce „storage lesion‟ of the blood.  Red blood cells subjected to 
„storage lesion‟ exhibit cell changes such as morphological changes, slowed metabolism, 
acidosis with decreased 2,3-DPG concentrations, decreased Hb nitric oxide binding, loss 
of functional pumps with loss of intracellular potassium and accumulation of sodium and 
loss of parts of the membrane (Liumbruno and Aubuchon 2010).  All of these defects in 
stored RBC could have an impact on the results of this work.   Previous use of alternative 
membrane oxygenator circuits have used vast quantities of blood obtained from abattoirs, 
typically of bovine origin (Vocelka et al 1993, Griffiths et al 1994, Gourlay and Taylor 
1994, Beckley et al 1996).  In this circuit, the quantities of blood required were much less 
due to the compact nature of the circuit.  Equine blood was chosen as it is commercially 
available from horse donors where the age and gender can be specified.  The blood is 
freshly withdrawn and used within a week of delivery to optimise gas transfer potential.  
Additionally, the haematocrit is kept within a consistent range (Hct 40-50 %) from the 
supplier.  As the blood is commercially available it allows for reproduction of the 
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methodology.  Alternative animal species were considered but the size of the horse 
enabled one donor to supply blood to complete a single circuit with haemolysed solution.  
There are differences between equine and human blood that have to be acknowledged.  
Clerbaux et al (1993) compared blood of horse with human blood.  The equine RBC is 
slightly smaller at 5-6 µm compared to human (6-8 µm).  The haemoglobin structure is the 
same comprising two alpha and two beta chains.  There is slightly more 2,3 DPG present 
in equine RBCs compared to human RBCs, yet the P50 of equine blood is lower at 23.8 
±0.8 mmHg compared to human P50 26.6 mmHg (Clerbaux et al 1986 and 1993).  Equine 
blood has a higher affinity for oxygen compared to human blood resulting in a leftward 
ODC shift.  The differences in equine and human ODC would not affect the ODC tests 
carried out in this work as control data was taken from the same circuit and donor as the 
„treated‟ group.  Calculations of DO2 were based on Severinghaus which is related to 
human blood.  When a correction factor was applied to the Severinghaus formula for 
equine blood (based on data from Clerbaux et al 1993) there was no significant difference 
in Severinghaus and Clerbaux corrected DO2 calculations (p=0.854) (Appendix 2).  
Despite minor differences in equine and human blood, the use of equine blood does not 
detract from the results and conclusions so derived.  
 
 
7.2 Effects of the Volatile Anaesthetic Isoflurane on Gas Transfer 
 
The test circuit was used to determine the effects of Isoflurane on gas transfer in the 
membrane oxygenator.  This volatile anaesthetic is routinely used during cardiopulmonary 
bypass, being administered via the membrane oxygenator.  Manufacturers of membrane 
oxygenators do not advocate use of volatile anaesthetic agents in their devices as they 
have insufficient data supporting the relicensing requirements of regulatory authorities.  
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The literature review highlighted a lack of data demonstrating the effects of volatile 
anaesthetic agents on gas transfer in membrane oxygenators, although studies have been 
conducted in bubble type oxygenators (Price et al 1988, Henderson et al 1988, Nussmeier 
et al 1988 and 1989).  Work in this circuit demonstrated adequate transfer of Isoflurane 
across the polypropylene membrane oxygenator which concurred with previous research 
by Henderson et al 1988, Stern et al 1989, Hickey et al 1996, Lockwood 1999 and 
Wiesenack et al 2002.  The wash-out time observed in this circuit was substantially lower 
than that quoted in previous work.  Those data were established in the clinical setting and 
were subjected to patient uptake of Isoflurane.  This in vitro circuit was not influenced by 
patient distribution of Isoflurane, thus Isoflurane was rapidly removed from blood across 
the membrane.  Preliminary data in this circuit supported an increased oxygen uptake        
(M O2) in the presence of Isoflurane without a change in PO2 (Borland et al 2007b).  No 
other research groups have reported such an effect.  This observation led to the 
modification of the circuit equipment to facilitate simultaneous PO2 and sO2 monitoring at 
varying FiO2 replicating the ODC.  Early data showed a venous left ODC shift which is 
associated with poor oxygen offloading in the tissues but enhanced oxygen uptake in the 
lungs (Borland et al 2007b).  This finding was supportive of the previous increase in M O2 
but was not Isoflurane dose dependent casting doubts on the effects seen.  Further 
investigations into the increased M O2 with Isoflurane highlighted the critical factor being 
the FiO2-FeO2 difference in the M O2 calculation.  Exploration of the methodology found 
that the Isoflurane vaporiser positioning had a profound impact on the FiO2 reading when 
it was switched on.  With the FiO2 analyser placed prior to the Isoflurane vaporiser there 
was an increase in FiO2 readings when the vaporiser was used, thus an artificially elevated 
FiO2 resulted.  By repositioning the FiO2 analyser post vaporiser, the actual FiO2 delivered 
to the membrane oxygenator was observed.  Repeating the experimental work with 
appropriate positioning of the Isoflurane vaporiser revealed that Isoflurane had no effect 
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on oxygen transfer in the membrane oxygenator.  The venous and arterial ODCs were 
unaffected by Isoflurane administration to the circuit blood.  The oxygen uptake finding 
was consistent with those reported by Muhle et al (2001).  Muhle‟s study was limited by 
the 30 second exposure time not being adequate for an effect to occur when other groups 
have reported lengthier wash-in and wash-out times.  Muhle‟s single-pass methodology 
was limiting to the length of time the circuit could be run.  This work sought to address 
these issues by utilising a continuously run circuit over a longer time duration, to ensure 
equilibrium was reached between the blood and gas phases.  No other research group have 
conducted experiments to show the effect of Isoflurane administered via the membrane 
oxygenator on the ODC (Borland et al 2007b).  The experimental work conducted with 
this circuit design has developed ODC methodology and concluded that Isoflurane does 
not affect oxygen carriage in the blood. 
 
By utilising a diffusion limited gas (NO) the impact of Isoflurane on membrane integrity 
was investigated in this circuit. The methodology used in this work was vastly different 
from previous approaches.  Crosbie et al (1998) exposed samples of polypropylene 
membrane to Isoflurane for extended periods prior to light microscopic evaluation, which 
showed no structural changes. They concluded that Isoflurane would not affect oxygen 
transfer across a polypropylene membrane oxygenator.  Lanquetot (2005) evaluated 
clinical data from patients undergoing cardiopulmonary bypass with oxygenator Isoflurane 
anaesthesia administration.  The author determined that oxygen transfer data was not 
affected by Isoflurane anaesthesia in the membrane oxygenator.   In this research, there 
were physical constraints in accessing the membrane material from the oxygenator 
housing once the unit had been exposed to equine blood.  Drilling a hole in the outer 
oxygenator casing followed by sample extraction via cork borer was explored but there 
were concerns about damage sustained by the membrane material during the process.  This 
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alternative approach was devised to assess membrane integrity during the Isoflurane 
administration.   If the structure or efficiency of the membrane was affected by Isoflurane 
then an effect would be observed in a diffusion limited gas.  In this work, DNO did not 
increase in the presence of Isoflurane concluding that Isoflurane does not affect the 
integrity of the polypropylene membrane.   
 
 
7.3 Resistance of the Erythrocyte and Surroundings on DNO 
 
The circuit enabled the effects of haemolysis on gas transfer to be investigated.  Gross 
haemolysis is not feasible in vivo due to the detrimental affects sustained by the lungs and 
kidneys.  Haemolysis occurs when the RBC membrane is disrupted, liberating its contents 
into the RBC surroundings (plasma).  Clinical haemolysis occurs in infections (bacterial or 
parasitic), autoimmune conditions or genetic disorders.  The importance of the RBC 
membrane in overall gas transfer can be investigated in a circuit such as this.  Gas 
diffusion describes the transfer of gas from the alveolar membrane to binding with 
haemoglobin.  The process involves gas moving across the alveolar membrane where it 
diffuses through plasma, crosses the RBC membrane before binding with haemoglobin.  
In diffusion limited gas such as carbon monoxide or nitric oxide there is no influence from 
blood flow or ODC so Roughton and Forster‟s (1957) equation reflects this. 
 
 
    
 
 
    
  
 
       
 
 
Where, DL is the overall resistance to lung diffusion, DM is the resistance of the 
membrane, Vc is the pulmonary capillary blood volume and   is the specific conductance 
of the gas with 1 ml blood. 
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The importance of RBC resistance has been disputed with regards to lung function testing 
where NO is utilised.  The current standards describe the test as a single breath procedure 
with CO (Forster 1983), but a more recent procedure has emerged that combines results of 
both NO and CO transfer across the lungs (Guenard et al 1987, Borland et al 1989).  NO 
has a faster binding to haemoglobin and is independent of inspired oxygen concentrations 
that can affect carbon monoxide uptake.  Limitations have prevented NO use in lung 
function testing due to concerns with the length of breath holding, equipment sensitivity 
and NO toxicity.  RBC resistance to NO has implications for the use of NO in lung 
function testing.  The overall DLNO would not be reflective of DMNO depending on the 
resistance proportion attributed to the RBC.  Guenard et al (1987) speculated that DLNO 
would equal DMNO due to the rapid and irreversible nature of the binding between NO 
and haemoglobin.  It was thought that θNO could be considered infinite.  Heller and 
Schuster (1998) reported that the diffusion element (DMNO) accounted for 98 ±6% of the 
overall resistance to alveolar-capillary NO transfer suggesting that any resistance exerted 
by the RBC would have minimal impact on DLNO.  Other groups have questioned the 
importance of the RBC on DLNO, suggesting that DLNO is not just NO transfer across the 
alveolar membrane but also includes the diffusion of NO within the capillary plasma and 
the RBC (Borland et al 2006 and 2010).   
 
In this apparatus, the methodology was amended to investigate the effects of haemolysis 
on DNO.  Initially, the circuit blood was gradually haemolysed by addition of water 
resulting in gross haemolysis but as this was not clinically representative, so a haemolysed 
(free Hb) solution was made and added to the circuit blood.  These experiments (Chapter 
5) concluded that haemolysis of the circuit blood and addition of free Hb solution to the 
circuit resulted in an associated increase in DNO.  The cause of the DNO resistance was 
attributed to one of three areas; RBC membrane, RBC interior or the plasma surrounding 
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the RBC (Borland et al 2006).  During gross haemolysis of the circuit blood, the RBC 
membrane and interior resistance was eradicated and the liberated Hb from the lysed 
RBCs also reduced the RBC surroundings resistance. Therefore, the initial work could not 
reliably conclude the source of DNO resistance.  Free Hb solution addition to the circuit 
blood reduced the plasma resistance but further lysis induced by the free Hb solution 
addition could not be eliminated.  To determine if resistance to DNO in the circuit blood 
was due to the RBC surroundings, an HBOC was added to the circuit blood.  After HBOC 
addition, the circulating volume was haemolysed to determine if the RBC membrane or 
interior was influential in DNO.   
 
DNO increased up to 143% (ranged 29 to 143 %) with gradual Oxyglobin addition to the 
circuit.  This result concluded that the RBC surroundings (plasma) provide resistance to 
DNO in this in vitro circuit.  The outcome of this work concurred with a study conducted 
by Liu (2002) whereby competition NO diffusion experiments previously conducted by 
Vaughn et al (2000) were mathematically modelled and analysed.  Liu (2002) concluded 
that competition methodology of rocker mixing the blood did not remove the extracellular 
barrier and the predominant RBC resistance to DNO was due to the surrounding unstirred 
layer.  When whole blood flows through pulmonary capillaries there is a boundary layer 
effect whereby the distance between the alveolar membrane and RBC is increased with 
flow.  Oxyglobin reduces the boundary effect as free Hb penetrates the plasma 
surrounding the RBC and that between the RBC and endothelial layer.  Oxyglobin reduces 
DNO resistance by partaking in NO uptake and bypassing the RBC membrane and 
interior.  In the oxygenator model, the blood flow channel is much larger than the 
pulmonary capillaries which facilitates laminar flow characteristics and therefore may 
exhibit a larger boundary effect.  However, these oxygenators have mixing structures 
within the blood channels to minimise the laminar flow characteristics.  The resistance of 
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the RBC surroundings on DNO was also substantiated when three dogs underwent DLNO 
tests before and after three successive equal volume-exchange transfusions with 
Oxyglobin.  DLNO rose 57 ±16% after Oxyglobin transfusions (Borland et al 2010).     
 
Post Oxyglobin addition to the circuit blood, there was a progressive addition of water to 
lyse the RBCs.  This methodology was to determine if the RBC membrane or interior 
provided resistance to DNO, based on the idea that if either provided resistance then a 
further DNO increase would be observed.  Other groups have cited intracellular resistance 
(Sakai et al 2008) and/or transmembrane resistance (Vaughn et al 2000) to DNO in their 
work.  In this experiment, DNO did not significantly increase further with haemolysis of 
the circuit blood although there was a small increase from a mean 17.17 ±3.86 
ml/min/mmHg (250 ml Oxyglobin) compared to 19.31 ±4.08 ml/min/mmHg (haemolysis).  
This result would conclude that the RBC membrane and interior do not provide resistance 
to DNO, although the methodology presented here may not fully explore this theory.  
Firstly, Oxyglobin and free Hb liberated from the RBCs during lysis have shown an 
associated curvilinear increase in DNO.  The DNO increase is apparent after a small 
addition of free Hb or Oxyglobin to the circuit reducing the boundary effect exerted by 
plasma.  The subsequent observed DNO plateau indicates that the threshold of resistance 
exerted by the unstirred plasma layer has been achieved.  Post Oxyglobin haemolysis 
removes the RBC membrane and releases intracellular Hb but the resistance of the RBC 
membrane will have no further impact on DNO as the overriding plateau caused by 
Oxyglobin and free Hb mask the membrane effect.  Alternatively, if the RBC encapsulated 
outer Hb has bound NO during the Oxyglobin addition phase, this is thought to provide a 
barrier to further NO penetration of the RBC (as described by Sakai et al 2008).  Upon 
haemolysis, Hb within the central area of the RBC not previously exposed to NO will be 
liberated and would essentially be partaking in NO uptake within the plasma where the 
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effect (if small by comparison to Oxyglobin) would be lost within the overall DNO.  It 
must be acknowledged that the conclusion from this work regarding the RBC membrane 
and interior resistances is not robust.  To define the resistance applied by the RBC 
membrane and its interior, alternative experiments need to be conducted to validate the 
findings from this work.  It would be necessary to demonstrate that red cell deformation 
had no effect on DNO thus forming the basis of future experiments.  Despite this, the 
study has suggested that the traditional lung transfer equation for DNO, as detailed by 
Roughton and Forster (1957), may not be fully representative of the specific resistances 
encountered, such as plasma.   
 
 
    
 
 
    
  
 
      
 
 
In this equation (above) DLNO is the overall gas transfer for NO, DMNO is membrane 
transfer for NO, θ is the blood conductance for NO and Vc is the pulmonary capillary 
blood volume.  With the data and results from this work an important resistance to DNO 
by the RBC surroundings (plasma) has been isolated.  In the collaborative work conducted 
in dogs with exchange transfusion of Oxyglobin, 37% of the overall resistance to DLNO 
was attributed to the erythrocyte-related barrier (Borland et al 2010).  This finding 
demonstrates the potential impact of clinical haemolysis or HBOC transfusion on DLNO.   
In patients with significant clinical haemolysis or post HBOC transfusion, lung function 
impairment may not be highlighted with the current DLNO lung function testing.  Presence 
of free Hb or HBOC in the circulation may enhance DNO in these patients.  To rectify 
this, the calculation of DNO resistance should be modified to incorporate plasma 
resistance.  
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7.4 NO Binding Potential of the HBOC Oxyglobin and the Implications  
 
The membrane oxygenator circuit was used to determine if the Haemoglobin-Based-
Oxygen-Carrier (HBOC) Oxyglobin affected gas transfer of DO2, DNO and DCO.  
Principally, the methodology was devised to investigate DNO resistance of the RBC 
surroundings by adding an HBOC to reduce the boundary layer whilst maintaining intact 
circulating RBCs.  HBOCs have been linked to pulmonary hypertension, systemic 
hypertension, myocardial infarction and stroke (Natanson et al 2008) due to the theoretical 
endothelial NO scavenging potential in the vasculature (Irwin 2008).  Oxyglobin was 
assessed for its NO scavenging potential via the uptake of NO across the membrane.  The 
use of a membrane oxygenator circuit to assess and quantify NO uptake by an HBOC is a 
unique and novel investigation.   By simultaneously measuring blood sO2 and PO2, the 
circuit was used as a continuous tonometer enabling the affects of Oxyglobin on venous 
and arterial ODCs to be assessed.   
 
The ability of Oxyglobin to bind NO was demonstrated and quantified.  NO uptake 
increased by up to 143% on addition of Oxyglobin to the circuit blood.  The NO binding 
potential of Oxyglobin via the membrane oxygenator is immense.  In dogs, DLNO 
increased after exchange transfusion of Oxyglobin of 57 ±16% (Borland et al 2010) 
further supporting NO scavenging of Oxyglobin.  The hypothesis that HBOCs bind 
endothelial NO resulting in HBOC associated vasoconstriction is supported by this work.  
Yu et al (2009) corroborated this theory by demonstrating that NO synthase deficient mice 
do not exhibit hypertensive effects when transfused with HBOC, compared to non-
deficient normal mice.  The same authors have shown that inhaled NO treatment prior to 
and during an HBOC transfusion can reduce the vasoconstrictive effects (Yu et al 2008 
and 2009).  In the collaborative canine study (Borland 2010), systemic and pulmonary 
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blood pressures were unaltered during exchange transfusion of Oxyglobin with NO 
inhalation.  Pre-treatment of patients with inhaled NO prior to HBOC transfusion is a 
novel approach.  For cardiothoracic patients undergoing cardiopulmonary bypass, pre-
treatment with inhaled NO would be via the membrane oxygenator of the 
cardiopulmonary bypass circuit as the lungs would be deflated during the procedure.   
Body et al (1999) demonstrated that NO does not affect the structural integrity of 
polypropylene membrane oxygenators.  This work shows that NO readily passes across 
the microporous polypropylene membrane oxygenator. 
 
The manufacturing process of Oxyglobin incorporates an increase in P50 to enhance 
oxygen offloading to the tissues.  Previous theories linked enhanced HBOC P50 to 
hypertension via autoregulation of the blood vessels in response to increased arteriolar 
blood partial pressure of oxygen.  Therefore a small number of HBOCs were developed 
with a lower than normal P50.  The study by Natanson et al (2008) associating HBOCs to 
increased mortality and MIs incorporated HBOCs with higher and lower oxygen affinities, 
rendering the autoregulation theory unlikely.  The ODC work carried out in this circuit 
demonstrated a right ODC shift post Oxyglobin transfusion to the circuit.  The P v O2 for 
a given SvO2 is elevated thus increasing the oxygen partial pressure difference in the 
tissues orchestrating better oxygen delivery.   Oxyglobin significantly shifted the P50 from 
32.50 mmHg (circuit blood) to 35.20 mmHg (circuit blood combined with Oxyglobin).  In 
a right shift of the ODC, uptake of oxygen across the membrane would be reduced 
however M O2 remained stable throughout the Oxyglobin addition.  The lack of M O2 
effect would be due to the reduction in M O2 from the right shift being masked by oxygen 
taken up by Oxyglobin.   
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As previously discussed Oxyglobin readily binds NO.  The affects of NO-bound 
Oxyglobin on the ODC is understudied, so this area was investigated in this research.  Pre-
treatment of patients with NO prior to HBOC transfusion (Yu et al 2008 and 2009) may 
affect the ODC.  This work has demonstrated that NO significantly shifted the ODC of 
circuit blood to the left due to irreversible binding of NO to haemoglobin. The P50 of NO-
bound circuit blood was 26.12 mmHg compared to the non-NO exposed circuit blood P50  
29.41 mmHg.  If NO can shift the ODC of the circuit blood to the left, but Oxyglobin has 
demonstrated a right shift of the circuit blood, concern was raised about the effects of NO-
bound Oxyglobin on the circuit blood.   Tests in this apparatus demonstrated a leftward 
shift in the venous ODC with NO-bound Oxyglobin.  Oxyglobin has an enhanced P50 of 
35 mmHg to increase oxygen offloading but when combined with NO, the P50 
significantly reduced to 22.71 mmHg compared to 25.34 mmHg for the circuit blood.  A 
reduction in P50 would result in poor oxygen offloading in the tissues.  These tests cannot 
determine the cause of the reduced P50 i.e. as a result of NO-bound Oxyglobin or NO-
bound whole blood, as NO was administered via the membrane prior to and during the 
Oxyglobin addition.  The ODC effect may not be as significant in patients undergoing 
HBOC transfusion that binds endothelial NO compared to patients pre-treated with NO 
prior and during an HBOC transfusion.  The beneficial effects of HBOCs with elevated 
P50 would be lost if patients undergo NO pre-treatment.  Similarly, HBOCs with a low P50 
coupled with NO binding may reduce the blood P50 to unacceptably low levels affecting 
oxygen carriage of the blood.  To further address the ODC effects of NO-bound HBOCs, 
the circuit could be primed solely with HBOC and the ODC conducted with and without 
NO via the membrane.  In conclusion, vasoconstriction as a result of NO scavenging by 
Oxyglobin may be coupled with a reduction in P50 resulting in poorly perfused and poorly 
oxygenated organs.  This work has demonstrated a potential dual mechanism for increased 
risk of MI and mortality of endothelial NO scavenging and increased oxygen affinity of 
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NO-bound HBOCs.  This finding has not been published and substantiated by any other 
group.  
  
7.5 Limitations and Further Work 
 
The circuit designed for this work is based upon a commercially available membrane 
oxygenator.  Structurally, there are differences between the membrane oxygenator and 
lungs however such models can provide valuable diffusion data of gases in response to 
varying physiological parameters.  The predominant differences between the membrane 
oxygenator and lungs are the surface area, pulmonary capillary volume, cross-sectional 
diameter of the blood pathway, blood transit time and non-pulsatile blood flow.   Between 
run variations were attributed to the differences between membrane oxygenator batch 
productions which can be eliminated by the study design.  In this case, comparison of 
control versus treatment group was made using the same apparatus and repeated as 
necessary with complete new circuits. 
 
The methodology used in this work to determine the resistances exerted by the RBC 
membrane and interior to DNO was not robust in order to support the evident conclusion.  
To clarify DNO resistance of the RBC membrane, normal RBCs could be compared to 
altered RBCs with a reduced or increased RBC membrane surface area.  Carlson and 
Camroe (1958) demonstrated that DNO was comparable between discoidal and spherical 
RBC of similar volume, which suggested that the RBC interior is not a limiting factor.  In 
crenated RBCs they noted a decrease in DNO.  This may be a result of the reduced RBC 
membrane surface area or an effect of a resultant thickened membrane.  Similar work to 
that described by Carlson and Camroe (1958) could be explored in this apparatus. 
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The work encompassing NO scavenging effects of Oxyglobin in this circuit has given 
insight into the possible vasoreactive mechanisms seen clinically.  The risks associated 
with clinical administration of HBOCs and the lack of licensed products available limits 
replication of this work for the foreseeable future.  This type of circuit would be ideal to 
investigate the NO scavenging potential of HBOCs with differing P50 characteristics to 
determine if this affects NO scavenging capacity of the HBOC.  The effects of NO on the 
ODC of HBOCs could be clarified as this may critically affect oxygen delivery.  To avoid 
NO scavenging by HBOCs the optimal solution would be haemoglobin encapsulation.  
Sakai et al (2010) demonstrated reduced NO uptake by liposome encapsulated Hb 
compared to an HBOC and free Hb.   The substance used to encapsulate the Hb would 
need to be developed with consideration of its permeability to NO and O2.  The circuit 
designed in this work would represent an ideal testing apparatus for such innovative 
products.   
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Conclusion 
 
In this work, a novel in vitro membrane oxygenator circuit was developed to test gas 
exchange simulating arterial and venous blood gas parameters.   
 
The circuit tests have shown that the RBC surroundings (plasma) provide significant 
resistance to nitric oxide diffusion.  In lung function testing DMNO cannot equal DLNO as 
the reaction rate of nitric oxide with blood does not equal infinity.   
 
The work has demonstrated a significant uptake of nitric oxide by the HBOC Oxyglobin 
supporting its potential to scavenge endothelial nitric oxide in vivo, resulting in 
vasoconstriction.  Nitric oxide bound Oxyglobin shifts the circuit blood ODC to the left 
resulting in poorer oxygen delivery to the tissues.    
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Figures 
 
 
Figure 3.10  Effects of Blood Flow (Q ) with 1 Cell on PO2; PaO2 ♦ showed a very 
slight decrease over the blood flow range 0.1- 2.5 l/min whereas P v O2 ■ showed a very 
slight increase.  The resultant Pc O2 ▲ remained static throughout the blood flow range.  
PaO2 averaged 63.44 ±33.57 mmHg, P v O2 averaged 21.51 ±7.97 mmHg and P c O2 was 
34.37 ±5.83 mmHg for 1 cell. 
 
 
 
Figure 3.11  Effects of Blood Flow (Q ) with 2 Cells on PO2; PaO2 ♦ showed a very 
slight decrease over the blood flow range 0.1- 2.5 l/min whereas P v O2 ■ showed a very 
slight increase.  The resultant Pc O2 ▲ remained static throughout the blood flow range.  
PaO2 averaged 81.45 ±34.66 mmHg, P v O2 averaged 27.36 ±8.58 mmHg and P c O2 was 
41.75 ±6.85 mmHg for 2 cells. 
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Figure 3.12  Effects of Blood Flow (Q ) with Surface Area (SA) on M O2; Increasing 
blood flow from 0.2 to 2.5 l/min for 1 cell ♦ and 2 cells ■ corresponded with a linear 
increase in M O2.  M O2 for 1 cell ranged 23.28 to 93.11 ml/min (run 1, p=0.018), 229.46 
to 321.24 ml/min (run 2, p=0.004) and 34.35 to 137.40 ml/min (run 3, p=0.002).  M O2 
ranged 23.28 to 93.11 ml/min (run 1, p=0.050), 183.57 to 275.35 ml/min (run 2, p=0.032) 
and 49.07 to 161.93 ml/min (run 3, p=0.006) for 2 cells. 
 
 
 
Figure 3.13  Effects of Blood Flow (Q ) and Surface Area (SA) on DO2; Increasing 
blood flow from 0.2 to 2.5 l/min for 1 cell ♦ and 2 cells ■ corresponded with a linear 
increase in DO2.  DO2 for 1 cell ranged 0.21 to 0.90 ml/min/mmHg (run 1, p=0.011), 1.91 
to 2.63 ml/min/mmHg (run 2, p=0.008) and 0.22 to 0.95 ml/min/mmHg (run 3, p=0.002). 
DO2 for 2 cells was calculated as 0.23 to 0.99 ml/min/mmHg (run 1, p=0.017), 1.54 to 
2.36 ml/min/mmHg (run 2, p=0.014) and 0.31 to 1.20 ml/min/mmHg (run 3, p=0.005).   
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Figure 3.14  Effects of Blood Flow (Q ) with 1 Cell on PCO2; PaCO2 ■ increased 
curvilinearly with increasing blood flow from 10 mmHg at 0.1 l/min to a mean 36.25 ± 
2.22 mmHg at 1.0-2.5 l/min.  P v CO2 ♦ similarly decreased over the blood flow range 
from 63 mmHg at 0.1 l/min to a mean 48.25 ±2.36 mmHg over 1.0 – 2.5 l/min.  Pc CO2 ▲ 
(calculated from P v CO2 and PaCO2) averaged 40.83 ±2.48 mmHg.   
 
 
 
Figure 3.15 Effects of Blood Flow (Q ) with 2 Cells on PCO2; PaCO2 ■ increased 
curvilinearly with increasing blood flow from 10 mmHg at 0.1 l/min to a mean 31.75 
±5.38 mmHg at 1.0-2.5 l/min.  P v CO2 ♦ similarly decreased over the blood flow range 
from 65 mmHg at 0.1 l/min to a mean 47.25 ±0.96 mmHg over 1.0-2.5 l/min. Pc CO2 ▲ 
was calculated from P v CO2 and PaCO2 and averaged 39.00 ±2.28 mmHg. 
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Figure 3.16  Effects of Blood Flow (Q ) and Surface Area (SA) on M CO2;  M CO2 
increased linearly from 51.03 to 137.40 ml/min for 1 oxygenator cell ♦ and 52.51 to 
140.83 ml/min for 2 oxygenator cells ■. 
 
 
 
 
 
Figure 3.17  Effects of Blood Flow (Q ) and Surface Area (SA) on DCO2;  DCO2 
increased linearly from 2.28 to 14.52 ml/min/mmHg for 1 oxygenator cell ♦ and 2.46 to 
11.78 ml/min/mmHg for 2 oxygenator cells ■.    
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Figure 3.18 Effects of Blood Flow (Q ) and Surface Area (SA) on Shunt Fraction; 
where ♦ represents 1 cell and ■ represents 2 cells.  Shunt fraction increased linearly with 
increasing blood flow (p=0.009).  Shunt fraction ranged from 0.084% at 0.1 l/min up to 
37% at 2.5 l/min.  Shunt fraction for 1 cell and 2 cells was not significantly different 
(p=0.051). 
 
 
 
 
Figure 3.19 Effects of Blood Flow (Q ) and Surface Area (SA) on DNO; DNO was not 
affected by changes in blood flow from 0.1 to 2.5 l/min (p=0.333).  Increasing surface area 
significantly increased DNO (p=0.002).  DNO for 1 cell ♦ averaged 5.72 ±1.61 
ml/min/mmHg and for 2 cells ■ averaged 9.71 ±3.62 ml/min/mmHg.  
 
 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 0.5 1 1.5 2 2.5 3
Sh
u
n
t 
Fr
ac
ti
o
n
Blood Flow l/min
1 cell
2 cells
0
2
4
6
8
10
12
14
16
0 0.5 1 1.5 2 2.5 3
D
N
O
 m
l/
m
in
/m
m
H
g
Blood flow l/min
DNO 1 cell
DNO 2 cells
196 
 
 
 
 
Figure 3.20 Effects of Blood Flow (Q ) and Surface Area (SA) on DCO; DCO was not 
significantly affected by changes in blood flow from 0.1 to 2.5 l/min (p=0.079).  DCO was 
significantly affected surface area with 1 cell ♦ averaging 1.07 ±0.21 ml/min/mmHg and 2 
cells ■ averaging 1.46 ±0.35 ml/min/mmHg for run 1 (p=0.039).  In run 2 DCO for 1 cell 
♦ averaged 0.81 ±0.17 ml/min/mmHg and for 2 cells ■ averaged 1.13 ±0.25 
ml/min/mmHg (p=0.026).  
 
 
 
 
Figure 3.21 Effects of Blood Flow (Q ) on Diffusion (D); where ■ DCO2 > ♦ DNO > ▲ 
DO2 > ● DCO. 
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Figure 3.22 Effects of Oxygenator Gas Flow (F) on PO2; PaO2 ♦ increased initially 
from 47.25 mmHg (0.5 l/min) to 65.25 mmHg (2.5 l/min) after which the PaO2 averaged 
69.88 ±5.46 mmHg over the gas flow range 5 to 15 l/min.   P v O2 ■ increased from 29.25 
mmHg (0.5 l/min) to 37.5 mmHg (2.5 l/min) before averaging 36.63 ±1.10 mmHg over 
the 5 to 15 l/min gas flow range.  P c O2 ▲ increased from 37.00 mmHg (0.5 l/min) to 
47.48 mmHg (2.5 l/min) before averaging 48.19 ±0.29 mmHg for gas flows 5 to 15 l/min.  
 
 
 
 
Figure 3.23 Effects of Oxygenator Gas Flow (F) on M O2; M O2 increased linearly with 
increasing oxygenator gas flow from 41.90 ml/min at 0.5 l/min to 139.67 ml/min at 15 
l/min (p=0.004).  
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Figure 3.24 Effects of Oxygenator Gas Flow (F) on DO2; DO2 increased with increasing 
oxygenator gas flow from 0.50 ml/min/mmHg at 0.5 l/min to 1.25 ml/min/mmHg at 15 
l/min (p=0.007).  
 
 
 
 
Figure 3.25 Effects of Oxygenator Gas Flow (F) on PCO2; Increasing oxygenator gas 
flow would impact on the removal of CO2 from the „venous‟ blood.  PaCO2 ♦ slightly 
decreased with increasing oxygenator gas flow.  In run 1, PaCO2 reduced from 30 mmHg 
at 0.5 l/min to 15.75 mmHg at 5 l/min (p=0.042).  In run 2, PaCO2 reduced from 48 
mmHg at 2.5 l/min down to 30 mmHg at 15 l/min (p=0.008).  P v CO2 ■ also decreased 
from 30.75 mmHg (0.5 l/min) to 19.50 mmHg (5 l/min) in run 1 and from 67.5 mmHg 
(2.5 l/min) to 56.25 mmHg (15 l/min) in run 2. 
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Figure 3.26 Effects of Oxygenator Gas Flow (F) on DNO and DCO; DNO ♦ increased 
linearly with increasing oxygenator gas flow 2.5 to 15.0 l/min (p<0.001) from 4.76 
ml/min/mmHg (2.5 l/min) up to 11.19 ml/min/mmHg (15 l/min).  DCO ■ showed no 
change with increasing oxygenator gas flow (p=0.932) averaging 1.36 ±0.28 
ml/min/mmHg over the oxygenator gas flow range 2.5 to 15.0 l/min.  
 
 
 
 
Figure 3.27 Effects of Oxygenator FiO2 on PO2; Over the FiO2 range achieved, PaO2 ♦ 
increased linearly from 19 mmHg up to 527 mmHg (p<0.0001).  In contrast P v O2 
(p<0.0001) and P c O2 (p<0.0001) increased curvilinearly.  P v O2 ■ increased initially 
from 16 mmHg at FiO2 4.9% up to 40 mmHg at a FiO2 17.3% after which P v O2 
averaged 48.98 ±3.64 mmHg.  P c O2 ▲ increased from 17.5 mmHg at FiO2 4.9% up to 
50.1 mmHg at FiO2 21%, after which P c O2 averaged 72.80 ±4.58 mmHg.  
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Figure 3.28 Effects of Oxygenator FiO2 on M O2; M O2 increased linearly (p<0.0001) 
when plotted against FiO2, from 18.48 ml/min at FiO2 4.9% up to 229.46 ml/min at FiO2 
98%.  
 
 
 
 
Figure 3.29 Effects of Oxygenator FiO2 on DO2; DO2 showed a complex relationship 
with FiO2.  Lilienthal DO2 ♦ increased sharply from 0.77 ml/min/mmHg at FiO2 7.4% up 
to 1.66 ml/min/mmHg at FiO2 8.9%.  DO2 then steeply decreased down to 0.91 
ml/min/mmHg at FiO2 21% before averaging 0.45 ±0.17 ml/min/mmHg at FiO2 25 to 
98%.  Piiper‟s DO2 ■ increased sharply from 0.77 ml/min/mmHg at FiO2 7.4% up to 1.66 
ml/min/mmHg at FiO2 8.9%.  The DO2 then steeply decreased down to 0.97 
ml/min/mmHg at FiO2 21% before averaging 0.67 ±0.13 ml/min/mmHg at FiO2 25 to 
98%.   
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Figure 3.30 Effects of Oxygenator FiO2 on DCO; DCO significantly decreased linearly 
from 1.98 ml/min/mmHg to 0.50 ml/min/mmHg with increasing FiO2 over the range 4.9-
98% (p=0.011) 
 
 
 
 
 
Figure 3.31 Effects of Oxygenator (Hypoxic) FiO2 on DNO; DNO was unaffected by 
FiO2 in the hypoxic range 4.9-20% with DNO averaging 5.08 ±0.30 ml/min/mmHg 
(p=0.617). 
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Figure 3.32 Effects of Oxygenator (Hyperoxic) FiO2 on DNO; DNO was unaffected by 
increasing FiO2 in the hyperoxic range 21-98% with DNO averaging 10.00 ±0.94 
ml/min/mmHg (p=0.639) 
 
 
 
 
 
Figure 3.33 Effects of Oxygenator FiO2 on Shunt Fraction;  At a standard blood flow 
rate (2.5 l/min) the shunt fraction decreased curvilinearly with increasing FiO2 (p<0.0001).  
At low FiO2 (4.9%), the shunt was calculated as 82.2% reducing to 18.5% at FiO2 21%.  
At higher FiO2 (38-98%) the shunt fraction averaged 0.93 ±0.007%. 
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Figure 3.34 Effects of Deoxygenator FiCO2 on pH; pH decreased with increasing FiCO2 
♦ arterial pH decreased from 7.73 to 7.12 (p<0.0001) and ■ venous pH decreased from 
7.71 to 6.93 (p<0.0001). 
 
 
 
 
 
 
Figure 3.35 Effects of Deoxygenator FiCO2 on PCO2; Both P v CO2 (p<0.0001) and 
PaCO2 (p<0.0001) increased linearly with increasing FiCO2.  For the FiCO2 range 2.26 to 
23.8% P v CO2 ♦ was 12 to 125 mmHg and PaCO2 ■ ranged 11 to 67 mmHg.  P c CO2 ▲ 
increased linearly from 11.5 to 96 mmHg (p<0.0001). 
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Figure 3.36 Effects of Deoxygenator FiCO2 on M CO2; M CO2 increased linearly with 
increasing FiCO2 from 34.06 ml/min (at 2.26%) to 221.16 ml/min (at 23.8%) (p<0.0001).  
 
 
 
 
 
 
 
Figure 3.37 Effects of Deoxygenator FiCO2 on DCO2; DCO2 ♦ started high at 11.65 
ml/min/mmHg at FiCO2 2.26% and then decreased curvilinearly to 3.29 ml/min/mmHg at 
FiCO2 23.8% (p=0.031).  Modified Piiper DCO2 ■ started at 11.76 ml/min/mmHg at 
FiCO2 2.26% and gradually decreasing to 3.52 ml/min/mmHg at FiCO2 23.8%.  
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Figure 3.38 Effects of P v CO2 on PO2; PaO2 ♦ curvilinearly (p<0.0001) decreased from 
135 mmHg (P v CO2 13 mmHg) to 96 mmHg (P v CO2 43 mmHg) with increasing          
P v CO2, plateauing at 90 ±2.89 mmHg (P v CO2 43 to 125 mmHg). P v O2 ■ increased 
curvilinearly (p<0.0001) from 26 mmHg (P v CO2 12 mmHg) to 48 mmHg (P v CO2 125 
mmHg).  
 
 
 
 
Figure 3.39 Effects of Deoxygenator FiCO2 on M O2; where ♦ represents run 1 and ■ 
represents run 2.  M O2 increased linearly with increasing P v CO2 (p<0.001) from 104.7 
ml/min (P v CO2 15 mmHg) to 190.36 ml/min (P v CO2 125 mmHg).   
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Figure 3.40 Effects of Deoxygenator FiCO2 on DO2; where ♦ represents run 1 and ■ 
represents run 2.  DO2 increased linearly with increasing P v CO2 (p<0.0001) from 0.74 
ml/min/mmHg (P v CO2 15 mmHg) to 1.62 ml/min/mmHg (P v CO2 125 mmHg).  
 
 
 
 
Figure 3.41 Effects of P v CO2 on FeO2; where ♦ represents run 1 and ■ represents run 
2.  To investigate the impact of P v CO2 on PaO2 the FeO2 was plotted against P v CO2.  
FeO2 decreased linearly with increasing P v CO2 (p<0.0001) from 23.4% (P v CO2 12 
mmHg) to 21.6% (P v CO2 125 mmHg).   
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Figure 3.42 Effects of P v CO2 on Oxygenator RER; where ♦ represents run 1 and ■ 
represents run 2.  The RER increased from 0.30 (P v CO2 12 mmHg) to 1.59 (P v CO2 
125 mmHg) in response to increasing P v CO2 (p<0.0001). 
 
 
 
 
Figure 3.43 Effects of P v CO2 on DNO and DCO; DNO ♦ was unaffected by 
increasing deoxygenator FiCO2 ranging 7.8-23% with DNO averaging 6.19 ±0.89 
ml/min/mmHg (p=0.509).  DCO ■ increased linearly with increasing deoxygenator FiCO2 
ranging 7.8-23% with DCO increasing from 0.45 ml/min/mmHg to 3.24 ml/min/mmHg 
(p=0.022). 
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Figure 3.44 Effects of RER Correction Factor on Oxygenator FiO2 with Varying 
Deoxygenator FiCO2; With a correction factor applied to the FiO2 values ♦, 
corresponding to the increasing oxygenator FeCO2, the oxygenator FiO2 significantly 
decreases with increasing P v CO2 (R
2
=0.841, d.f.=14, p<0.0001).  FiO2 reduced from 
0.26 (P v CO2 13 mmHg) to 0.24 (P v CO2 125).  
 
 
Figure 3.45 Effects of RER Correction Factor on MO2 with Varying Deoxygenator 
FiCO2; The resultant corrected M O2 shows no significant change with increasing            
P v CO2 (R
2
=0.217, d.f.=14, p=0.080) averaging 106.50 ±14.52 ml/min. 
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Figure 3.46 Circuit Hb Concentration Achieved During Hb Addition Over Time; The 
haematocrit ranges achieved were 7.3-31.0% (run 1), 6.5-27.1% (run 2) and 0.66-5.7% 
(run 3). 
 
 
 
 
 
Figure 3.47 Effects of Hct on pH;   pHv (p<0.0001) and pHa (p<0.001) were seen to 
increase linearly during the blood addition for the experimental runs encompassing Hb 6.5 
to 31.0 g/dl.  In run 1 ♦ pHv ranged 6.66-7.10 and ■ pHa ranged 6.73-7.13.  Similarly in 
run 2 ▲ pHv ranged 6.64-7.17 and ● pHa ranged 6.84-7.31.  For run 3 with lower Hct 
levels the pHv and majority of pHa values were below that detected by the analyser <6.5.   
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Figure 3.48 Effects of Hct on PO2; PaO2 (p<0.0001) and P v O2 (p=0.023) showed a 
curvilinear relationship when plotted against Hb concentration.  The PaO2 was high with 
the saline prime (Ӿ run 3 = 169mmHg) but reduced until the Hct was approximately 20% 
stabilising between 50 to 60 mmHg (♦ run 1) or 80-90 mmHg (▲ run 2).  The P v O2 read 
low with saline prime at 10 mmHg (● run 3) but increased up to a Hct of 15% where P v
O2 stabilised between 35-38 mmHg (■ run 1) and 40-45 mmHg (Χ run 2).   
 
 
 
 
 
Figure 3.49 Effects of Hct on M O2; The M O2 (p<0.0001) increased curvilinearly over 
the Hct range with significant increase from Hct 0% to 15% before plateauing.  In run 1 ♦ 
with FiO2 21% M O2 rose from 71.7 ml/min (0%) to a mean of 252.43 ±46.47 ml/min.  In 
run 2 ■ with FiO2 26.3%, M O2 started at 63.39 ml/min at 0% increasing to a mean of 
151.17 ±0 ml/min.  Run 3 ▲ revealed a gradual increase in M O2 over the Hct range 0.66-
5.71 rising from 63.66 ml/min to 146.92 ml/min with an oxygenator FiO2 26.5%. 
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Figure 3.50 Effects of Hct on DO2; DO2 (p<0.0001) increased curvilinearly over the Hct 
range with significant rise from Hct 0 to 15% before plateauing.  DO2 started at 0.33 
ml/min/mmHg at 0% increasing to a mean of 1.17 ±0.02 ml/min/mmHg.  At lower Hct 
range (0.66-5.71) a gradual increase in DO2 was observed rising from 0.75 ml/min/mmHg 
to 0.98 ml/min/mmHg. 
 
 
 
 
 
 
Figure 3.51 Effects of Hct on M CO2; At lower Hct range (▲) 0.66-5.71 M CO2 
increased curvilinearly from 259.46 ml/min to 297.90 ml/min (p=0.004).  At the higher 
Hct range (■) 6.5-27.1 M CO2 started at 119.34 ml/min (Hb=0) but maintained a mean M
CO2 182.71 ±4.43 ml/min thereafter in the presence of RBC.   
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Figure 3.52 Effects of Hct on DCO2; Across the whole Hct range 0.66-27.1 DCO2 
increased curvilinearly (p=0.002).  DCO2 increased from 6.77 ml/min/mmHg to 8.36 
ml/min/mmHg over the Hct range 0.66-5.71 ▲.  At the higher Hct range DCO2 was 4.94 
ml/min/mmHg with the saline prime and maintained a mean 8.82 ±0.66 ml/min/mmHg 
over the Hct range 6.45-27.1 ■.   
 
 
 
 
 
 
Figure 3.53 Effects of Hct on DNO and DCO; DNO ♦ significantly increased with rising 
Hct (p<0.0001) from 0.68 ml/min/mmHg at Hct 0.66 up to 7.08 ml/min/mmHg at Hct 
27.1.  DCO ■ increased curvilinearly with increasing Hct (p<0.0001) from 0.34 
ml/min/mmHg (saline prime) up to 1.09 ml/min/mmHg at Hct 27.1. 
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APPENDIX 1  
Checklist of Circuit Hardware and Disposable Items. 
 
 
 
 Circuit Hardware Checklist 
Stockert Roller Pump 
Medtronic Heater/Cooler 
Pressure Gauge 
8 Tubing Clamps 
CDI 500 Analyser with Calibration Gases 
Spectrum Medical M2 Saturation Monitor with 3/8” wraparound sensors. 
Cobe Sat/Hct Saturation Monitor 
100% Oxygen Cylinder with Regulator 
Air Cylinder with Regulator 
N2 Cylinder with Regulator 
1000ppm NO in N2 Cylinder with Regulator 
CO (0.3%) in oxygen (19%) and Helium (11%) Cylinder with Regulator 
5% CO2 in balanced N2 Cylinder with Regulator 
100% CO2 Cylinder with Regulator 
Deoxygenator Gas Line 
Oxygenator Gas Line 
Deoxygenator Gas Exhaust Line 
Oxygenator Gas Exhaust Line 
2 x Gas line O2 Analyser Teledyne X300 
 
 
 
 Disposable Items for Circuit 
PVC tubing 3/8” 
PVC tubing 1/2” 
2 x Fluid Administration Line 
Pressure Dome 
2 x Cobe Duo Oxygenators with Integral Reservoirs 
2 x CDI 500 „Arterial‟ pH, PO2 and PCO2 Sensors 
3/8”x3/8” Luer Lock Connector 
3/8”x1/2” Connector with Luer Lock 
3/8” Cobe Sat/Hct sensor connector 
2 litres 0.9% NaCl 
Horse Blood (donated within 21 days) 
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APPENDIX 2  
Bohr Integration Procedure via Excel Spreadsheet.   
Methodology devised by Dr. C. Borland (2010). 
 
 
Bohr Integration Procedure via Excel Spreadsheet 
Methodology devised by Dr. C. Borland (2010) via personal email communication dated 
6
th
 September 2010. 
 
A computer based calculation of DO2 using Bohr‟s integration method 
"How Bohr's integration works.” 
In calculus the area under the curve of a function between two points equals the area of a 
rectangle.  This has height equal to the mean value of the function and length the distance 
between the points (19.0-16.3).  Rearranging: the mean value equals the area divided by 
the distance between the two points.  Bohr obtained the area between Pv(Sv) and Pa(Sa) 
by planimetry and plotted PO2 (or rather 1/(PA-p) on the y axis and O2 saturation 
(expressed as content) on the x axis (opposite to usual practice fig 1.).The average 1/(PA-
p) = 0.02 is shown from Pv(Sv) 45.9(16.3) and 74.7 (19). 
 
 
16.3 19.0 
45.9 
74.7 
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A computer spreadsheet makes integration (estimating the area under the curve) of a 
complex function very straightforward provided a formula for the function is available.  
The spreadsheet “counts the squares” to estimate area.  An infinitesimal unit of oxygen 
content (we used 0.1) forms the side of the square while the base is the change in PO2 or 
rather, 1/PA-Pc.  The integral is the value for each “square” added onto the value of the 
previous.  The area of Sv is subtracted from Sa and then divided by (Sa-Sv) to give P c O2 
P(KpA) vol% Saturation 
P 
(severinghaus mmHg) 1/P-p vol% Integral 
6.105115 16.3 81.5 45.78836 0.016337 16.3 0.199218041 
9.965414 19 95 74.7406 0.030999 19 0.254687079 
 
Where: 
Severinghaus‟ formula gives PmmHg from saturation=EXP(0.385*LN((((S/100)^-1)-1)^-
1)+3.32-((72*(S/100))^-1)-(0.17*(S/100)^6)) 
1/(PA-p) = subtracts P Severinghaus from estimated “alveolar” PO2. 
Integral =0.1*1/(P-p) +∑1/(P-p)  multiplies each estimate of 1/(P-p) by the infinitesimal 
change in oxygen content (0.1) and adds it to the value from the row above.  This process 
goes from 0.1 to 20ml/ml. 
 
So that using M O2 of  400ml/min alveolar PA 104 mmHg, Pv of 46 mmHg and Pa of 
77mmHg and hence 1/(PA- P c O2) of  (0.255-0.199)/(19-16.3)= 0.021 multiplied by 400 = 
8.30 ml/min/Hg and Mean Pc = 107 – 1/.0207=58.8mmHg.  It will be noted that the 
average 1/(PA-Pc) can also be obtained as average of 1/(PA- P c O2) over all the rows 
corresponding to Sv to Sa eg =AVERAGE(E183:E210) =0.021.  This is not the same as 
the average of 0.1992 and 0.25468 = 0.227. 
 
Initially we obtained 1/(PA- P c O2) by scrolling down the array to find the rows 
corresponding to Pa and Pv and entering them into the formulae.  The excel command 
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VLOOKUP speeds up the process by finding the value for the integrals corresponding to 
Pa and Pv. 
 
We were working with horse blood and here the relevant algorithm is from Clerbaux et al 
which gives saturation if pressure is known: 
SO2 = 100 x (3.103x10
-2
 x PO2+2 x 8.451x10
-4
x PO2
2
+3x1.447x10
-5
x PO2
3
+4x3.961 x 10
-
6
x PO2
4
)/(4 x (1+3.103x10
-2
 x PO2+ 8.451x10
-4
x PO2
2
+1.447 x 10
-5
x PO2
3
+3.961 x 10
-6
x 
PO2
4 
Instead of starting with increments of oxygen content we start with increments of PO2 of 
0.1mmHg, then in the next column display saturations using Clerbaux‟s formula.  The 
integration is identical, multiplying the saturation by 0.1mmHg and adding to the value in 
the cell above. 
 
Pv 
Corresponding 
sat Pa 
Corresponding 
sat integralv Integral Av sat 
Av 
P 
45.8 85.66113012 74.7 95.19345636 2045.44904 4695.820712 91.70836237 58.3 
Using 
averages      91.68750984 58.3 
 
Columns e.g. Pv and Pa can then be copied and pasted from the experimental results 
worksheet directly and the column of P c O2 pasted back. 
 
The following table shows comparison of the calculations using the Severinghaus and 
Clerbaux et al algorithms. Bohr and Piiper calculations agree extremely well and the 
difference between Severinghaus and Clerbaux DO2 are negligible. Independent t test on 
the DO2 data comparing Severinghaus and Clerbaux with an assumed equal variance 
t=0.184, n=93 and p=0.855 (two-tailed) or 0.427 (one-tail). 
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PaO2 
mmHg    
FAO2 
% 
PAO2 
mmHg 
P v
O2 
mmHg 
P c O2 
mmHg 
Gas 
flow 
l/min 
FeO2 
% 
FiO2 
% 
M O2 
ml/min 
71.25 19.4 145.9 34.50 49.20 5 18 21 137.6 
71.25 19.4 145.9 39.75 53.00 5 18 21 137.6 
70.50 19.4 145.9 45.00 56.20 5 18 21 137.6 
 
 
 
 
 
 
P c O2 (Severinghaus) 
mmHg 
P c O2 (Clerbaux) 
mmHg 
DO2 
(Severinghaus) 
ml/min/mmHg 
DO2 
(Clerbaux) 
ml/min/mmHg 
48.7 49.2 1.41 1.42 
52.8 53 1.48 1.48 
56.9 56.2 1.54 1.53 
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APPENDIX 3 
Borland CDR, Dunningham H, Bottrill F, Vuylsteke A. Modelling Lung NO and CO 
Transfer using a Membrane Oxygenator.  ATS 2005, San Diego. 
 
Rationale: The diffusing capacity for nitric oxide (DNO) is generally accepted to reflect 
alveolar-capillary diffusion alone but debate remains whether this includes diffusion 
within the pulmonary capillary and whether the value for θNO is infinity or 4.5 ml ml
-1
 min
-
1
 torr
-1
 ie approximately sixfold θCO in normoxia .To help resolve this debate we have 
modelled lung nitric oxide and carbon monoxide gas transfer using a membrane 
oxygenator (Cobe Duo CML.) 
 
Methods: the oxygenator was primed with freshly drawn horse blood.A mixture of 5 parts 
per million nitric oxide (NO), 0.02% carbon monoxide (CO) and 19% oxygen was 
directed into the gas inlet port at a flow rate of 5 L min 
-1
 and the diffusing capacity (D) 
calculated from inlet and outlet NO and CO concentrations and gas flow rate. 
 
Results: DNO = 10.98 (SD 0.193) ml.min
-1
 torr
-1
 and DCO = 0.452 (SD 0.042) ml.min
-1
 torr
-
1
 .DNO
 
and
 
DCO increased
 
(p<0.001) with
 
blood volume and haemoglobin concentration. 
DNO
 
but
 
not
 
DCO increased with haemolysis (p<0.001) indicating NO dependence on 
diffusive resistance associated with the red cell. DCO but not DNO fell with increasing 
oxygen tension (p<0.05).Both DNO and DCO fell with increasing gas flow rate (p<0.01).No 
statistically significant change in DNO or DCO occurred with changing blood flow rate. 
 
Conclusion: Using the Roughton and Forster relationship (1/D = 1/Dm + 1/θVc) and the 
post haemolysis value of DNO to estimate the membrane diffusing capacity (Dm), we 
estimate that θNO exceeds θCO by at least twenty five fold. 
 
Conclusions: It is possible to model NO and CO gas transfer using a membrane 
oxygenator and investigate variables such as haemoglobin concentration in isolation. Our 
data suggest a higher value for θNO than previous laboratory estimates. 
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APPENDIX 4 
Borland CDR, Dunningham H, Bottrill F, Vuylsteke A. Can a membrane oxygenator 
be a model for lung NO and CO transfer?  JAP 2006; 100:1527-1538. 
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APPENDIX 5 
Borland CDR, Dunningham H, Bottrill F, Vuylsteke A. Can a Membrane 
Oxygenator be a Model for Lung Oxygen and Carbon Dioxide Transfer?  ATS 2007, 
San Francisco. 
 
 
 
We have previously developed a membrane oxygenator model to study lung nitric oxide 
and carbon monoxide gas exchange (Borland C, Dunningham H, Bottrill F and Vuylsteke 
A J Appl Physiol 2006;100:1527-1538.)To investigate a membrane oxygenator as a model 
of oxygen and carbon dioxide gas exchange two oxygenators were connected to form a 
circuit continuously perfused with horse blood at a flow of 2.5 L min
-1
. The “lung” 
oxygenator was ventilated by 28% oxygen with the remainder nitrogen and the “tissue” 
deoxygenator by 7% carbon dioxide in nitrogen to achieve normoxia and normocapnoea. 
The oxygen diffusing capacity measured by modified Bohr‟s integration was 1.87 ml min-
1
 torr
-1
 and carbon dioxide diffusing capacity was 19.3 ml min
-1
 torr
-1
.DO2 and DCO2 were 
minimally affected by haemoglobin concentration, haemolysis, surface area or blood 
volume.DO2 increased in hypoxia whereas DCO2 was only affected by the addition of 
carbonic anhydrase.DCO2 was unaffected by blood flow whereas DO2 increased to a 
plateau. By applying Cotes and Meade‟s extension of Roughton and Forster‟s relationship 
1/D = 1/Dm +1/(βQ+ θVc) and using previously estimated values for Dm and Vc θO2 = 
4.94 ml min
-1
 torr 
-1
 ml
-1
 and θCO2 = 4.03 ml min
-1
 torr 
-1
 ml
-1
 
 
In this model DO2 appears limited by chemical reaction and blood flow and minimally 
diffusion limited even in hypoxia. Conversely DCO2 appears entirely reaction limited. 
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APPENDIX 6 
Borland CDR, Dunningham H, Bottrill F, Vuylsteke A.  Isoflurane Increases Oxygen 
Uptake by a Membrane Oxygenator.  ATS 2007, San Francisco. 
 
 
 
We have previously developed a membrane oxygenator model to study lung gas exchange 
(Borland C, Dunningham H, Bottrill F and Vuylsteke A J Appl Physiol 2006;100:1527-
1538.)We wished to see whether a volatile anaesthetic altered oxygen exchange. Two 
oxygenators were connected to form a circuit continuously perfused with horse blood at a 
flow rate of 2.5 litres/minute. The “lung” oxygenator was ventilated by 26% oxygen with 
the remainder nitrogen and the “tissue” deoxygenator by 7% carbon dioxide in nitrogen to 
achieve normoxia and normocapnoea. Increasing concentrations of isoflurane 1-5% were 
added to the inlet of the “lung” oxygenator in random order. Addition of isoflurane was 
associated with an increase in oxygen uptake from 82.85 (SD 15.17) ml/min to 174.75 
(SD 29.01) ml/min. To further investigate this phenomenon the system was used as a 
tonometer by simultaneously measuring partial pressure (PO2) using an in line optical 
fluorometric analyser (CDI 500 Terumo systems) and saturation (sO2) using a Cobe 
saturation meter with probes in the “arterial” and “venous” blood lines. Addition of 
isoflurane had no significant effect (p >0.05) on “arterial” blood PO2 or sO2 or on 
“venous” PO2 but a highly significant (p= 0.007), dose related effect on venous sO2 due to 
a leftward shift of the venous, but not arterial oxygen dissociation curve. A volatile 
anaesthetic appears to have the potential to increase tissue oxygen delivery and could be of 
benefit in the severely hypoxic patient. 
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APPENDIX 7 
Dunningham H, Borland C, Bottrill F, Gordon D, Vuylsteke A.  Modelling Lung and 
Tissue Perfusion Using a Membrane Oxygenator Circuit.  Perfusion 2007; 22:231-
238. 
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APPENDIX 8 
Borland CDR, Bottrill F, Dunningham H, Vuylsteke A, Yilmaz C, Dane DM, Hsia 
CCW.  Significant erythrocyte membrane resistance to nitric oxide diffusion in the 
lung.  ATS 2009, Vienna. 
 
 
Lung diffusing capacity for nitric oxide (DLNO) is used to measure alveolar membrane 
conductance (DMNO) but disagreement remains as to whether DMNO equals DLNO, i.e., 
whether theta-NO is infinity or less. We previously showed in a membrane oxygenator 
circuit that theta-NO is less than infinity since hemolysis increased DNO (J Appl Physiol 
2006;100:1527-1538). Here we progressively added free haemoglobin (Hb) blood 
substitute (bovine Hb glutamer-200, Dechra, Overland Park, KS), to our oxygenator 
circuit observing an increase in DNO from 13.4 to 18.6 ml min
-1
 torr
-1
 (n=3 P<0.001) . In 3 
anesthetized dogs, DLNO and DLCO measured by rebreathing before and after each of 3 
successive equal volume exchange transfusions with bovine Hb glutamer-200 (10 ml/kg 
each, total exchange of 30 ml/kg). At baseline, DLNO averaged 4.5 x DLCO. After 
exchange transfusion DLNO rose 57 16% (mean SD) from baseline (p<0.01).  
 
 
Thus, both in vitro and in vivo data demonstrate a finite theta-NO. We conclude that 
erythrocyte membrane imposes considerable resistance to alveolar-capillary NO uptake. 
DLNO is sensitive to dynamic hematological factors, and is not a pure index of the 
conductance of the alveolar tissue membrane. 
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APPENDIX 9 
Borland CDR, Dunningham H, Bottrill F, Vuylsteke A, Yilmaz C, Dane DM, Hsia 
CCW. Significant blood resistance to nitric oxide transfer in the lung. JAP 2010; 
108:1052-1060. 
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